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Abstract. The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially 
identified as a key regulator of insulin-dependent glycogen synthesis. GSK-3 was 
subsequently shown to function in a wide range of cellular processes including 
differentiation, growth, motility and apoptosis. A number of mechanisms have been 
shown to allow differential regulation of GSK-3; these include modulation by upstream 
signals, control of substrate specificity and GSK-3 localisation. The aim of this project 
was to better characterise the role of GSK-3 in the social amoeba Dictyostelium 
discoideum and to investigate the possibility that GSK-3 activity is directed through 
interactions with specific GSK-3 binding proteins.
In this study I generated both mammalian and Dictyostelium cell lines expressing GSK-3 
homologues tagged with GFP. I demonstrated that the addition of this tag did not 
obviously alter cellular localization or the ability of GSK-3 to interact with known 
protein binding partners. I also confirmed that these fusion proteins retained kinase 
activity and that the levels of GSK-3 (3 over-expression used in this study were not 
detrimental to cell viability.
I further characterized the role of GSK-3 in the social amoebae Dictyostelium, using both 
knockout and over-expression cell lines to demonstrate that this protein fulfils multiple 
roles during early development. Dark-field time-lapse microscopy techniques were 
employed to identify a role for GSK-3 in co-ordinating chemotaxis and cellular 
polarization. During the course of this project I also identified a requirement for GskA in 
cytokinesis when cells were grown in shaking culture.
Finally, both the mammalian and Dictyostelium cell lines generated in this study were 
used for affinity chromatography experiments and a number of potential GSK-3 binding 
partners were identified.
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Chapter 1 
Introduction
1.1 Introduction
The aim of this project was to better characterise the role of the serine/threonine kinase 
Glycogen Synthase Kinase 3 (GSK-3) in the social amoeba Dictyostelium discoideum, 
and to investigate the possibility that GSK-3 activity is directed through interactions with 
specific protein binding proteins.
GSK-3 is a highly conserved kinase that functions in multiple signalling pathways 
including Wnt and Hedgehog signal transduction, protein synthesis, glycogen 
metabolism, mitosis and apoptosis. These many roles of GSK-3 cannot be separated 
either temporally or spatially and GSK-3 is itself subject to stringent regulation via 
several mechanisms:
• Splice variants of GSK-3 exhibit differential activity towards specific substrates
• GSK-3 isoforms perform tissue specific roles
• Direct phosphorylation of an N-terminal serine residue of GSK-3 (S9 of GSK-3 (3) 
is associated with inhibition of kinase activity
• Direct phosphorylation of a tyrosine residue located within the catalytic domain 
of GSK-3 (Y216 of GSK-3 P) is associated with an increase in kinase activity
• Differential localization of GSK-3 affects the ability of the kinase to target 
specific substrates
• Interactions between GSK-3 and scaffolding proteins direct or inhibit the activity 
of GSK-3 towards specific substrates
In this study I examined the role of GSK-3 in Dictyostelium, and investigated whether 
this protein was subject to these same mechanisms of regulation. I also investigated 
whether the activity of either mammalian GSK-3 p or Dictyostelium GskA was directed 
through previously uncharacterized protein binding interactions.
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1.2 GSK-3 genes
GSK-3 was originally identified in mammals [6, 7], and homologues have been found in 
all eukaryotes. These homologues share a significant degree of sequence homology; 
species as distant as humans and Dictyostelium share over 80% similarity within their 
kinase domains [12] (Figure 1.1). Protein function is also well conserved between GSK-3 
proteins from distantly related species: mammalian GSK-3 (5 under the control of the 
GAPDH promoter was able to rescue a temperature sensitivity defect in Saccharomyces 
cerevisiae cells in which all four GSK-3 homologues have been deleted [13].
Two GSK-3 isoforms encoded by distinct genes have been identified in mammals: 
GSK-3a (51 KDa) and GSK-3 (3 (47KDa). Both proteins are widely expressed, with 
particularly high levels in the brain [16]. The a  and p isoforms share over 98% identity 
within their kinase domains but differ in their N-termini [22]. Despite a high degree of 
similarity and functional overlap, these isoforms are not redundant in vivo; GSK-3f3-tm\\ 
mice reportedly die during embryogenesis (between E l3.5 and E l4.5) as a result of liver 
degeneration caused by widespread hepatocyte apoptosis [23]. This phenotype is similar* 
to that observed in Rel-A- [26] and IkB kinase-2- [27] null mice and was thought to be 
indicative of a role for GSK-3 p in the NFkB signalling pathway. Recently, however, 
GSK-3f3-null mice were crossed to a different genetic background, and while the authors 
reported that these mice died perinatally, they did not exhibit liver degeneration, instead 
these mice exhibited defects in mid-line development [28]. In contrast, GSX-5a-null mice 
were found to be viable but displayed altered glucose and insulin sensitivity* [29].
GSK-3p can be differentially spliced; Mukai et al. [30] identified a variant containing a 
13-amino acid insert within the kinase domain (GSK-3 p2) (Figures 1.1 and 1.2) that was 
preferentially expressed in the brain and had decreased activity towards the microtubule- 
binding proteins Tau and MAP IB [30, 31]. The mechanism by which this insertion alters 
the biochemical properties of the protein remains unclear. Very few kinases exhibit 
differential splicing within their catalytic domain. Exceptions to this rule include JNK 
[32] and MEK5 [37]; splice variants of these proteins contain additional amino acids 
between subdomains IX and X of their catalytic domains [39]. Alternatively spliced JNK 
[32] exhibits altered activity towards known substrates, while an insert within the same
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Figure 1.1 A lignm ent o f GSK-3 proteins
All seq u en ces were obtained from the NCBI website. Key residues involved in 
primed substrate recognition (R96, R180 and K205), autoinhibition (S9) and 
increased activity (Y216) are highlighted. R esidues that contact Axin ( | )  or FRAT 
(oif) are also highlighted. Mutation of K85 renders the kinase inactive.
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region of MEK5 alters the intracellular localisation of the kinase [37]. The site of the 13- 
amino acid insertion in GSK-3 p lies between subdomains X and XI; GSK-3p is the only 
known protein to exhibit splicing between these subdomains. This site is remote from the 
substrate-binding groove, making it unlikely that it would directly interfere with substrate 
access (Fig. 1.2). Instead, the insertion may promote or interfere with GSK-3-scaffold 
interactions (discussed later) or indirectly alter substrate binding through induced 
conformational changes.
A second splice variant of GSK-3/3 lacks exon 10 and is expressed most prominently in 
the CNS [42]. Exon 10 of GSK-3/3 encodes a region outside the catalytic domain and is 
poorly conserved between species and between a  and p isoforms. The activity of this 
variant remains to be characterised.
Recently, alternately spliced GSK-3/3 was reported to be associated with disease 
progression. An intronic single nucleotide polymorphism (SNP) within the GSK-3/3 gene 
was identified that regulated the selection of splice acceptor sites and was associated with 
the expression of a splice variant of GSK-3/3 lacking exons 9 and 11. This SNP was found 
to be present at a higher frequency in individuals suffering from Parkinsons disease 
compared to non-diseased individuals and expression of this splice variant was found to 
correlate with increased phosphorylation of Tau, a substrate for GSK-3 [44]. Examination 
of the crystal structure of GSK-3 p revealed that loss of exon 9 only resulted in a minor 
change in the proteins structure and one could speculate that the resultant protein would 
be catalytically active. The amino acids encoded by exon 11 do not form part of the 
crystal structure of GSK-3 and it is unclear w7hat affect loss of these residues w'ould have. 
Another splice variant of GSK-3/3 lacking exons 8 and 9 was isolated from blast crisis 
chronic myeloid leukemia progenitor cells exhibiting increased p-catenin levels [45]. 
GSK-3 regulates p-catenin levels as a component of the WNT signalling pathway 
(discussed later) and this splice variant was reported to exhibit decreased activity within 
this pathway [45]. The validity of these findings requires further investigation. However, 
examination of the crystal structure of GSK-3 p revealed that loss of the amino acids 
encoded by exons 8 and 9 would result in a substantial modification in protein structure. 
It may be that this splice variant exhibits an inability to phosphorylate and regulate p- 
catenin levels because the protein is non-functional.
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1.3 GSK-3 substrates
GSK-3 demonstrates a preference for pre-phosphorylated (primed) substrates, 
recognizing the consensus sequence S/T-X-X-X-Phospho-S/T, where the first S/T residue 
is the target for GSK-3 phosphorylation, ‘X’ represents any amino acid and the S/T C- 
terminal to the GSK-3 target residue has undergone priming phosphorylation [48]. The 
relative activity of GSK-3 towards individual substrates differs considerably. However, 
the requirement for priming of substrates is observed across a range of substrates. 
Priming decreases the Km of the substrate: for example, prior phosphorylation of the 
GSK-3 substrate p-catenin by casein kinase 1 at S45 decreased the Km 30-fold [49].
The crystal structure of GSK-3 p has been elucidated [41, 50, 51] and provided insight 
into the mechanism by which phospho-primed substrates are recognised. The residues 
R96, R180 and K205 were found to be located within close proximity7 of each other on 
the surface of the protein and create a region of positive charge (Figure 1.2). This region 
was proposed to interact with the primed phospho-S/T residue and to align the substrate 
within the substrate-binding groove such that the kinase activation loop and catalytic 
residues are optimally orientated [50]. Consistent with this proposal, mutation of 
substrate-priming sites dramatically reduced GSK-3 phosphorylation [54, 55], while a 
corresponding mutation in GSK-3 p that substituted the positive charge of R96 for an 
alanine residue dramatically reduced the ability of the protein to phosphorylate its primed 
targets [55, 56]. The importance of priming phosphorylation for GSK-3 function is 
supported by the observation that the key residues (R96, R180 and K205) are found in all 
GSK-3 homologues examined (Figure 1.1).
Specific substrates are primed for GSK-3 phosphorylation by different priming kinases, 
w7hose activity can be regulated in a pathway-specific manner. Consequently, the affinity 
of GSK-3 towards specific substrates can be controlled by the availability and activity7 of 
the priming kinase for a given substrate. For example, the collapsin response mediator
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Figure 1.2. Schem atic representation o f GSK-30
R esidues involved in primed substrate recognition (R96, R180 and K205) and 
autoinhibition (S9) are highlighted. The scaffold-binding region (SBR) is marked in 
blue; this region interacts with scaffolding proteins including Axin (shown in red) and 
FRAT
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proteins CRMP2 and CRMP4 were both identified as substrates for GSK-3. CRMP2 was 
found to be primed by Cdk5 alone, whereas either Cdk5 or DYRK2 were able to prime 
CRMP4 [57]. Inhibition of both Cdk5 and DYRK2 prevented phosphorylation of both 
CRMP isofonns, whereas only CRMP2 phosphorylation was affected in Cdk5~~ cells 
[57], indicating that GSK-3 phosphorylation of these isoforms can be differentially 
regulated in response to cellular cues.
A number of proteins have been presented as un-primed substrates for GSK-3 [58-60]. 
However, stoichiometric phosphorylation of an un-primed substrate has only been 
demonstrated for the microtubule-binding protein Tau [62]: recombinant Tau, expressed 
and purified from E.coli, is stoichiometrically phosphorylated at S396 by GSK-3 p. Sub- 
stoichiometric phosphorylation at S46, T50, S202, T205 and S404 was also reported [62]. 
In the absence of phospho-substrate contacts with R96, R180 and K205, the interactions 
required to facilitate Tau phosphorylation must be provided through alternative means. 
As Tau is itself a large protein (ranging from 50-67 kDa in weight), it is conceivable that 
Tau and GSK-3 may interact within regions outside the immediate substrate 
binding/phosphate-recognition domain and that these interactions promote the 
phosphorylation of S396.
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1.4 Inhibitory phosphorylation of GSK-3
The kinase activity of GSK-3 was found to be inhibited through phosphorylation of a 
serine residue located at the N-terminus of the protein (S21 and S9 of GSK-3a and 
GSK-3 P, respectively) [63, 64]. Dajani et at. [50] demonstrated that a phospho-peptide 
based on the N-terminus of GSK-3 p could act as a competitive inhibitor towards primed 
GSK-3 substrates. This led to the suggestion that the phosphorylated N-terminus of 
GSK-3 auto-inhibits its activity by looping back into its own active site. The proposal 
being that the phospho-serine interacted with the region of positive charge generated by 
R96, R180 and K205 (residues refer to GSK-3 P), mimicking the primed residue of a 
GSK-3 substrate (Figure 1.2). Consistent with this mechanism of inhibition, substitution 
of R96 for an alanine residue abolished the ability of the phosphorylated N-terminal 
peptide to inhibit GSK-3 p activity [56].
A number of kinases have been reported to phosphorylate S21/9 of GSK-3a and GSK-3 p 
in the context of specific signalling pathways: PKB targeted GSK-3 in response to insulin 
signalling [65], PKA targeted GSK-3 in response to increases in cAMP levels [66], 
p90RSK/MAPKAP kinase-1 phosphorylated GSK-3 following activation by EGF or PDGF 
[64, 67] and p70 ribosomal S6 kinase (p70S6K) phosphorylated GSK-3 in response to 
stimulation by insulin and other growth factors [63]. Phospho-S21/9 autoinhibition was 
also suggested to be involved in the regulation of GSK-3 activity during Wnt signalling 
[68, 69] and in the control of microtubule stability [70, 71] (see later for detailed 
discussions of these functions). It was therefore surprising that homozygous knock-in 
mice in which both S21 and S9 of GSK-3a and GSK-3 p were replaced with alanine 
residues were viable and healthy [72]. Glycogen metabolism was partially disrupted in 
these mice (discussed below). However, McManus et cil [72] reported no other obvious 
phenotypes and specifically demonstrated that Wnt signalling was not affected. 
Analogous studies in Drosophila showed that the equivalent S9A pseudosubstrate 
mutation did not interfere with insulin/PI3K-dependent growth regulation, although a 
S9E mutation showed signs of mild Wnt pathway deregulation [73]. It is therefore 
tempting to speculate that, despite the literature to the contrary and with the exception of 
glycogen metabolism, S21/9 phosphorylation does not represent a primary mechanism by
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which GSK-3 activity is regulated. Instead, serine phosphorylation of GSK-3 may 
represent a means of subtly altering GSK-3 activity within specific signalling pathways. 
The observation that S9 of GSK-3 (3 is only conserved in metazoans (excluding 
Caenorhabditis elegans) further supports the idea that this is a recent adaptation and 
perhaps a less essential mechanism of GSK-3 regulation.
1.5 Activating phosphorylation of GSK-3
GSK-3 is a member of the CMGC family of protein kinases. This group consists of 
cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAPKs), glycogen 
synthase kinases (GSKs) and CDK-like kinases (CLKs) [39, 74]. The kinase activity of 
several CMGC family members, including MAPK2 (also known as ERK2), is dependent 
upon the phosphorylation of tyrosine (Y185 in MAPK2) and threonine (T183 in MAPK2) 
residues located within the activation loop of the protein [75]. Phosphorylation of 
MAPK2 by MEK was reportedly required to bring the activation loop into an active 
conformation for substrate binding and resulted in a 100- to 500-fold increase in activity 
[75]. Hughes et al. [76] investigated the possibility that GSK-3(3 activity was regulated in 
a similar fashion; Y216 was identified as being phosphorylated in vivo, and 
phosphorylation of this residue was later shown to be associated with a 5-fold increase in 
Kcat [50, 76]. In place of the phospho-T183 located in the activation loop of MAPK2, 
GSK-3(3 has a valine residue (V214). However, structural comparisons suggest that the 
primed phosphate of GSK-3 P’s substrate would occupy a 3-dimensional location 
equivalent to the phosphate of MAPK2’s T183 suggesting that the primed substrate of 
GSK-3 may functionally substitute for the activating changes induced by MEK 
phosphorylation of T 183 in MAPK2. The conformational change associated with Y216 
phosphorylation in GSK-3P is minimal, and the un-phosphorylated protein is active [50]. 
The underlying mechanisms responsible for regulating tyrosine phosphorylation of 
GSK-3 remain controversial. Recombinant GSK-3p expressed and purified from E. coli 
was found to be phosphorylated on Y216 and underwent further phosphorylation upon 
incubation with Mg2+ATP [62, 76, 77]. However, this phosphorylation was not shown to 
be stoichiometric. Lochhead et al. [78] recently proposed that GSK-3 
autophosphorylation represents a transient capacity, specific to a partially folded state, for
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GSK-3 to target its own tyrosine residues. However, it remains unclear whether GSK-3 
autophosphorylation is an intramolecular rather than intermolecular event.
Mammalian GSK-3 was also reportedly phosphorylated by distinct tyrosine kinases in 
trans. For example, in neuronal cells, the tyrosine kinase Pyk2 phosphorylated GSK-3 (3 
following stimulation with lysophosphatidic acid (LPA) [79] although the physiological 
phosphatase(s) that dephosphorylate tyrosine residues within GSK-3 remain to be 
identified.
In Dictyostelium, a role for GSK-3 tyrosine phosphorylation has been defined in the 
regulation of cell differentiation and patterning during development (discussed in detail 
later). In the absence of an abundant food source, Dictyostelium aggregate, using cAMP 
as a chemoattractant. The 7-transmembrane receptor cAR3 [80] responded to increased 
cAMP levels by activating the tyrosine kinase ZAK-1. ZAK-1, in turn, phosphorylates 
GskA (GSK-3) on Y214 (analogous to Y216 of GSK-3p) as well as Y220 [81, 82]. 
Mutation of either Y214 or Y220 of GskA reduced kinase activity [81]. The Y220 
residue that was phosphorylated by ZAK-1 is conserved in mammalian GSK-313 (Y222) 
but was not found to be phosphorylated in preparations from insect cells that were 
catalytically active and contained phospho-Y216 [50].
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1.6 Regulation of glycogen synthesis
GSK-3 was originally identified for its role as a negative regulator of glycogen synthesis 
[6] (for a review see [83]). In the absence of insulin, the metabolic enzyme glycogen 
synthase (GS) was found to be phosphorylated by casein kinase II (CK2) at S657 [84]. 
This primed GS for sequential phosphorylation at S653, S649, S645 and S641 by GSK-3 
and inhibited GS activity [7, 48]. Increases in blood glucose lead to the release of insulin, 
which in turn initiates a signalling cascade involving the insulin receptor (IR), the insulin 
receptor substrate (IRS) and the activation of both phosphoinositide 3 kinase (PI3K) and 
protein kinase B (PKB) [85]. Active PKB was found to inhibit GSK-3 by 
phosphorylating S21 and S9 of the GSK-3a and GSK-3 p isoforms, respectively [65]. 
Inhibition of GSK-3 leads to the accumulation of active GS and the subsequent assembly 
of UDP-glucose into glycogen.
Recently, evidence has emerged that GSK-3a and GSK-3 p perform tissue specific roles 
in the regulation of this pathway. Both GSK-3a and GSK-3 p were expressed and 
phosphorylated by PKB in response to insulin signalling in both hepatic and skeletal 
muscle tissue [29, 86]. However, GSK-3a was found to principally regulate GS activity 
within hepatic cells [29] while GSK3P was primarily responsible for the regulation of GS 
activity within skeletal muscle [72, 86].
This is the first clear example of where both GSK-3a and GSK-3 p are capable of 
performing a common role in a pathway but their activities are differentially directed in a 
tissue specific manner. The idea that GSK-3 isoforms perform functionally divergent, 
tissue specific roles would argue that additional levels of regulation must be employed to 
compartmentalize these proteins such as differential expression, intracellular localization 
or scaffolding into different multi-protein complexes.
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1.7 Regulation of the canonical Wnt pathway
The Wnt signal transduction pathway has been shown to direct many differentiation 
events during embryonic development and to regulate stem cell fate in adult organisms 
(for reviews see [87-89]). In the ‘canonical’ Wnt signalling pathway, Wnt ligands were 
found to stabilise levels of the transcriptional activator p-catenin (Figure 1.3). Stable 
p-catenin was shown to complex with TCF/LEF transcription factors and initiate 
transcription of Wnt target genes. GSK-3 has been shown to phosphorylate several 
intracellular components of the Wnt signal transduction pathway, the most well 
characterized of these being p-catenin. In the absence of Wnt ligands, p-catenin was 
shown to be phosphorylated at S45 by casein kinase l a  (C K la) [55, 90], which primed it 
for sequential GSK-3 phosphorylation at T41, S37 and S33 [91, 92]. Phosphorylated 
p-catenin was recognised by the F-box protein pTrCP, a component of the E3 ubiquitin 
ligase complex, and targeted it for degradation via polyubiquitination and proteasomal 
degradation [93].
P-catenin alone was found to be a poor substrate for GSK-3 in vitro. Efficient 
phosphorylation of P-catenin required the formation of a multi-protein complex (also 
known as the ‘destruction complex’) that minimally comprised the scaffolding protein 
Axin, adenomatous polyposis coli (APC), C K la and either GSK-3 isoform [94-96]. Axin 
directly bound and mediated interactions between C K la, GSK-3 and their substrate 
P-catenin [94-97]. Axin was found to bind GSK-3 at a site distant from the substrate- 
binding domain in a region defined as the ‘scaffold-binding region’ (SBR) [98] (Figure 
1.2). In the presence of Axin, GSK-3-directed phosphorylation of p-catenin increased 
600 000-fold relative to the un-scaffolded reaction [49, 96]. Axin itself is a substrate for 
GSK-3, and phosphorylation decreased its proteolysis and increases p-catenin binding 
[94, 96, 99], although the GSK-3 target residues within Axin have not been directly 
identified. The tumour suppressor protein APC was found to bind both Axin and 
P-catenin and is also a substrate of GSK-3; APC is phosphorylated on a series of 20- 
amino acid repeats in a CK1- and GSK-3-dependent manner [100-102]. APC 
phosphorylation increases its affinity for p-catenin by 300- to 500-fold [103]. Xing et 
al.[104] proposed that APC phosphorylation regulates the dynamics of P-catenin binding
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and release during a cycle of P-catenin degradation. Similarly, Ha et al. [105] proposed 
that the levels of phospho and non-phospho APC function as a rheostat to control the 
absolute levels of p-catenin in both the presence and absence of Wnt ligands.
In the presence of Wnt ligands P-catenin phosphorylation and turnover is inhibited. Wnt 
ligands were found to bind the extracellular domains of the Wnt co-receptors Frizzled 
(Fz) and low-density lipoprotein (LDL) receptor-related protein (LRP) 6 (LRP6) [106- 
109]. Activation of Fz via Wnt ligand binding led to recruitment and phosphorylation of 
the PDZ containing protein Dishevelled (Dvl) [110-113]. Dvl has been shown to bind 
directly to Axin[l 14].
Axin was also found to bind to phosphorylated LRP6 [60, 115-117]. Several recent 
studies have found evidence that GSK-3 also interacts with LRP6 and is the kinase 
responsible for the phosphorylation of a series of conserved PPPSP motifs that are 
essential for Axin binding [60, 115, 118-120]. Synthetic peptides based on these PPPSP 
motifs were found to bind GSK-3 and acted as competitive inhibitors in a phospho- 
specific manner [118, 120]. The ability of these peptides to bind to GSK-3 was 
independent of SBR binding status, i.e. binding occurred equally well in the presence or 
absence of a peptide based on the GSK-3-interaction domain (GID) of Axin. Conversely, 
Zeng et al [115] found GSK-3 was only able to phosphorylate LRP6 when bound to 
Axin; mutation of the SBR region of GSK-3 (L396Q), such that the protein exhibited 
reduced affinity towards Axin was sufficient to prevent phosphorylation of LRP6 in vivo. 
Taken together, these findings may be indicative of a positive feedback mechanism 
whereby an Axin: GSK-3 complex is initially recruited to the membrane, perhaps via an 
interaction between Axin and Dvl that is recruited to the membrane following Wnt 
activation. A localized increase in GSK-3 would then lead to increased phosphorylation 
of LRP6, which in turn would lead to increased binding between GSK-3 and phospho- 
LRP6 via the substrate binding groove and an inability for GSK-3 to phosphorylate |3- 
catenin or other substrates.
The PPPSP motifs of LRP6 do not constitute a typical GSK-3 substrate site, since they do 
not contain a priming residue. And, in contrast with its role in the turnover complex, this 
proposed function for GSK-3 would result in the stabilisation of P-catenin.
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In Xenopus embryos, Wnt signalling was proposed to promote the dissociation of GSK-3 
from Axin through the action of FRAT, also know as GBP (GSK-3-binding protein). 
FRAT/GBP contains a GSK-3 interaction domain (GID) and was found to compete with 
Axin for binding to the SBR of GSK-3 [121]. Depletion of FRAT/GBP prevented 
|3-catenin/TCF-dependent transcription and the formation of the Xenopus primary 
embryonic axis, while ectopic expression of FRAT/GBP induced axis duplication and the 
accumulation of |3-catenin [122]. However, FRAT homologues have not been found in 
Drosophila or C. elegans, suggesting that the protein is not a central component of a 
primitive Wnt pathway. Furthermore, Van Amerongen et al. [123] showed that the three 
murine FRAT homologues are dispensable for Wnt signal transduction during 
development.
In addition to directing the efficient phosphorylation of j3-catenin, it has recently been 
proposed that the Axin: GSK-3 complex may perform a more general role in the 
regulation of cellular signalling. Kim et al. [124] identified 42 proteins that were 
candidates for GSK-3 -regulated phosphorylation, proteasomal degradation or both. This 
study identified transcription factors, RNA associated proteins, metabolic proteins, 
proteins that formed part of the cytoskeleton or membrane and signalling molecules that 
were all targets for GSK-3 directed phosphorylation and/or degradation. Interestingly, 
phosphorylation of 12 of these proteins could be inhibited through the addition of a 
peptide based on the GID of Axin. Indicating that phosphory lation of these substrates 
may require the formation of a multi-protein complex. Furthermore, levels of these 12 
proteins were stabilized by the addition of Wnt ligands, indicating that a branch or 
branches of the Wnt signal transduction pathway were responsible for regulating the 
absolute levels of these proteins in the cell.
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1.8 Regulation of Hedgehog signal transduction
The Hedgehog (Hh) and Wnt signalling pathways frequently cooperate to direct cellular 
proliferation, differentiation and pattern formation during embryonic development. 
GSK-3 plays a role in regulating proteolysis in both the Wnt and Hh pathways, and it has 
been suggested that this role may reflect the evolution of two pathways from a common, 
ancestral signal transduction module (reviewed in [125-127]).
The Hedgehog signal transduction pathway was initially identified and characterized in 
Drosophila where there is a single Hedgehog ligand (Hh) (Figure 1.4). Hh ligands were 
shown to stabilize and stimulate the activity of full-length cubitus interruptus (Ci), a 
protein shown to act as a transcriptional activator of Hh target genes [128, 129].
In the absence of Hh ligands, Ci was found to be phosphorylated at S856 and S892 by 
PKA and subsequently at S852, S884 and S888 by GSK-3 [130, 131]. Phospho-Ci was 
further phosphorylated by members of the CK1 family, leading to its recognition by 
pTrCP and proteosomal processing [131, 132]. In contrast with Wnt signalling, in which 
P-catenin is fully degraded, full-length Ci (Cil55) was found to be only partially 
processed, generating a truncated protein (Ci75) that acts as a transcriptional repressor of 
Hh target genes[129].
As discussed previously, efficient p-catenin phosphorylation requires the formation of the 
multi-protein destruction complex. Similarly, efficient phosphorylation of Cil55 was 
found to be dependent on the formation of a multi-protein complex known as the 
‘hedgehog-signaling complex’ (HSC). This multi-protein complex consists minimally of 
the kinesin-like protein Costal-2, and the serine/threonine kinase Fused (Fu), Suppressor 
of fused (Su (Fu)), PKA, GSK-3 and CK1[21, 133-135]. In addition to facilitating 
efficient phosphorylation of C il55, this complex was found to localize to microtubules in 
an ATP dependent manner and prevented the nuclear translocation of Cil55[21, 133- 
136].
In the absence of Hh ligands the transmembrane Hh receptor protein Patched (Ptc) was 
found to inhibit the activity of a second Hh receptor protein, Smoothened (Smo) [137]. At 
present, the mechanisms involved in this inhibition remain poorly understood. However it 
is likely that alterations in phosphorylation state, protein stability and subcellular 
localization are involved [138-140].
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In response to an Hh ligand, repression of Smo was shown to be alleviated [140-142]. 
Smo was found to bind directly to Costal-2, sequestering it to the membrane [143-145]. 
Translocation of Costal-2 was found to correlate with accumulation and translocation of 
C il55 to the nucleus.
Many of the key components responsible for Hh signal transduction in Drosophila are 
conserved in mammals. However much less is known about the mechanisms of Hh signal 
signalling in this system. Studies performed so far indicate that additional levels of 
complexity exist, for example there are 3 hedgehog ligands in mammals; Indian 
hedgehog (Ihh), Desert hedgehog (Dhh) and Sonic hedgehog (Shh). Each of these ligands 
were found to be differentially expressed during development with Shh being the most 
wide-spread [146]. Similarly, there are multiple Ci homologues; Glil, Gli2 and Gli3, 
each of which is subject to differential regulation. Furthermore, these proteins perform 
divergent roles with Glil and Gli2 acting primarily as transcriptional activators of 
hedgehog target genes while Gli3 exists in 2 forms (similar to Ci) and acts as both a 
transcriptional repressor and activator of Hh target genes [147].
Mammalian orthologues of Costal-2, Fused and Su (Fu) have all been identified. Kif-7, a 
member of the kinesin family has been proposed to be the mammalian orthologue of 
Costal-2. Recent mouse knockout studies have confirmed that Kif-7 is a component of 
the Shh pathway and is essential for correct processing of Gli3 in mammals[148, 149]. 
Fused was found to be essential for embryonic patterning in Drosophila [150]. However 
Fu null mice are viable and demonstrate no Hh related phenotypes [151] perhaps 
indicating that Fused performs a divergent role in mammalian Hh signalling. Similarly, 
the mammalian Su (Fu) was found to bind directly to GSK-3 and facilitate efficient 
phosphorylation of Gli3 in place of Kif-7 (Costal-2)[152] suggesting, that despite the 
conservation of several components of this pathway, the mechanisms by which Hh signal 
transduction occurs has diverged since the separation of the vertebrate and invertebrate 
lineages.
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1.9 Regulation of the cytoskeleton by GSK-3
Neurons are highly polarized cells consisting of a single axon and multiple dendrites that 
are structurally and functionally distinct [153]. Initially, a nerve cell body will generate 
lamellipodia at the cell surface, followed by the extension of multiple immature neurites. 
During this process, one neurite will undergo a transition and initiate a period of rapid 
growth to form an axon. The remaining immature neurites develop more slowly and 
become dendrites [154]. Multiple signalling pathways cooperate to bring about these 
changes in cell structure, and GSK-3 performs roles in several of these pathways.
The extension of immature neurites requires the assembly of a stable microtubule 
infrastructure. Microtubules consist of a - and p-tubulin dimers and cycle between phases 
of growth and shrinkage (reviewed in [155]). Polymerization and stability of 
microtubules is regulated by a number of microtubule-associated proteins (MAPs). 
GSK-3 has been shown to phosphorylate several MAPs, including CLASP2[156], APC 
[157], Tau [158] and MAP2C [159]. Each of these MAPs influences stability through 
direct interactions with microtubules, but the mechanisms remain unclear. GSK-3- 
phosphorylated forms of APC, Tau and MAP2C all exhibit decreased affinity towards 
microtubules and fail to stabilize them [157-159]. Components of the Wnt signalling 
pathway may regulate the ability of GSK-3 to phosphorylate these targets; Dishevelled 
(Dvl) and Axin were both shown to localize to microtubules and influence their stability 
by inhibiting GSK-3 activity [160], although the mechanism is not known. Unlike the 
canonical Wnt pathway, this system does not influence gene transcription, indicating that 
these proteins function in a microtubule-specific pathway [160].
The establishment of the presumptive axon seemingly requires the inhibition of GSK-3 
activity; Jiang et al. [161] demonstrated that S9-phosphorvlated GSK-3 p localized most 
strongly to the tip of the presumptive axon. Furthermore, treatment with GSK-3 
inhibitors, shRNA against GSK-3 p or peptides containing a GID led to the formation of 
multiple axons at the expense of dendrites [161]. Recently, Gartner et al. [162] reported 
that the neurons of S21A GSK-3a/S9A GSK-3 p double knock-in mice develop normally. 
The neurons of these mice were still sensitive to GSK-3 inhibitors, indicating that while 
regulation of GSK-3 activity is important, serine phosphorylation alone is not sufficient
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to determine the identity of the presumptive axon. It was interesting that peptides 
containing a GID caused the formation of multiple axons, suggesting that scaffolding 
proteins may interact with and direct GSK-3 activity within these cells.
Neurite retraction also correlated with GSK-3 activity; the inhibitory guidance molecule 
Semaphorin-3A (Sema3A) was shown to influence the availability of phospho-S9 
GSK-3 p located at the leading edge of the axon and caused neurite retraction [163]. The 
GSK-3 substrates CRMP2 and CRMP4 were both identified as downstream targets of 
Sema3A signalling, and phosphorylation of these proteins reduced their ability to 
stabilise growth cones via the actin cytoskeleton [164, 165].
Careful regulation of microtubule dynamics is also required during mitosis to orient and 
assemble a spindle apparatus that accurately segregates chromosomes. Wakefield et al. 
[70] reported that GSK-3 p localises specifically to mitotic microtubules and to the 
centrosome. Furthermore, inhibition of GSK-3 caused defects in astral microtubule 
length, chromosome alignment and an increase in the frequency of micronuclei [70, 166, 
167], suggesting that GSK-3 activity is required during mitosis. Loss-of-function studies 
in a number of systems have shown that cell division can proceed in the absence of 
GSK-3 but report that the process is more prone to error and delay. In S. cerevisiae, 
deletion of the GSK-3 homologue MCK1 increased the rate of mitotic chromosome loss 
[168], while in C. elegans, RNAi depletion of GSK-3 interfered with mitotic spindle 
orientation in 4 cell-stage embryos [169]. In Drosophila embryos, loss of GSK-3 (sgg) 
interfered with interactions between spindle tubules and cortical actin [170]. Depletion of 
other canonical components of the Wnt signalling pathway induced related phenomena. 
For example, loss of APC in Xenopus extracts or expression of truncated APC in 
colorectal tumour cells was associated with defects in mitotic spindle assembly [171, 
172]. Similarly, loss of /3-catenin or expression o f AXIN2 was found to be associated with 
increases in mitotic errors [91, 173]. These findings, in conjunction with the 
characterisation of the roles of Dvl and Axin during neurite extension, may be indicative 
of a central role for components of the Wnt pathway in the regulation of microtubule 
dynamics.
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1.10 Regulation of apoptosis and cell viability
GSK-3 was shown to induce apoptosis in response to a range of stimuli including DNA 
damage [52], hypoxia [174], removal of NGF [175] or BDNF [176], exposure to 
staurosporine and heat shock [177]. GSK-3 elicits a response to these stimuli through the 
regulation of transcription factors (discussed below) including p53 [52] and heat shock 
factor-1 [178]. Furthermore, as part of a pro-apoptotic signalling cascade, GSK-3 
phosphorylates and inhibits the translation initiation factor eIF2B, providing a link 
between the global regulation of protein synthesis and cell survival [179, 180]. 
Conversely, complete loss of GSK-3 p also resulted in apoptosis due to a failure to 
activate the TNFcx/NFkB survival signalling pathway [23]. These observations make it 
difficult to predict the outcome of GSK-3 inhibition in particular systems due to the range 
of potentially conflicting roles that may be played.
1.11 Regulation of transcription factors
A plethora of putative GSK-3 substrates have been identified, a large proportion of these 
are transcription factors that include c-Jun [181, 182], c-Myc [183], CREB [184], NFATc 
[185, 186], HSF-1 [178, 187] and STATa [188]. GSK-3 negatively regulates the activity 
of these transcription factors via a number of different mechanisms. For example, N- 
terminal phosphorylation of NFATc or STATa by GSK-3 induced nuclear export [185, 
188], while phosphorylation of c-Myc at S62 by GSK-3 targeted the protein for ubiquitin- 
mediated proteolysis [183]. In contrast, c-Jun, CREB, F1SF-1 and NFATc exhibited 
reduced binding affinity towards their target DNA sequences following GSK-3-directed 
phosphorylation [186, 187, 189, 190].
The ability of GSK-3 to target transcription factors clearly requires multiple levels of 
regulation to ensure differential targeting of substrates. Specifically, localisation of 
GSK-3 is fundamental in regulating its activity towards transcription factors in the same 
way that localization of GSK-3 to mitotic spindles is key to regulating its role in spindle 
dynamics. Removal of growth factors or treatment with staurosporine causes nuclear 
accumulation of GSK-3 that presumably alters the access of GSK-3 to nuclear targets. 
Conversely, both FRAT- and Axin-bound GSK-3 were shown to be exported from the
29
nucleus via a CRM-1-dependent mechanism [191, 192]. Mutations to the SBR of GSK-3 
enhanced nuclear accumulation, suggesting that scaffolding proteins including Axin and 
FRAT are at least in part responsible for GSK-3 nuclear export.
1.12 The role of GSK-3 in Dictyostelium
Dictyostelium amoebae exist as individual cells in the presence of an abundant food 
source. Upon starvation, up to 100,000 amoebae will aggregate to form a multicellular 
structure (Figure 1.5). The aggregation of single cells is coordinated by the pulsatile 
release of cyclic AMP (cAMP). cAMP acts as a chemo attractant and as a regulator of 
developmental gene expression via signal transduction through a family of cAMP 
receptors, cARl and cAR3 which have a high affinity for cAMP, and low-affinity cAMP 
receptors cAR2 and cAR4.
Under these conditions cells form a mound surrounded by an extracellular matrix and 
begin to differentiate into pre-spore and pre-stalk cells [193]. These cells re-distribute 
themselves within the mound as it becomes a finger-like structure and frequently topple 
over to form migratory slugs. Upon finding favourable conditions a slug will undergo 
terminal differentiation to form a fruiting body consisting of a ball of spores supported on 
a stalk.
The Dictyostelium genome encodes a single GSK-3 homologue, GskA. Expression of 
GskA is not essential for cell survival; gskA null cells are viable [194]. However, these 
cells do exhibit developmental abnormalities; slugs migrate shorter distances and fruiting 
bodies develop with an enlarged basal disc and small spore head [194].
The pre-stalk marker ecmB wras found to be ectopically expressed in gskA null cells 
[194]. Expression of ecmB and subsequent stalk cell differentiation is inhibited by cAMP 
while spore cell differentiation requires cAMP. Since loss of GskA results in aberrant 
ecmB expression and expansion of the proportion of stalk cells it would suggest that 
GskA normally acts as part of a pathway to repress stalk cell differentiation during 
development [194, 195].
In addition to inappropriate ecmB expression, Strmecki et al [196] reported that 193 
genes exhibited altered expression in the gskA null cell line. A list of these genes with 
details of the fold change in expression was provided in a personal communication with
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Gareth Bloomfield (Appendix Table A.l). Analysis of the gene ontology (GO) terms for 
these genes revealed that a significant number of proteins that were under-represented in 
the gskA nulls were associated with catabolic and proteolytic processes (Appendix Table
A.2). A significant number of genes that were reportedly over-represented are associated 
with processing of ATP, and biosynthetic and metabolic pathways linked to 
ribonucleotides (Appendix Table A.3).
The dual-specificity kinase, Zakl, was found to act downstream of cAR3 and directly 
phosphorylate Tyr214 of GskA (analogous to Tyr 216 of mammalian GSK-3 P) [80, 82]. 
As described previously, phosphorylation of Tyr214 is associated with an increase in 
kinase activity. It has been suggested that the combinatorial actions of ZAK1 and an un­
identified tyrosine phosphatase may act to differentially regulate GskA activity during 
development and as such direct differential expression of cell type markers[81].
Despite the identification of a role for GskA during development and the characterization 
of the downstream consequences of its loss, only a single GskA substrate has been 
identified; the transcription factor STATa. Phosphorylation of STATa by GskA is 
associated with increased nuclear export [188]. A comprehensive list of STATa target 
genes is not yet available so it is unclear whether the affects on gene expression seen in 
the gskA null cell line can be solely attributed to mis-regulation of STATa activity. 
However, given the large number of GSK-3 substrates identified in other systems this is 
unlikely.
There is emerging evidence that GskA activity may be directed towards specific 
substrates by interacting with binding proteins; specific point mutations (V267G and 
E268R) introduced into the scaffold-binding region of mammalian GSK-3 p were found 
to completely abrogate an interaction with Axin, while the ability of GSK-3 p to associate 
with FRAT was only minimally affected. To date, no Axin homologue has been 
identified in Dictyostelium. However, Fraser et al [98] reported that expression of 
mutated GskA V267G/E268R in wild type Dictyostelium (Ax2) cells resulted in an 
altered morphology: cells failed to polarize correctly, exhibited a rounder leading edge 
and very slow contraction of the cell rear. Indeed, the trailing edge of the cell was often 
dragged along as a bulge. Additional bulges and constrictions were also observed along
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Figure 1.5 The Dictyostelium developmental cycle
In response to starvation, cells aggregate together using cAMP as a chemo-attractant, 
forming a loose aggregate after approximately 10 hours. T hese aggregates becom e  
tighter over the next few hours and form a finger-like structure. T hese finger-like 
structures frequently topple over to form pseudoplasmodium or ‘slu gs’, which migrate 
towards a source of light. Upon finding favourable conditions a slug will re-enter 
development and over the next 8 hours undergo terminal differentiation to form a 
mature fruiting body.
This image is used with permission of copyright holders
(Copyright, M.J. Grimson & R.L. Blanton, Biological S c ien ces  Electron Microscopy 
Laboratory, T exas Tech University)
18 hours 
Mexican hat 20-22 hours " 
Early culm inants
10 hours  
L o o se  aggregate
12~hou rs 
Tight 
aggregate
14- liours 
Tipped 
>  aggregate
Mfgrating slug
32
the body of the cell. The dominant effect of expressing this mutated protein could lead 
one to propose that GskAs role(s) in Dictyostelium is directed through the formation of 
one or more multi-protein complexes.
1.13 Dictyostelium chemotaxis
Chemotaxis, the directed migration of cells through a gradient of signalling molecules, is 
a dynamic process that requires directional sensing, cell polarization, adhesion and 
motility (reviewed in [197-199]).
This process has been extensively studied in Dictyostelium. In the absence of a chemo- 
attractant Dictyostelium cells extend pseudopodia at random. However, cAMP 
stimulation was found to lead to localized F-actin polymerization at the leading edge of 
the cell and formation of an actomyosin network at the rear [200]. This actomyosin 
network contains myosin II and provides the contractile force that helps release the cell 
from the substratum, allowing the posterior to move forward [201, 202]. Myosin II was 
also found along the lateral sides of cells, where it increases the cortical tension, 
providing a physical barrier restricting the formation of lateral pseudopodia [200]. 
Efficient chemotaxis during Dictyostelium development requires cells to detect and 
respond to extracellular cAMP. Multiple signalling pathways are involved in directing 
chemotaxis, including the PI3K/ PI(3,4,5)P3 signalling pathway. The cAMP receptors 
and heterotrimeric G-proteins responsible for binding cAMP and transmitting the signal 
to downstream effectors were found to be uniformly distributed over the cell surface 
[203, 204]. Binding of cAMP to its receptor led to the localized activation of Ras, which 
in turn activated phosphatidylinositol-3-kinase (PI3K) [205]. Following Ras activation, 
PI3K was recruited to the membrane where it is responsible for the phosphorylation of 
PI(4,5)P2 to form PI(3,4,5)P3 [206-208]. Concurrently, PTEN, the phosphatase 
responsible for de-phosphorylating PI(3,4,5)P3 to form PI(4,5)P2, dissociated from the 
plasma membrane at the leading edge and was restricted to the lateral sides and rear of 
the cell [207, 208]. These events led to the localized synthesis and accumulation of 
PI(3,4,5)P3 at the leading edge of the cell and subsequent F-actin polymerization.
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PI(3,4,5)P3 was found to recruit pleckstrin homology (PH) domain-containing proteins, 
such as cytosolic regulator of adenylate cyclase (CRAC), PhdA and PkbA to the plasma 
membrane. Indeed, the localized accumulation of PI(3,4,5)P3 has frequently be visualized 
by through expression of this PH domain fused to GFP [209-214].
Although the precise mechanisms by which PI(3,4,5)P3 accumulation promotes F-actin 
polymerization remain unclear it is likely that this ability to locally concentrate PH- 
domain containing-proteins is pivotal; loss of PhdA or PkbA led to a reduction in actin 
polymerization and cellular polarization respectively[215, 216].
Cellular polarization defined by the asymmetric accumulation of PI(3,4,5)P3 at the 
leading edge of the cell and PTEN at the rear became further pronounced over time 
through the ability of PI3K to associate with, and become concentrated at sites enriched 
in cortical F-actin. Cellular polarization also involved the rearrangement of microtubules 
to enable motor proteins such as dynein and kinesin to perform directed membrane 
trafficking, and reorientation of the microtubule-organizing centre (MTOC) towards the 
direction of migration.
Lithium, a GSK-3 inhibitor, has been shown to affect chemotaxis, and it has been 
proposed that this affect may be mediated through inhibition of GSK-3 [217]. However, 
until recently this suggestion has not been explored further (See Chapter 4 for details).
1.14 Dictyostelium Cytokinesis
Cytokinesis involves a highly co-ordinated series of events that leads to the formation of 
two daughter cells [218-220] (Figure 1.6). Initially, a mitotic spindle forms and 
chromosomes become aligned along the equator of the cell. During anaphase, as the 
chromosomes separate and move towards opposite poles of the cell, the contractile ring, 
consisting of actin filaments interspersed with myosin II, accumulates equatorially at the 
cell cortex. Myosin II-dependent constriction of the contractile ring causes furrowing of 
the cell membrane and as telophase progresses the cleavage furrow constricts so that only 
a cytoplasmic bridge links the two daughter cells. Finally, the two cells are separated 
following scission of this cytoplasmic bridge. This method of cytokinesis is termed 
‘cytokinesis A’.
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In Dictyostelium, cells that lacked the gene encoding myosin II heavy chain (mhcA) or 
had the mhcA gene silenced by over-expression of antisense RNA failed completely to 
undergo cytokinesis when grown in shaking culture [221, 222]. These cells increased in 
size and accumulated nuclei until they eventually lysed. However, these cells were viable 
when grown on a solid surface [221, 222]. Neujahr et al [223, 224] report that when 
grown on a solid surface these cells were capable of forming a cleavage furrow and 
divided via a process termed ‘cell-cycle coupled, adhesion dependent cytokinesis’ or 
‘cytokinesis B \ This method of cytokinesis was found to be an extremely robust process, 
despite taking approximately twice as long as cytokinesis A [225].
Nagasaki et al [226] reported that when these large, multinucleate mhcA null cells were 
allowed to adhere to a solid surface these cells rapidly underwent a series of divisions to 
become mono-nucleate. This method of cytokinesis was not linked to progression of the 
cell cycle, and involved the cells forming multiple leading edges that tore the cell into 
multiple fragments. This process was later termed ‘traction-mediated cytoflssion’ or 
‘cytokinesis C’ [226, 227].
More recently, a fourth method of cytokinesis has been described, ‘cytokinesis D’, which 
requires the assistance of a neighbouring cell. This neighbouring cell performs the role of 
‘midwife’ by chemotaxing towards the equator of the mitotic cell and passing over the 
intracellular bridge between daughter cells aiding severage [226, 228]. This method of 
completing cytokinesis is clearly different to typical scission and appears to occur at low 
frequency in Dictyostelium unless the pathways controlling Cytokinesis A and 
Cytokinesis B are both disrupted. Nagasaki et al [228] demonstrated that nearly half the 
cytokinesis events that occurred in mhcA null cells involved the attraction of a 
neighbouring cell to the cleavage region. Furthermore, Nagasaki et al [228] demonstrated 
that cells that lacked gene encoding the beta subunit of the trimeric G protein (Gp) and 
were incapable of chemotaxis, did not show such midwifery. The authors also 
demonstrated that in wild-type cells, PI(3,4,5)P3 became enriched in the anterior region 
of midwifmg cells, consistent with the view that this midwifery was directed by 
chemotaxis towards a source of cAMP.
The underlying signalling pathways responsible for mediating the different forms of 
cytokinesis remain largely unclear, however there is emerging evidence PI3K signalling
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performs a role in more than one method of cytokinesis. Janetopoulos et al [229] found 
that cells lacking both PI3K and PTEN activity (piJk1'2',pten null cells) failed to divide 
when grown in shaking culture. The authors demonstrated that in wild-type cells, Ras, 
PI3K and associated PI(3,4,5)P3 accumulation was uniformly suppressed at the onset of 
cytokinesis as cells rounded up [229, 230]. Concurrently, PTEN was found to be evenly 
distributed at the cellular cortex. As cells progressed through mitosis, PTEN localisation 
became limited to the developing furrow, which coincided with myosin II accumulation. 
Simultaneously, activated Ras and PI(3,4,5)P3 could be seen to gradually accumulate to 
the polar ruffles during spindle assembly, cell elongation, and cytokinesis [229, 230]. 
When the daughter cells separated from one another, cortically localized PI(3,4,5)P3 
increased dramatically, resulting in high levels of random pseudopod extension [230]. 
Cells lacking Gp (gfi-) still exhibited Ras activation, and associated PI3K / PI(3,4,5)P3
signalling, during cytokinesis, suggesting that a Gg-independent Ras/PI3K signalling 
pathway may perform a fundamental role in regulating cytokinesis A.
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Figure 1.6. Mechanisms of cytokinesis in Dictyostelium
Dictyostelium undergo cytokinesis via one of four proposed m odels. Cytokinesis A is a 
myosin-dependent, adhesion independent method while Cytokinesis B represents a 
myosin-independent, adhesion-dependent method. Cytokinesis C occurs when cells 
that have becom e multi-nucleate in shaking culture are returned to a solid surface. This 
form of cytokinesis occurs independent of position in the cell cycle (shown here at a 
lower ‘magnification’). Cytokinesis D requires the services of a midwife cell to complete 
cytokinesis.
Proteins implicated in each of these models are highlighted.
Based on a diagram in Uyeda, T.Q. and A. Nagasaki, Variations on a theme: the many 
m odes of cytokinesis. Curr Opin Cell Biol, 2004. 16(1): p. 55-60.
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1.15 Aims of this study%/
The aim of this study was to gain a better understanding of the role performed by GskA 
in Dictyostelium, and the mechanisms by which GskA activity is regulated. In order to 
achieve that aim I assessed and characterized the phenotype of a gskA null cell. I then 
expressed a series of GskA-GFP fusion proteins in a gskA null background and assessed 
the ability of each of these fusion proteins to rescue aspects of the gskA null phenotype.
Multiple roles for mammalian GSK-3 p have previously been identified and well 
characterised. Several mechanisms by which this protein can be regulated have also been 
identified. However, it still remains unclear whether GSK-3 p activity is 
compartmentalized to ensure separation of each role, or if a single stimulus co-ordinates 
multiple responses through a common pool of GSK-3 p. Compartmentalization of GSK- 
3p does occur through binding to scaffolding proteins that direct activity towards specific 
substrates, as seen with the Wnt signalling pathway. A Wnt signal transduction pathway 
has not been identified in Dictyostelium. However, there is emerging evidence that 
protein binding may also be important in directing the activity of GskA.
As part of this current study I investigated whether binding to specific proteins 
represented a general mechanism by which GSK-3 activity was regulated. Specifically, I 
attempted to identify novel GSK3P or GskA binding partners using affinity 
chromatography and mass spectrometry analysis.
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Chapter 2 
Materials and Methods
2.1 Cloning
Throughout this project, all plasmids constructed were primarily screened by restriction 
digest. All enzymes were supplied by New England Biolabs and used in the appropriate 
buffer. For screening of plasmid clones, approximately 0.5 pg of DNA from each was 
digested with enzyme and analysed by agarose gel electrophoresis. Clones to be used for 
protein expression were then subsequently sequenced. Ligations were carried out at room 
temperature for approximately 1-2 hours using T4 DNA ligase (New England Biolabs). 
Generally a 3:1 molar ratio of vector : insert was used.
2.1.1 Dictyostelium Vectors
pDXA GFP2
The pDXA GFP2 (Accession No. AF269235) vector contains coding sequence for the 
GFPmut2 variant of green fluorescent protein flanked by multiple cloning sites allowing 
incorporation of additional coding sequence to produce either N or C-terminal fusion 
proteins. GFPmut2 expression is under the control of the constitutive actin promoter 
actl5 [233]. This vector provides G418 resistance and contains Ddp2; a cis-acting 
extrachromosomal replication element. To enable extrachromosomal replication pDXA 
GFP2 must be co-transfected with the pREP vector, in the absence of pREP this vector 
will be maintained via chromosomal integration [234].
pDXA GskA-GFP2
H. Williams previously cloned the coding region of GskA into pDXA GFP2 via Kpnl and 
Nsil restriction sites, such that a GskA-GFP2 fusion protein was expressed under the 
control of actl 5.
pDXA GskA-GFP2 Y214G / pDXA GskA-GFP2 R96E / pDXA GskA-GFP2 K85R
H. Williams previously introduced separate point mutations into the coding region of the 
pDXA GskA-GFP2 vector using the Stategene QuikChange Site-Directed Mutagenesis 
Kit as per the manufacturers direction. Mutations were introduced to alter K85, R96 or 
Y214 of GskA to argenine (K85), glutamic acid (R96) and glycine (Y214) residues.
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2.1.2 Mammalian Vectors
pSK(-) GSK-3 p
The coding region of human GSK-3 p was previously cloned into the vector pSK(-) via 
EcoRl/HincII restriction sites, such that a C-terminally tagged 6xHis-GSK-3p fusion 
protein was encoded. This plasmid was a kind gift from the Woodgett lab.
pEGFP-N3
The pEGFP-N3 vector (Accession No. U57609) is commercially available from 
BDBioscience. This vector contains coding sequence for the EGFPmutl variant of green 
fluorescent protein, which contains the double-amino-acid substitution of Phe-64 to Leu 
and Ser-65 to Thr [235]. The coding sequence of the EGFP gene also contains more than 
190 silent base changes that correspond to human codon-usage preferences [236]. A 
multiple cloning sites located upstream of the EGFPmutl coding region allows 
incorporation of additional coding sequence to produce C-terminal fusion proteins. 
EGFPmutl expression is under the control of the constitutive CMV promoter. This vector 
confers G418 resistance.
pEGFP-N3-GSK-3 p
The coding region of GSK-3 p (lacking the STOP codon) was cloned into the pEGFP-N3 
vector via Ndel and Kpnl restriction sites, GSK-3 p-EGFPmutl fusion protein was 
expressed under the control of the CMV promoter.
pCR-Blunt II-TOPO GSK-3 P
A PCR product encoding the coding region of GSK-3 p, flanked 5’ by Ndel and Aflll 
restriction sites and 3" by a Kpnl restriction site, was introduced into the pCR-Blunt II- 
TOPO vector as per manufacturers instructions. This plasmid was used as an intermediate 
between PCR product and the pEGFP-N3-GSK-3p vector.
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pcDN A5/FRT /T O
The pcDNA5/FRT/TO vector is commercially available from Invitrogen and is designed 
for use with the Flp-In T-REx System. The pcDNA5/FRT/TO vector encodes a hybrid 
human cytomegalovirus (CMV) / Tetracycline Operator 2 (TetCb) promoter. Briefly, this 
promoter consists of a CMV immediate early enhance/promoter into which 2 copies of 
the Tet02 sequence have been inserted in tandem. These Tet02 sequences are 19 
nucleotides long each, and act to confer regulation by tetracycline to the promoter [237- 
241]. Down-stream of the CMV/Tet02 promoter is a multiple cloning site that allows 
incorporation of a gene of interest. The pcDNA5/FRT/TO vector also contains a single 
Flp recombinase target (FRT) site for Flp recombinase-mediated integration of the vector 
into the Flp-In T-REx HEK 293 host cell line when co-transfected with the pOG44 
vector. This vector confers hygromycin resistance.
pcDNA5/FRT/TO GSK-3 (3-GFP
The coding region of GSK-3 p-EGFPmutl was cloned into the pcDNA5/FRT/TO vector 
via Aflll and Notl restriction sites, such that a GSK-3 |3-EGFPmut 1 fusion protein was 
expressed under the control of the CMV/TetC>2 hybrid promoter.
pcDNA5/FRT/TO EGFPmutl
The coding region of EGFPmutl was cloned into the pcDNA5/FRT/TO vector via Kpnl 
and Notl restriction sites, such that the EGFPmutl protein was expressed under the 
control of the CMV/TetC>2 hybrid promoter.
pOG44
The pOG44 vector is a Flp recombinase expression vector, commercially available from 
Invitrogen and is designed to be used with the Flp-In T-REx System. When cotransfected 
with the pcDNA5/FRT/TO vector into the Flp-In 293 host cell line, the Flp recombinase 
expressed from pOG44 mediates integration of the pcDNA5/FRT/TO vector into the 
genome via Flp recombination target sites. The pOG44 vector encodes a CMV promoter, 
followed by a synthetic intron (to enhance expression of FLP gene) and FLP gene in 
series. This vector confers ampicilin resistance.
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pcDNA 3.1 FLAG-Axl
E. Fraser previously constructed a vector encoding a quadruple FLAG tagged portion of 
Axin (corresponding to amino acids 367-701) under the control of a CMV promoter. This 
plasmid contains a pcDNA3.1+ backbone (Invitrogen).
pcDNA 3.1 FLAG-Axl L521P
E. Fraser previously introduced point mutations into the coding region of the pcDNA 3.1 
FLAG-Axl vector using the Stategene QuikChange Site-Directed Mutagenesis Kit as per 
the manufacturers direction. A mutation was introduced to alter L521 of Axin to a proline 
residue.
pcDNA 3.1 FLAG-FRAT
E. Fraser previously constructed a vector encoding a quadruple FLAG tagged FRAT 
under the control of a CMV promoter. This plasmid contains a pcDNA3.1+ backbone 
(Invitrogen).
pcDNA 3.1 FLAG-FRAT K208A/E209Q
E. Fraser previously introduced point mutations into the coding region of the pcDNA 3.1 
FLAG-FRAT vector using the Stategene QuikChange Site-Directed Mutagenesis Kit as 
per the manufacturers direction. Mutations were introduced to alter K208 and E209 to 
alanine and glutamine residues respectively.
2.2 PCR
cDNA encoding GSK3(3 was amplified by PCR using the Pfu proofreading polymerase 
(Promega) as per the manufacturers instructions. The following primers were used: 
GC AGGCC AT AT GCTT A AGT GAT CAT GT C A / AC A ATT AT CG AT GGT GG AGTT G 
GAAGC. The PCR product was then gel-purified and cloned into pCR-Blunt II-TOPO 
(Invitrogen) before validation.
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2.3 Cell eulture
2.3.1 Dictyostelium cell culture
Dictyostelium cells were grown axenically in HL-5 medium (14 g/L proteose peptone, 7 
g/L yeast extract, 13.5 g/L glucose, 0.5 g/L Na2HPC>4 , 0.5 g/L KLLPO^pH 6.4.) 
(Formedium) for normal culture and antibiotic selections. All transformed cell lines were 
grown in the presence of 40 p,g ml*1 Geneticin (G418). The gskA null strain [194] was 
grown in the presence of 1 Opig ml*1 Blasticidin. Cells were also allowed to develop on 
SM agar plates (10 g/L proteose peptone, 1 g/L yeast extract, 10 g/L glucose, 1.9 g/L 
KH2PO4 , 1.3 g/L K2HPO4 .3 H2O, 0.49 g/L MgSC>4 , 17 g/L agar) on a lawn of Klebsiella 
aerogenes by standard methods.
For long-term storage of cell lines, cells were resuspended in freezing media at 10 cells 
ml' 1 then frozen at -80°C in 500pl aliquots in cryovials. Cells were restored from long­
term storage by rapidly defrosting and re-suspending them in axenic media before 
transferring to 9cm plate with 1% heat killed E.coli.
Except where otherwise stated, the Ax2 strain was used as wild-type and the (Ax2)!gskA 
null strain was used as the parent of all mutants. Cells were both starved and washed in 
KK2 buffer (16.5 mM KH2P 0 4, 3.8 mM K2HP04 pH 6.2). When required, cells were 
pelleted by centrifugation at 700 x g for 2 minutes.
2.3.2 Mammalian cell culture
  T*X   T ' l  /
The Flp-In T-REx 293 cell line is commercially available from Invitorgen and is 
derived from human embryonic kidney (HEK) -293 cells [242]. This parental cell line 
w?as obtained from the American Type culture collection (item number CRL-1573). The 
Flp-In T-REx 293 cell line has previously been transfected such that two cassettes have 
integrated randomly into the genome (Figure 2.1). The first of these cassettes encodes a 
LacZ-Zeocin fusion gene expressed from an SV40 promoter. The LacZ-Zeocin fusion 
gene incorporates an FRT site directly downstream of the ATG start codon. This cassette 
cofers Zeocin resistance to the cells that, following transfection (and integration through 
the aforementioned FRT site) of the pcDNA5/FRT/TO vector is lost.
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The second cassette encodes the Tetracycline repressor (TetR) gene under control of a 
CMV promoter, followed by a Blasticidin resistance gene under control of an SV40 
promoter. In the absence of tetracycline, the tetracycline repressor protein binds to and 
prevents expression from the CMV/Tet02 hybrid promoter located on the 
pcDNA5/FRT/TO vector.
Flp-In T-REx 293 cells were grown in D-MEM supplemented with 10% heat inactivated 
Fetal Calf Serum (Gibco), 1% Pen/Strep, 0.5% L-Glutamine 50mg/ml (GIBCO).
Prior to transfection, media was supplemented with lOOpg/ml zeocin and 12pg/ml 
blasticidin. Following transfection, media was supplemented with 300pg/ml hygromycin 
and 12mg/ml blasticidin.
For long-term storage of cell lines, cells were resuspended in freezing media at 107 cells 
ml-1 then frozen at -80°C in 1ml aliquots in cryovials. Cells were restored from long­
term storage by rapidly defrosting and re-suspending them in warm tissue culture media 
before transferring to T80 tissue culture flask (Nunc).
In all cases, except where otherwise stated, the Flp-In T-REx 293 cells was used as wild- 
type and is the parent of all mutants. When required, cells were pelleted by centrifugation 
at 750 x g for 5 minutes.
2.4 Transformations
2.4.1 Dictyostelium transformations
Cells were transformed by electroporation as previously described [243-245]. Briefly, 107 
cells, growing in log-phase were washed once in ice-cold electroporation buffer (50mM 
sucrose in KK2) before being resuspended to a final volume of 800pl in an 
electroporation cuvette. 20 pg of plasmid DNA was then added and incubated on ice for 
10 minutes. Cells were electroporated at lkV before a further 10 minute incubation on 
ice. The cells were then transferred into a 10cm petri dish and 8pi of salt solution (0.1M 
MgCE, 0.1M CaCE) added. After a further 20 minutes the cells were then finally 
resuspended in 10 ml of non-selective axenic media containing Streptomycin sulphate 
and 1% heat killed E. coll
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After 24 hours, cells were transferred into 6 x 96 well plates in the presence of 40 pg/ml 
G418. After approximately 2 weeks, multiple clones were selected and transferred into 
individual wells of a 24 well plate for screening.
2.4.2 Mammalian transformation
Cells were transfected using TransFectin™ lipid reagent (BioRad) as per the 
manufacturers instructions. Briefly, cells were seeded onto 6-well plates the day before 
transfection, such that they were approximately 80% confluent on the day of transfection. 
On the day of transfection, the cell media was aspirated and replaced with 2 ml media 
containing no antibiotics. Cells were allowed to settle for a minimum of two hours.
500pl of DNA-TransFectin complexes (2.2pg plasmid DNA; 10:1 ratio of pOG44 
plasmid to plasmid of interest, 8pl TransFectin reagent, all in 500pl Optimem) was added 
and cells were left for a further 4 hours. After 4 hours the media was aspirated off and 
replaced with antibiotic free media.
After 24 hours, cells were washed with PBS and treated with trypsin. Cells were 
resuspended in 3 ml of media and transferred to 9cm plates containing 7ml of antibiotic 
free media. Cells were incubated over night to allow them to recover from trypsin 
treatment and attach to the plate. After 24 hours, media was aspirated and replaced with 
media containing 300jig/ml hygromycin and 12pg/ml blasticidin.
After approximately 2 weeks, multiple clones were seen and transferred into individual 
wells of a 24 well plate for screening.
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Figure 2.1. Schematic 
representation of Flp-In T- 
REx system
A. The Flp-In T-REx 293 cell 
line are derived from HEK293 
cells and contain 2 cassettes  
integrated into their genom e. 
The first en cod es a LacZ- 
Zeocin fusion protein 
downstream of an FRT site. 
The second encodes the 
Tetracycline repressor (TetR) 
protein under the control of a 
CMV promoter.
The plasmid pcDNA5/TO/FRT 
GSK3|3-GFP en cod es GSK3p- 
GFP under the control of a 
CMV/Tet operator fusion 
promoter.
B. Following transfection into 
the Flp-In T-REx 293 cells, the 
PCDNA/TO/FRT Gsk3p-GFP 
plasmid undergoes site 
directed integration into the 
genom e via a Flp recombinase 
reaction.
C. The resultant T-REx 
GSK3p-GFP cell line contains 
a stably integrated cassette  
encoding the GSK3p-GFP 
fusion. In the ab sen ce of 
Tetracycline or tetracycline 
derivative the protein product 
of the TetR gen e sits on the 
Tet Operator promoter 
seq u en ce preventing gene  
expression. In the presence of 
Tetracycline the Tet repressor 
protein undergoes a 
conformational change such 
that it can no longer bind to the 
Tet Operator sequence and 
gen e expression of the 
GSK3|3-GFP fusion can occur.
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2.5 Screening of clones
2.5.1 Screening of Dictyostelium clones
After the isolation of independent clones, each was grown in 1ml culture in a 24 well 
plate. When each well became confluent, they were resuspended in KK2. After 2 hours, 
cells were resuspended and 40 pi transferred to a glass-bottomed chamber slide (Lab- 
Tek) containing 1 ml KK2. Cells were then left for 30 minutes to attach and recover 
before the KK2 was aspirated and replaced with fresh KK2.
Cells were observed for GFP fluorescence using the Olympus 1X71 inverted microscope 
with a 20x objective, fluorescent cells were selected for further analysis.
2.5.2 Screening of T-REx 293 GSK3p-GFP and GFP cell lines
After the isolation of independent clones, each was grown in duplicate in a 24 well plate. 
When cells were 80% confluent one of each duplicate was treated with 0.5mg/ml 
doxycyclin for 4 hours. Following incubation, media was aspirated from w-ells cells and 
cells were harvested in 4xNuPage buffer and assessed by western blot.
Cells were further assessed to ensure integration had occurred into the correct site using 
the LacZ assay (see below7).
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2.6 Immunofluorescence
2.6.1 Dictyostelium immunofluorescence
For immunofluorescence imaging, cells were seeded onto 16mm glass coverslips, and 
allowed to adhere for 30 minutes. Coverslips were then washed twice in KK2 and fixed 
in 3% paraformaldehyde (in water) for 20 minutes. Cross-linking was quenched in 30mM 
glycine. Coverslips were then washed three times with PBS and cells were permeabilised 
in 0.1% TritonX (in PBS) for 5 minutes. Slides were washed in PBS and incubated in 
3%BSA (in PBS) for 1 hour. Samples were then stained with M2-mouse cx-Sgg primary 
antibody (1:1,000 dilution Upstate) for one hour, washed three times, and then a Alexa 
Fluor 647-conjugated a-mouse IgG secondary antibody (1:1,000, Sigma) for a further 
hour. Coverslides were washed three times (PBS) and incubated with lpg/ml 4\6- 
Diamidino-2-phenylindole dihvdrochloride (DAPI) in water. Coverslips were then 
washed in water and mounted on slides using Mowiol. Images were taken using the 
Olympus 1X71 inverted microscope with an oil immersion 60x objective.
2.6.2 Mammalian immunofluorescence
For immunofluorescence imaging, cells were seeded onto 16mm glass coverslips, and 
cultured for 24 hours before being induced for a further 24 hours with 2ng/ml 
doxycycline. Coverslips were washed twice in PBS and fixed in 3% paraformaldehyde 
(in PBS) for 20 minutes. Cross-linking was quenched in 30mM glycine. Coverslips were 
then washed three times with PBS and cells were permeabilised in 0.1% TritonX (in 
PBS) for 5 minutes. Slides were washed in PBS and incubated in 3%BSA (in PBS) for 1 
hour. Samples were then stained with rabbit ot-GSK3|3 primary antibody (1:1,000 dilution 
BD Biosciences) for one hour, washed three times, and then a Alexa Fluor 647- 
conjugated a-rabbit IgG secondary antibody (1:1,000, Sigma) for a further hour. 
Coverslides were washed three times (PBS) and incubated with lpg/ml 4’,6-Diamidino- 
2-phenylindole dihydrochloride (DAPI) in water. Coverslips were then washed in water 
and mounted on slides using Mowiol. Images were taken using the Olympus 1X71 
inverted microscope with an oil immersion 60x objective.
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2.7 Western blot
2.7.1 Dictyostelium western blots
For western blotting, 107 cells were lysed in 500j.il lysis buffer (lOOmM NaCL 50mM 
Tris, 0.5% NP-40, 10% glycerol) supplemented with a Roche complete inhibitor tablet. 
500pil of NuPage buffer (50 mM Tris-HCL pH 6.8, 100 mM dithiothreitol, 2% SDS, 
0.1% bromophenol blue, 10% glycerol) was added and samples were boiled for 5 minutes 
to denature proteins before running on a 4-12% Bis-Tris gel (Invitrogen). The protein 
from 1.5xl05 cells was loaded per lane. Western blotting was then carried out using 
standard methods. A table giving details of the antibodies used in this study can be found 
below. In all cases Pierce ECL reagent was used as HRP substrate.
2.7.2 Mammalian western blots
Unless otherwise stated, cells from a one well of a 6-well dish were lysed 500j.il of 
NuPage buffer (50 mM Tris-HCL pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% 
bromophenol blue, 10% glycerol) and samples were boiled for 5 minutes to denature 
proteins. Samples were then passed through a fine-gauge needle several times before 
running on a 4-12% Bis-Tris gel (Invitrogen). lOjxl wras loaded per lane.Western blotting 
was then carried out using standard methods. A table giving details of the antibodies used 
in this study can be found below. In all cases Pierce ECL reagent was used as HRP 
substrate.
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Antibody Species raised in
Dilution used 
a t Supplier
Anti-CSRP2 Chicken 1:1000 Sigma
Anti-CSNK2A2 Goat 1:1000 Sigma
Anti-Sgg (Used 
to detect GskA) Mouse 1:1000 UpState
Anti-GAP-DH Mouse 1:1000 Sigma
Anti-GFP Mouse 1:10000 Roche
Anti-alpha
tubulin Mouse 1:1000 Sigma
Anti-LimE Mouse 1:10 c /o  Prof. Annette Miiller-Taubenberger
Anti-HNRNP Mouse 1:1000 Sigma
Anti-GSK-3|3 Rabbit 1:1000 BD Biosciences
Anti-FttB Rabbit 1 :10000 c /o  Prof. Annette Miiller-Taubenberger
Anti-MLCKA Rabbit 1:2000 c /o  Prof. John Spudich
Anti-TalB Rabbit 1 2000 c /o  Prof. Kei Inouye
Anti-SUPT16h Rabbit 1 1000 Sigma
Anti-Sod 1 Rabbit 1 1000 Sigma
Anti-mouse Horse 1 10000 VectaLabs
Anti-rabbit Goat 1 10000 VectaLabs
Anti-goat Horse 1 10000 VectaLabs
Table 2.1 List of antibodies used in this study
2.8 FACS sorting of Dictyostelium cells
FACS sorting of Dictyostelium cells was performed with the help of Kirsty Richardson 
using the FACS Aria cell sorter from BD Biosciences. Following transformation, cells 
designated for FACS analysis were not transferred to 96-well plates but were left to grow 
in a 9cm dish. After approximately 2 weeks, when multiple colonies were visible, the 
selective axenic media was aspirated and replaced with low fluorescent media (llg /L  
Glucose, 0.68g/L KH2PO4, 5g/L Casein Peptone, 6 .8 mg/L NH4CI, 37.1mg/L MGCI2 ,
l.lmg/L CaCl2, 8.11mg/L FeCl3, 4.48mg/L Na2-EDTA, 2.30mg/L ZnS04, l.llm g/L  
H3B 03, 0.51mg/L MnC12.4H20 , 0.17mg/LCoCl2, 0.15mg/L CuS05.5H20  O.lmg/L
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(NH4)6M07024.4H20) (Formedium). 24 hours later cells were harvested and washed 
twice in ice cold KK2 before being resuspended to a final volume of 107 cells/ml and 
held on ice. Immediately prior to sorting, cells were passed through a sterile 40pm cell 
strainer (BD Biosciences) to prevent cell clumping. Cells were loaded into the FACS 
Aria cell sorter and separated based on GFP fluorescence. Following sorting, cells wrere 
centrifuged at 700 g, and resuspended in non-selective axenic media containing 
Streptomycin sulphate and 1% heat killed E. coll Cells wrere transferred to w7ell of a 6- 
well dish and allowed to recover.
After 24 hours, cells were transferred into 6x96 well plates in the presence of 40 pg/ml 
G418. After approximately 2 wreeks, multiple clones wrere selected and transferred into 
individual wells of a 24 wrell plate for screening.
2.9 Mammalian LacZ Assay
LacZ assays w'ere perfonned using the Beta-Glo system (Promega). Cells were cultured 
to -80% confluency before being seeded into 96 well plates at a density of 3X103 
cells/ml. 48 hours later, cells were lysed by the addition of 30pl Glo-lysis buffer 
(Promega) and shaken at room temperature for 30 minutes. 30pi of Beta-Glo reagent was 
the added to the cell lysate, wftich was shaken for a further thirty minutes at room 
temperature before luminescence levels w'ere assessed using the FluoStar Optima.
2.10 Mammalian Wst-1 Assay
Wst-l assays were performed using the ‘Cell Proliferation Reagent WST-1' (Roche). 
Cells were cultured to -80% confluency before being seeded into 96 well plates at a 
density of 3X105 cells/ml, reference wells containing media but no cells were included on 
each plate. 24 hours later, cells wrere induced with Ong/ml, 5ng/ml, lOng/ml, 20ng/ml, 
40ng/ml, 60ng/ml, 80ng/ml or lOOng/ml doxycycline. Cells were incubated for 24 or 48 
hours. 10ml of Wst-1 reagent w7as added to each well and plates wrere incubated for a 
further hour. Absorbance readings at 450nm and 590nm were taken using the FluoStar 
Optima.
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2.11 Kinase Assay
Dr William Ryves synthesized both the pre-phosphorylated and un-phosphorylated forms 
of the GSM peptide substrate used in this study. The GSM peptide has the following 
sequence -  RRRPASVPPSPSLSRHSSHQRR where S indicates a phospho-serine 
introduced during synthesis.
2.11.1 Dictyostelium kinase assay
Cells were seeded onto SM agar with Klebsiella aerogenes at a density of 106 cells/ml 
and cultured for 48hours. Cells were then harvested and washed in KK2 to remove any 
bacteria before being pelleted, frozen on dry ice and lysed (lysis buffer: 150mM NaCl, 
50mM Tris, 0.5% NP-40, 10% glycerol supplemented with a Roche complete inhibitor 
tablet). Samples w7ere held on ice for 20 minutes before being centrifuged at 4000rpm and 
being passed through a 0.2pM filter.
Samples were normalized based on their GFP fluorescence. Briefly, 50ul of neat lysate 
and lysate diluted 1:2 and 1:4 were added in triplicate to a black-walled 96 well plate 
with a series of GFP standards (Roche). Fluorescence levels were assessed using the 
FluoStar Optima.
Lysates containing 3 5 jig GFP were added to 20jil GFP-Trap coupled to agarose beads 
(Chromotek) and incubated for 1 hour at 4°C. Beads were washed 3 times with kinase 
buffer (150mM NaCl, 50mM Tris, 10% glycerol) and re-suspended in 400jil of kinase 
buffer. lOjixl of each bead suspension was added in triplicate to a black-walled 96 well 
plate. (20pl of the bead suspension was removed to a separate tube, centrifuged to 
remove buffer and re-suspended in 20jil NuPage buffer, boiled for 5 minutes and lOpl 
wras run on a 4-12% Bis-Tris gel for western blot to confirm equal loading.)
40pl of a master mix containing 50jiM ATP, 12.5|iM MgCL and 425 jiM GSM substrate 
was added to each well and samples were incubated at room temperature for 32 minutes. 
Where activity was measured over a series of time points samples were incubated for 2, 
4, 8, 16, 32 or 64 minutes. 50pl of Kinase-Glo reagent (Promega) was added directly to 
the 96-w7ell plate and was incubated at room temperature for a further 30 minutes. 
Luminescence levels were assessed using the FluoStar Optima.
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2.11.2 Mammalian kinase assay
Cells were cultured to -50% confluency in 4 xT180 flasks before being induced with 
2ng/ml doxycycline for 24 hours. Cells were harvested, wrashed in PBS and 5x107 cells 
were pelleted, frozen on dry ice and lysed (lysis buffer: 150mM NaCl, 50mM Tris, 0.5% 
NP-40, 10% glycerol supplemented with a Roche complete inhibitor tablet). Samples 
were held on ice for 20 minutes before being centrifuged at 4000rpm and being passed 
through a 0.2pM filter.
Lysates were added to 20pl of GFP-Trap coupled to agarose beads (Chromotek) and 
incubated for 1 hour at 4°C. Beads were washed 3 times with kinase buffer (150mM 
NaCl, 50mM Tris, 10% glycerol) and re-suspended in 400pl of kinase buffer. lOpl of 
each bead suspension was added in triplicate to a black-walled 96 wrell plate. 40pl of a 
master mix containing 50pM ATP, 12.5pM MgCty and 425 pM GSM substrate was 
added to each well and samples were incubated at room temperature for 2, 4, 8, 16, 32 or 
64 minutes. 50pi of Kinase-Glo reagent (Promega) was added directly to the 96-well 
plate and was incubated at room temperature for a further 30 minutes.
2.12 Dictyostelium Cell Sizing
Cells were grown to 80% confluency before being washed in KK2 and resuspended at a 
density of 106 cells/ml. 30pl of each cell sample was transferred to a glass-bottomed 
chamber slide (Lab-Tek) containing 1 ml axenic media and allowed to adhere for 30 
minutes. 5 Timelapse images were taken 5 seconds apart using the Olympus 1X71 
inverted microscope with a 20x objective.
2.13 Dictyostelium Multinucleate Assay
Cells were cultured to 80% confluency before being wrashed in KK2 and re-suspended in 
fresh axenic media at a density7 of 105 cells/ml. Cells were grown in shaking culture for 
48 hour before being seeded onto 16mm glass coverslips, and allowed to adhere for 10 
minutes. Coverslips w7ere then washed in KK2 and fixed in methanol at -20°C for 4 
minutes. Coverslips were then washed in KK2, and incubated with lpg/ml 4\6- 
Diamidino-2-phenylindole dihydrochloride (DAPI) in water for 5 minutes. Coverslips
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were washed in water and mounted on slides using Mowiol. Images were taken using the 
Olympus 1X71 inverted microscope with a 20x objective. To ensure that data were not 
biased, 25 images (creating a 5 by 5 grid) were taken at a time where only the initial field 
of view is defined.
2.14 Dictyostelium Cell Proliferation Assay
To assess proliferation rates in shaking culture cells were cultured to 80% confluency 
before being wrashed in KK2 and resuspended in fresh axenic media at a density of 105 
cells/ml. Cells were grown in shaking culture and samples were periodically removed and 
counted in triplicate on a haemocytometer (3 separate samples of lOpl each, counted 
once).
To assess proliferation rates on SM agar, cells were cultured to 80% confluency before 
being washed in KK2 and re-suspended at 105 cells/ml. Ipl of cells was spotted onto an 
SM agar plate spread with Klebsiella aerogenes. Each plate was prepared with 3 separate 
repeats for each cell line and a total of 6 plates prepared, creating 18 repeats for each cell 
line.
2.15 Dictyostelium Development assay
Cells were cultured to 80% confluency before being washed in KK2 and resuspended in 
fresh KK2 at a density of 106 cells/ml. 12-well plates were prepared containing 200pl 
non-nutirent KK2 agar in each well. 1ml of cells was seeded into each well and allowed 
to adhere for 30 minutes before excess liquid was aspirated off. Timelapse images of 
cells were taken ever}- 5 minutes, under dark-field conditions using Olympus 1X71 
inverted microscope with a 4x objective. The availability of an automatic stage made it 
possible to take multiple fields of view and as such 9 images, creating a 3 by 3 grid, were 
taken for each sample. Images were processed using ImageJ to create a ‘montage movie’ 
consisting of all 9 fields of view.
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2.16 Dictyostelium cAMP pulse assay
Cells were cultured to 80% confluency before being washed in KK2 and re-suspended in 
fresh KK2 at a density of 106 cells/ml. 6-well plates were prepared containing 1ml of 
non-nutirent KK2 agar in each well. 5ml of cells was seeded into each well and allowed 
to adhere for 30 minutes before excess liquid was aspirated off. Timelapse images of 
cells were taken every 30 seconds, under dark-field conditions using an Olympus 1X71 
inverted microscope with a 4x objective. The availability of an automatic stage made it 
possible to take multiple fields of view and as such 9 images, creating a 3 by 3 grid, were 
taken for each sample. Images were processed using ImageJ to create a ‘montage movie' 
consisting of all 9 fields of view.
2.17 Affinity purifications
2.17.1 Dicytostelium affinity purifications
Non-crosslinked samples
Cells were seeded onto SM agar with Klebsiella aerogenes at a density of 106 cells/ml 
and cultured for 48hours. Cells wrere harvested and washed in KK2 to remove any 
bacteria before being resuspended in fresh KK2 at a density of 108 cells/ml and cultured 
in shaken suspension for 4 hours. After 4 hours, 50ml of each cell suspension was 
pelleted and frozen on dry ice before being lysed in 10ml lysis buffer (150mM NaCl, 
50mM Tris, 10% glycerol supplemented with a Roche complete inhibitor tablet). 
Samples were incubated on ice for 20 minutes, centrifuged at 16,000rpm and passed 
through a 0.2pM filter. lOOpl of protein-G sepharose beads (GE Healthcare) covalently 
bound to anti-GFP antibody (Roche)(at a concentration of 2mg/ml) were added to each 
supernatant, these were incubated at 4°C for 1 hour. Beads were pelleted at 500g and 
washed 3 times with wash buffer (150mM NaCl, 50mM Tris, 10% glycerol supplemented 
with a Roche complete inhibitor tablet) before being resuspended in 50pl glycine (0.1M, 
pH2.5). Samples were incubated for 5 minutes at room temperature before being 
centrifuged at 500g. The supernatant was removed to a separate tube containing 7.5 pi 
Tris-HCl (1.5M, pH9.0). The elution process was repeated and 50pi of NuPage buffer 
was added to each sample, which were then boiled. Samples were dried in a vacuum
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before being reconstituted with 20f.il water and loaded onto a 4-12% Bis-Tris gel. This 
gel was then stained with a colloidal coomassie stain (Invitrogen).
Cross-linked samples
Cells were prepared as before. However, following the step where cells were shaken in 
KK2 for 4 hours, 50ml of each cell suspension was pelleted, re-suspended in 50ml 1% 
Paraformaldahvde (in water) and incubated for 20 minutes. Cross-linking was quenched 
by the addition of glycine (to a final concentration of 1.25mM) and a further incubation 
of 5 minutes. Samples were then pelleted and washed twice in KK2 before being lysed in 
10ml lysis buffer (150mM NaCl, 50mM Tris, 0.1% NP-40 and 10% glycerol 
supplemented with a Roche complete inhibitor tablet). Samples were incubated on ice for 
20 minutes, centrifuged at 16,000rpm and passed through a 0.2pM filter. 50pl of a GFP- 
Trap coupled to agarose beads (Chromotek) were added to each supernatant, these were 
incubated at 4°C for 1 hour. Beads were pelleted at 500g and washed 3 times with wash 
buffer (150mM NaCl, 50mM Tris, 10% glycerol supplemented with a Roche complete 
inhibitor tablet) before being resuspended in 50pl NuPage buffer. Samples were boiled at 
95° for 5 minutes (this reversed the cross-linking) and loaded onto a 4-12% Bis-Tris gel 
which was subsequently stained with a colloidal coomassie stain (Invitrogen).
Bands of interest were excised within a lamina flow-hood and shipped to the FingerPrints 
Proteomics Facility at Dundee University for analysis (see below for details).
2.17.2 Mammalian affinity purifications
Pull-downs to confirm interaction with known binding partners
T-REx GSK3J3-GFP and T-REx GFP cells were cultured to 60% confluency in 9cm 
dishes in media containing no antibiotics before being were transfected using TransFectin 
lipid reagent (BioRad) as per the manufacturers instructions. Plasmids encoding FLAG- 
Axinl (367-701), FLAG-Axin (367-701) L392P, Flag-FRAT and Flag-FRAT 
K208A/E209Q were each separately transfected into both cell lines; 3ml of DNA- 
TransFectin complexes (lOjig plasmid DNA and 50j.il TransFectin reagent each in 1.5ml 
Optimem) was added and cells were left for 4 hours. After 4 hours the media was 
aspirated off and replaced with antibiotic free media.
57
24 hours later cells were induced with 2ng/ml doxycycline and incubated for a further 24 
hours. Cells were then washed off the plate in 10ml PBS and were washed a further twice 
in PBS before being pelleted and lysed in 5ml of lysis buffer: 150mM NaCl, 50mM Tris, 
0.5% NP-40, 10% glycerol supplemented with a Roche complete inhibitor tablet. 
Samples were incubated on ice for 20 minutes, centrifuged at 4000rmp and passed 
through a 0.2pM filter. 20pl of GFP-binder beads (Chromotek) were added to each 
supernatant and were incubated at 4°C for 1 hour. Beads were centrifuged at 500g and 
washed twice in wash buffer 1 (150mM NaCl, 50mM Tris, 10% glycerol supplemented 
with a Roche complete inhibitor tablet), twice in wash buffer 2 (as wash buffer 1 but 
300mM NaCl) and twice in wash buffer 3 (as wash buffer 1 but 600mM NaCl). Beads 
were re-suspended in 50pl NuPage buffer and boiled for 5 minutes to release and 
denature bound proteins. At each stage 100 pi samples were taken and added to an equal 
amount of NuPage buffer to be loaded for western blot analysis.
Non-crosslinked samples
T-REx GSK3(3-GFP and T-REx GFP cells were cultured to 70% confluency before being 
induced with lOng/ml doxycycline for 4 hours. Cells were harvested and lysed in 10ml 
lysis buffer (150mM NaCl, 50mM Tris, 10% glycerol supplemented with a Roche 
complete inhibitor tablet). Samples were incubated on ice for 20 minutes, centrifuged at 
16,000rpm and passed through a 0.2pM filter. 100pi of protein-G sepharose beads (GE 
Healthcare) covalently bound to anti-GFP antibody (Roche)(at a concentration of 
2mg/ml) were added to each supernatant, these were incubated at 4°C for 1 hour. Beads 
were pelleted at 500g and washed 3 times with wash buffer (150mM NaCl, 50mM Tris, 
10% glycerol supplemented with a Roche complete inhibitor tablet) before being 
resuspended in 50pl glycine (0.1M, pH2.5). Samples w^ ere incubated for 5 minutes at 
room temperature before being centrifuged at 500g. The supernatant wfas removed to a 
separate tube containing 7.5pl Tris-HCl (1.5M, pH9.0). The elution process was repeated 
and 50pl of NuPage buffer was added to each sample, which w;ere then boiled. Samples 
were dried in a vacuum before being reconstituted with 20pi wrater and loaded onto a 4- 
12% Bis-Tris gel. This gel was then stained with a silver stain (GE Healthcare).
58
Cross-linked samples
T-REx GSK3P-GFP and T-REx GFP cells were cultured to 70% confluency before being 
induced with 2ng/ml doxycycline for 24 hours. Cells were harvested and re-suspended at 
a density7 of 107 cells/ml in 1% Paraformaldahyde (in PBS) and incubated for 20 minutes. 
Cross-linking was quenched by the addition of glycine (to a final concentration of
1.25mM) and a further incubation of 5 minutes. Samples were then pelleted and washed 
twice in PBS before being lysed in 10ml lysis buffer (150mM NaCl, 50mM Tris, 0.1% 
NP-40 and 10% glycerol supplemented with a Roche complete inhibitor tablet). Samples 
were incubated on ice for 20 minutes, centrifuged at 16,000rpm and passed through a 
0.2pM filter. 50j.il of GFP-binder beads (Chromotek) were added to each supernatant, 
these were incubated at 4°C for 1 hour. Beads were pelleted at 500g and washed 3 times 
with wash buffer (150mM NaCl, 50mM Tris, 10% glycerol supplemented with a Roche 
complete inhibitor tablet) before being resuspended in 50j.il NuPage buffer. Samples were 
then boiled and loaded onto a 4-12% Bis-Tris gel which was subsequently stained with a 
colloidal coomassie stain (Invitrogen).
2.18 SILAC
Cells were grown in custom-made DMEM (minus arginine and lysine; Pierce) 
supplemented with 10% dialvzed fetal calf serum (Pierce) and 1% 
penicillin/streptomycin, 12mg/ml blasticidin (both Invitrogen) and 300jig/ml hygromycin 
(Roche). L -arginine (84 p g/ml) and L- lysine (146 p g/ml lysine) were added to the Tight’ 
media, while L -arginine 13 C and L -lysine 13 C were added to the ‘heavy’ media at the 
same concentrations (all Pierce). T-REx GSK3b-GFP cells were cultured in ‘heavy' media 
while T-REx GFP cells were cultured in Tight’ media. Both cell lines were cultured for 8 
cell doublings to ensure complete incorporation of isotopic amino acids [246, 247].
T-REx GSK3P-GFP and T-REx GFP cells were cultured to 50-60% confluency before 
being induced with 2ng/ml and 0.4ng/ml doxycycline respectively for 24 hours. Cells 
were harvested and washed twice in PBS before being resuspended in 10ml lysis buffer 
(50mM NaCl, lOmM Tris, 0.5% NP-40 supplemented with a Roche complete inhibitor 
tablet) and incubated for 20 minutes on ice. Samples were spun at 4000rpm for 15
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minutes before being passed through a 0.2pM filter. Total protein levels were measured 
using the BCA protein quantification kit (Pierce). Samples containing 27mg total protein 
were combined with 100pi GFP binder beads (Chromotek) and incubated at 4°C for 1 
hour. Beads were spun briefly at 300g, washed once in PBS and re-suspended in 30ml 
NuPage buffer. Beads were boiled for 3 minutes, NuPage buffer removed and shipped on 
ice to Dundee Cell Products for analysis.
2.19 Mass Spectrometry Analysis 
(Performed by FingerPrints Proteomics Facility)
2.19.1 In-gel digestion
Each gel slice was subjected to in-gel digestion with trypsin. The resulting tryptic 
peptides were extracted by 1% formic acid, acetonitrile, lyophilized in a speedvac, 
(Helena Biosciences) and resuspended in 1% formic acid.
2.19.2 LC-MS/MS
Trypsin digested peptides were separated using an Ultimate U3000 (Dionex Corporation) 
nanoflow Liquid Chromatography (LC)-system consisting of a solvent degasser, micro 
and nanoflow pumps, flow control module, UV detector and a thermostated autosampler. 
10 pi of sample (a total of 2 pg) was loaded with a constant flow of 20pl/min onto a 
PepMap C l8 trap column (0.3 mm id x 5 mm, Dionex Corporation). After trap 
enrichment peptides were eluted off onto a PepMap C l8 nano column (75 pm x 15 cm, 
Dionex Corporation) with a linear gradient of 5-35% solvent B (90% acetonitrile with 
0.1% formic acid) over 65 minutes with a constant flow' of 300 nl/min. The HPLC system 
was coupled to a Linear Trap Quadruple (LTQ) Orbitrap XL (Thermo Fisher Scientific 
Inc) via a nano Electro-spray (ES) ion source (Proxeon Biosvstems). The spray voltage 
was set to 1.2 kV and the temperature of the heated capillary was set to 200°C. Full scan 
MS survey spectra (m/z 335-1800) in profile mode were acquired in the Orbitrap with a 
resolution of 60,000 after accumulation of 500,000 ions. The five most intense peptide 
ions from the preview scan in the Orbitrap were fragmented by collision induced 
dissociation (normalised collision energy 35%, activation Q 0.250 and activation time 30
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ms) in the LTQ after the accumulation of 10,000 ions. Maximal filling times were 1,000 
ms for the full scans and 150 ms for the MS/MS scans. Precursor ion charge state 
screening was enabled and all unassigned charge states as well as singly charged species 
were rejected. The dynamic exclusion list was restricted to a maximum of 500 entries 
with a maximum retention period of 90 seconds and a relative mass window of 10 ppm. 
The lock mass option was enabled for survey scans to improve mass accuracy [248]. Data 
were acquired using the Xcalibur software. Results were returned as two Mascot 
searches, the entire NCBInr and of the NCBInr database selected for taxonomy 
‘Dictyostelium discoideum’.
2.20 SILAC coupled Mass Spectrometry Analysis 
(Performed by Dundee Cell Products Ltd)
2.20.1 Gel electrophoresis and in-gel digestion
Each sample was reduced in SDS PAGE loading buffer containing lOmM DTT and 
alkylated in 50 mM iodoacetamide prior to being boiled and then separated by one- 
dimensional SDS-PAGE (4-12% Bis-Tris Novex mini-gel, Invitrogen) and visualized by 
colloidal Coomassie staining (Novex, Invitrogen). The entire protein gel lane was excised 
and cut into 10 gel slices each. Every gel slice was subjected to in-gel digestion with 
trypsin [249]. The resulting tryptic peptides were extracted by 1% formic acid, 
acetonitrile, lyophilized in a speedvac, (Helena Biosciences) and resuspended in 1% 
formic acid.
2.20.2 LC-MS/MS
Trypsin digested peptides w'ere separated using an Ultimate U3000 (Dionex Corporation) 
nanoflow' Liquid chromatography (LC)-system consisting of a solvent degasser, micro 
and nanoflow pumps, flow control module, UV detector and a thermostated autosampler. 
10 pi of sample (a total of 2 pg) w'as loaded with a constant flow' of 20pl/min onto a 
PepMap C l8 trap column (0.3 mm id x 5 mm, Dionex Corporation). After trap 
enrichment peptides wrere eluted off onto a PepMap Cl 8 nano column (75 pm x 15 cm, 
Dionex Corporation) with a linear gradient of 5-35% solvent B (90% acetonitrile with
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0.1% formic acid) over 65 minutes with a constant flow of 300 nl/min. The HPLC system 
was coupled to a Linear trap quadropole (LTQ) Orbitrap XL (Thermo Fisher Scientific 
Inc) via a nano electro spray (ES) ion source (Proxeon Biosystems). The spray voltage 
was set to 1.2 kV and the temperature of the heated capillary was set to 200°C. Full scan 
MS survey spectra (m/z 335-1800) in profile mode were acquired in the Orbitrap with a 
resolution of 60,000 after accumulation of 500,000 ions. The five most intense peptide 
ions from the preview scan in the Orbitrap were fragmented by collision induced 
dissociation (normalised collision energy 35%, activation Q 0.250 and activation time 30 
ms) in the LTQ after the accumulation of 10,000 ions. Maximal filling times were 1,000 
ms for the full scans and 150 ms for the MS/MS scans. Precursor ion charge state 
screening was enabled and all unassigned charge states as well as singly charged species 
were rejected. The dynamic exclusion list was restricted to a maximum of 500 entries 
with a maximum retention period of 90 seconds and a relative mass window of 10 ppm. 
The lock mass option was enabled for survey scans to improve mass accuracy [248]. Data 
w-ere acquired using the Xcalibur software.
2.20.3 Quantification and Bioinformatic Analysis
Quantification was performed with MaxQuant version 1.0.7.4 [250], and wras based on 
two-dimensional centroid of the isotope clusters within each SILAC pair. To minimize 
the effect of outliers, protein ratios were calculated as the median of all SILAC pair ratios 
that belonged to peptides contained in the protein. The percentage variability of the 
quantitation was defined as the standard deviation of the natural logarithm of all ratios 
used for obtaining the protein ratio multiplied by a constant factor 100.
The generation of peak list, SILAC- and extracted ion current-based quantitation, 
calculated posterior error probability, and false discovery rate based on search engine 
results, peptide to protein group assembly, and data filtration and presentation w^ as carried 
out using MaxQuant. The derived peak list was searched with the Mascot search engine 
(version 2.1.04; Matrix Science, London, UK) against a concatenated database combining 
80,412 proteins from International Protein Index (IPI) human protein database version 
3.6 (forward database), and the reversed sequences of all proteins (reverse database). 
Alternatively, database searches were done using Mascot (Matrix Science) as the
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database search engine and the results saved as a peptide summary before quantification 
using MSQuant (http://msquant.sourceforge.net/). Parameters allowed included up to 
three missed cleavages and three labeled amino acids (arginine and lysine). Initial mass 
deviation of precursor ion and fragment ions were up to 7 ppm and 0.5 Da, respectively. 
The minimum required peptide length was set to 6 amino acids. To pass statistical 
evaluation, posterior error probability (PEP) for peptide identification (MS/MS spectra) 
should be below or equal to 0.1. The required false positive rate (FPR) was set to 5% at 
the peptide level. False positive rates or PEP for peptides were calculated by recording 
the Mascot score and peptide sequence length-dependent histograms of forward and 
reverse hits separately and then using Bayes' theorem in deriving the probability7 of a 
false identification for a given top scoring peptide. At the protein level, the false 
discovery rate (FDR) was calculated as the product of the PEP of a protein's peptides 
where only peptides with distinct sequences were taken into account. If a group of 
identified peptide sequences belong to multiple proteins and these proteins cannot be 
distinguished, with no unique peptide reported, these proteins are reported as a protein 
group in MaxQuant. Proteins were quantified if at least one MaxQuant-quantifiable 
SILAC pair wras present. Identification was set to a false discovery rate of 1% with a 
minimum of two quantifiable peptides. The set value for FPR/PEP at the peptide level 
ensures that the worst identified peptide has a probability of 0.05 of being false; and 
proteins are sorted by the product of the false positive rates of their peptides where only 
peptides w-ith distinct sequences are recognized. During the search, proteins are 
successively included starting with the best-identified ones until a false discovery rate of 
1% is reached; an estimation based on the fraction of reverse protein hits.
Enzyme specificity w7as set to trypsin allowing for cleavage of N-terminal to proline and 
between aspartic acid and proline. Carbamidomethylation of cysteine was searched as a 
fixed modification, whereas ALacetyl protein, and oxidation of methionine were searched 
as variable modifications.
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Chapter 3
Characterization of GSK3B-GFP and 
GskA-GFP cell lines
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The primary objectives of this project were to characterize the role of GskA in 
Dictyostelium and to establish whether protein binding, or scaffolding of GSK-3 
represented a common mechanism by which GSK-3 activity could be compartmentalized 
and directed towards specific substrates.
In this chapter I describe the generation and characterization of both Dictyostelium and T- 
REx HEK 293 cell lines expressing GskA-GFP and GSK3-(3-GFP fusion proteins that 
will be used to facilitate those aims. I also describe the generation of a series of 
Dictyostelium cell lines expressing GskA-GFP fusion proteins harbouring point 
mutations that were used to further characterize the mechanisms by which GskA activity 
is regulated. I demonstrate that cell viability is not affected by the levels of GSK-3 over­
expression used in this study, that cellular localization was not altered by the addition of a 
GFP tag and that these GFP-fusion proteins were catalytically active.
3.1 Generation of Dictyostelium GskA-GFP cell lines
As described in Chapter 1, GskA is not essential for Dictyostelium cell viability, and gskA 
null cell lines have previously been generated in two different cell backgrounds [194, 
195]. In this study, gskA null cells generated in an Ax2 background were used.
The plasmid pDXA GskA-GFP2, encoding a GskA-GFP fusion protein and conferring G- 
418 resistance was electroporated into the gskA null cell line. This plasmid cannot 
replicate and exist extra-chromosomally unless it is co-transfected with the plasmid 
pREP. In the absence of the pREP plasmid, the pDXA GskA-GFP2 plasmid can only be 
maintained through chromosomal integration [234]. This approach was used to ensure 
stable expression from a single or low number of plasmid copies. Protein expression was 
initially screened through observation of GFP fluorescence and subsequently by western 
transfer, using as controls Ax2 and gskA null strains (Figure 3.1 A). Clones expressing 
GskA-GFP at endogenous, or close to endogenous levels were selected for further 
analysis.
Point mutation of specific residues of GSK-3 has previously been used as a method to 
characterize the role GSK3|3 in mammalian cells; mutation of Lys85 rendered the protein 
catalytically inactive [251], mutation of Arg96 prevented GSK3J3 from interacting
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efficiently with its primed substrates [54, 55] and mutation of Tyr216 reduced the 
catalytic activity' of the protein [73]. (Figure 1.1 and Figure 1.2) As part of this study 
analogous mutations were generated in Dictyostelium GskA in order to dissect the 
functional role of GskA; Plasmids that encoded GskA-GFP fusion proteins that contained 
a point mutation at Lys85 (K85R), Arg96 (R96E) or Tyr214 (Y214G) were each 
electroporated into the gskA null cell line. Again, clones were initially screened for GFP 
fluorescence and subsequently by western transfer (Figure 3.1B-E). The epitope 
recognised by the antibody used to detect GskA in this study extended over the Y214 
residue, and as such an additional western transfer was performed using an anti-GFP 
antibody in order to accurately determine expression levels in the GskA-GFP Y214G cell 
lines. The gskA-GskA-GFP clone-2 cell line was used as an additional control.
The GskA-GFP R96E cell lines generated in this study all demonstrated greatly elevated 
levels of the GskA fusion protein compared to both wild type and other mutated GskA- 
GFP fusions despite the plasmid being constructed from the same ‘parent' plasmid 
(Figure 3. IB). Sequencing of the GskA-GFP R96E plasmid did not reveal any indication 
as to why expression was higher.
In an attempt to recover clones expressing GskA-GFP R96E at lower levels cell were 
sorted using fluorescence activated cell sorting (FACS); heterogeneous populations of 
cells transformed with either pDXA GskA-GFP2 R96E or pDXA GFP2 (a plasmid 
expressing GFP only) were cultured in low' fluorescent media overnight before being 
sorted into four arbitrary categories based on their levels of fluorescence (Figure 3.2). 
These cells were then plated into 96-w-ell plates at low density', such that one would 
expect to recover individual colonies from one well in every ten. Very few7 GskA-GFP2 
R96E expressing colonies were recovered using this method and those that w'ere 
recovered expressed high levels of the fusion protein. Cells transformed with the pDXA 
GFP2 plasmid did yield the expected frequency of colonies and these colonies exhibited 
the expected levels of fluorescence (and inferred protein expression) based on their 
sorting, indicating that the FACS itself was not responsible for the low number of GskA- 
GFP2 R96E expressing colonies recovered.
Those colonies expressing GskA-GFP2 R96E that were recovered following FACS 
continued to express high levels of the protein. As such these cells were not used for
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further experiments as it was possible that the extended culturing and the stresses of the 
FACS may have introduced new mutations. Instead, colonies from the original 
transformations were used for further experiments.
The plasmid pDXA GFP2 was electroporated into both Ax2 and gskA null cell lines to be 
used as controls for later experiments. Individual clones were selected for GFP 
florescence and where possible clones that expressed GFP at similar levels to the gskA- 
GskA-GFP clone 2 were selected for further experiments (data not shown).
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Figure 3.2 FACS analysis of GskA-GFP R96E expressing cells
In order to recover cells expressing GskA-GFP R96E at levels similar to gskA null-GskA- 
GFP clone 2, mixed populations of cells w ere subjected to FACS. Mixed populations of 
cells expressing GskA-GFP R96E or GFP alone both exhibited a range of fluorescence 
levels. Cells were sorted into 4 arbitrary groups and allowed to recover overnight before 
being plated into 96-well plates to recover individual clones.
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3.2 Generation of T-REx GSK3|J-GFP cell lines
In order to express a Gsk3(3-GFP fusion protein in mammalian cells the plasmid 
pcDNA5/FRT/TO GSK-3 (3-GFP was co-transfected with pOG44 into the Flp-In T-REx 
HEK 293 host cell line (Figure 2.1). This resulted in the integration of a cassette 
encoding a tetracycline-inducible-GSK3p-GFP fusion protein into the genome via an 
FRT site (Figure 3.3). Integration into this FRT site resulted in a loss of Zeocin resistance 
and LacZ expression but conferred hygromyein B resistance to the resulting cell line. A 
control cell line that expressed GFP alone was generated by co-transfecting 
pcDNA5/FRT/TO GFP with pOG44 into the Flp-In T-REx HEK 293 host cell. Clones of 
each cell line were selected for their ability to express GSK3(3-GFP or GFP alone 
following induction with doxycycline (a tetracycline derivative) and for the loss of LacZ 
expression (Figures 3.3 and 3.4). TREx GSK3|3-GFP clone 3 and TREx GFP clone 2 
were selected for use in further experiments.
Several factors were considered when thinking about the levels of GSK3(3-GFP 
expression to use in this study; high levels of expression may have led to GSK3J3-GFP 
forming non-specific interactions within the cell and the identification of GSK3|3’s 
inclusion in non-physiologically relevant protein complexes. However for the purposes of 
identifying binding partners, ‘reasonable’ levels of expression wrere required. As such, a 
titration was performed to ascertain the appropriate induction concentration, such that the 
level of GSK3|3-GFP expressed in the cells matched the level of endogenous expression 
of GSK3p (Figure 3.5). Initial pull-down experiments wrere performed following 4 hours 
induction with lOng/ml doxycycline (see Chapter 5). However, in hindsight 4 hours was 
probably insufficient time for the fusion protein to be translated, correctly folded and 
incorporated into GSK3 ^ -containing protein complexes. Later experiments used cells 
induced for 24 hours with 2ng/ml doxycyclin (Figure 3.5).
Wst-1 assays were used to assess cell viability; Wst-1 is a tetrazolium salt that is cleaved 
by mitochondrial dehydrogenases into formazan [252]. This reaction results in a colour 
change from light to dark red. The amount of formazan produced directly correlates with 
the number of metabolically active cells in a population. Therefore, by treating cells with 
Wst-1 and measuring the amount of fonnazan produced it w^ as possible to make
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Figure 3.3 Mechanism of
Tetracycline/Doxycycline
induction
A. Tet repressor (TetR) 
protein is expressed in T- 
RExHEK 293 cells
B. TetR homodimers bind 
to the Tet operator 
seq u en ces, repressing 
transcription of the GSK- 
3p-GFP fusion gene.
C. When added, 
doxycycline binds to the 
tetR homodimers.
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Figure 3.4. Western blot 
analysis of T-REx GSK3p- 
GFP and T-REx GFP clones
A. T-REx GSK3P-GFP clones  
+/- treatment with doxycycline 
4 hours prior to lysis. Sam ples 
w ere immunoblotted with anti- 
GSK3p, anti-GFP and anti-a- 
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interpretations about the relative viability of cell populations following Doxycycline 
induction. T-REx GSK3p-GFP and T-REx GFP cell lines were both induced with a range 
of doxycycline concentrations for 24 and 48 hours in order to fully assess the effect of 
over expression on cell viability (Figure 3.6). The levels of doxycycline induction used in 
this study were shown not to significantly affect cell viability. However, higher 
concentrations of doxycycline (and inferred GSK3|3-GFP expression) did have minor 
effects on cell viability compared to control cell lines expressing GFP alone.
TREx GSK30-GFP clone 3
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Figure 3.6 Wst-1 Assays
T-REx GSK30-GFP and T-REx GFP cells were induced with the indicated 
concentration of doxycycline for (A) 24 and (B) 48 hours prior to treatment with 
Wst-1. Relative proliferation values were calculated in reference to wells 
containing cells that were not treated with doxycycline. The data presented are 
means +/- standard deviation of the mean of triplicate wells (n = 3)
Following 24 hours induction, the relative proliferation rates of T-REx GSK3p- 
GFP and T-REx GFP were not statistically different from each other up to a 
concentration of 20ng/ml (P>0.05, unpaired Mest) The relative proliferation rates 
after 48 hours induction were not statically different at any concentration (P>0.05, 
unpaired Mest).
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Figure 3.7. Localisation of GskA and GskA-GFP
Ax2 and gskA null cells w ere fixed with methanol and stained with both DAPI and an anti- 
sgg antibody. Cells expressing GskA-GFP fusion proteins or GFP were fixed and stained 
with DAPI. T hese cells w ere visualized for DAPI and GFP fluorescence. The im ages 
presented here are representative of the larger population (n>20)
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Figure 3.8. Localisation of GSK-3p and GSK-30-GFP
Untransfected T-REx HEK 293 cells +/- 24 hour induction with 2ng/ml Doxycycline were 
PFA fixed and stained with both DAPI and an anti-GSK-3p antibody. T-REx cells 
expressing either GSK-3p-GFP or GFP were induced with 2ng/ml Doxycycline for 24 
hours, PFA fixed and stained with DAPI. Cells were visualized for DAPI and GFP 
fluorescence. The im ages presented here are representative of the larger population of 
cells (n>20)
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3.4 Assessment of kinase activity
In order to demonstrate that both the Dictyostelium and mammalian fusion proteins 
retained catalytic activity, kinase assays were performed.
Ryves et al [253] previously described a specific and sensitive method of detecting GSK- 
3 activity from both Dictyostelium and mammalian crude cell extracts where they 
measured the incorporation of 32P-y-ATP into a peptide based on the GSK-3 substrate 
GS-2. This peptide, termed the ‘GSM peptide’ contained 3 overlapping GSK-3 
phosphorylation sites that corresponded to substrate sites 3a-c of glycogen synthase 
[254]. GSK-3 directed phosphorylation of the GSM peptide required pre-phosphorylation 
of serine 18. When a non-phosphorylated GSM peptide was used as a substrate for GSK- 
3, no significant phosphorylation above background levels was detected [253].
The mammalian T-REx cells used in this study expressed endogenous GSK3(3, therefore 
it was not possible to directly apply the methods outlined by Ryves et al [253]. Instead, 
both mammalian and Dictyostelium GFP-fusion proteins were first immuno-precipitated 
from whole cell lysates and immobilized on beads coated with an anti-GFP antibody. 
These beads were then used directly to assess catalytic activity. Initial kinase assays 
were performed in a total volume of 50pl of kinase buffer containing 50pM ATP, 
12.5mM MgCty and 425pM GSM, similar to the assay conditions described by Ryves et 
al [253] in terms of cell numbers (and inferred GskA / GSK-3(3 protein levels) ATP, 
MgCty and GSM concentration. The activity of each sample was measured over a series 
of time points to ensure saturation was not occurring. Activity was measured against both 
pre-phosphorylated GSM and un-phosphorylated GSM and the appropriate GFP control 
cell line was included to demonstrate that activity was specific.
The semi-purified nature of the protein samples used for these kinase assays meant that it 
was possible to use the Kinase-Glo luminescent kinase assay to measure catalytic activity 
by quantifying the amount of ATP that remained in solution following each kinase 
reaction. This method has previously been used to measure GSK-3 activity [167, 255- 
258] and represented a non-radioactive, high-through-put approach to quickly assess 
catalytic activity. This method measured the intensity of the luminescence generated by 
mono-oxygenation of beetle luciferin by luciferase, in the presence of Mg~ ATP. This
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reaction consumed one ATP molecule and produced one photon per turnover, Therefore, 
the resultant luminescence signal was proportional to the amount of ATP present and 
inversely correlated to GSK-3 kinase activity.
Kinase assays were terminated by the addition of the kinase-glo reagent and glow-type 
luminescence measured. Catalytic activity was calculated in reference to samples 
containing ATP, GSM and beads that were not incubated with cell lysate, and expressed 
as A-relative light units (A-RLU) (Figure 3.9). These experiments demonstrated that both 
the wild-type GskA-GFP and GSK-3 (3-GFP fusion proteins were catalytically active and 
that this activity was specific.
The catalytic activity of each of the Dictyostelium GskA-GFP mutant cell lines were also 
assessed using this technique. In order to directly compare the various GskA-GFP fusion 
proteins, cell lysates were first normalized based on GFP fluorescence (and inferred 
GskA-GFP protein content) to ensure an equal amount of protein was available to 
become immobilized on the anti-GFP beads. Equal levels of protein immobilization were 
confirmed by western transfer (Figure 3.10).
As expected, the kinase dead GskA-GFP K85R mutant did not exhibit any catalytic 
activity (Figure 3.10). The GskA-GFP Y214G mutant also failed to exhibit any kinase 
activity, which is consistent with other studies into the role of Y214 in Dictyostelium 
[81]. The GskA-GFP R96E mutant did exhibit a low level of catalytic activity towards 
the primed peptide relative to the non-phosphorylated peptide. This finding is consistent 
with other reports on the effect of mutating Arg96 [259] and is perhaps indicative that the 
residues R178 and L203 (analogous to R180 and L205 of mammalian GSK3|3 
respectively) retained the ability to interact with the primed substrate and orientate it 
appropriately across the catalytic grove.
The experiments described here do not represent a detailed study of the catalytic profiles 
of the various GSK-3-GFP fusion proteins. Such a study would certainly be informative, 
however this was not undertaken as part of this current scheme of work as the protein 
samples used here represented the products of crude affinity purifications and purified 
proteins would be required to fully assess the function of specific residues. However, the 
experiments presented here do demonstrate that both the wild-type GskA-GFP and GSK- 
3|3-GFP fusion proteins exhibited catalytic activity and that this activity was specific.
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Figure 3.10. Assessment of the kinase activity of GskA-GFP mutants
(A) Kinase a ssays were performed on each of the Dictyostelium gskA null GskA-GFP 
mutant cell lines, gskA null-GFP cells were included a s  a negative control. Reactions were 
performed with 50|uM ATP, 12.5mM MgCL and 425nM substrate at room temperature. The 
reaction time was set to 32 min. A RLU (Delta Relative Light Units) values were calculated 
in reference to wells containing ATP, substrate and beads that were not incubated with cell 
extracts. The data presented are m eans +/- standard deviation of the mean of triplicate 
wells (n = 3).
(B) A Western blot w as performed to demonstrate equal loading for the kinase assay, 
immunoblotted with an anti-GFP antibody.
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3.5 Conclusions
In this chapter I have described the generation of a series of Dictyostelium cell lines 
expressing different GskA-GFP fusion proteins that will be used in chapter 4 to further 
characterize the role of GskA in Dictyostelium. I have demonstrated that the addition of a 
GFP tag did not alter GskA localization and that wild-type GskA-GFP was catalytically 
active.
I have also described the generation of doxycycline inducible HEK 293 cell lines 
expressing GSK-3 (3-GFP or GFP alone. These cell lines will be used in chapter 5 to 
investigate whether GSK-3 {3 activity' is regulated through protein binding partners. I have 
demonstrated here that the levels of GSK-3|3 over-expression used in this study did not 
affect cell viability. I have also demonstrated that GSK-3 (3 localization was not altered by 
the addition of a GFP tag and that the GSK-3 (3-GFP fusion protein was catalytically 
active.
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Chapter 4
The role of GSK-3 in Dictyostelium
discoideum
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In the previous chapter I described the generation of Dictyostelium cell lines expressing a 
series of GskA-GFP tagged proteins. As these cell lines were generated in a gskA null 
background I was able to utilize them to further characterize the role of GskA in 
Dictyostelium, and evaluate the roles of key residues.
Here, I describe the use of dark field microscopy to further characterize the 
developmental phenotype of the gskA null cell line, and describe the ability of each of the 
GskA-GFP fusion proteins to rescue this phenotype. I will also describe a previously 
undocumented phenotype exhibited by the gskA null cell line that indicates that GskA is 
important for the regulation of cytokinesis in Dictyostelium. Where cell lines expressing 
GskA-GFP fusion proteins are discussed two independently derived clones were analysed 
(indicated in Figure 3.1) unless stated otherwise.
4.1 GskA performs a role during early development
The developmental phenotype of the gskA null cell line has previously been described; 
loss of GskA resulted in the formation of small fruiting bodies with a reduced spore head 
[194, 195]. In order to further characterize the developmental phenotype of the gskA null 
cell line and to establish whether the GskA-GFP construct was capable of rescuing this 
phenotype, time-lapse movies were taken over a period of 48 hours.
The gskA null cell line fonned numerous small aggregation territories. However, these 
cells did not obviously stream, rather the cells appeared to develop small, loose mounds 
in a random and disordered manner. At the mound stage, cells formed abnormal donut­
like structures before continuing on to develop into small fruiting bodies (Figure 4.1 and 
Figure 4.2). The formation of these donut-like structures has previously been described as 
a consequence of inhibiting cAMP-dependent activation of an adenylate cyclase (ACA) 
using caffeine [260, 261], and as a phenotype of cells over-expressing a constitutively 
active form of the Gal-subunit of heterotrimeric G-proteins [262]. 
gskA null cells expressing wild-type GskA-GFP were capable of streaming to a similar 
degree as Ax2 cells, although they were considerably slower in their initiation. The final 
fruiting bodies were also comparable in size to Ax2 (Figure 4.1 and Figure 4.2). Cells
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expressing kinase dead, GskA-GFP-K85R exhibited a gskA null phenotype, indicating 
that kinase activity was required.
Cells expressing either GskA-GFP-Y216G or GskA-GFP-R96E were able to stream, 
although aggregation territories were smaller than those of Ax2. The GskA-GFP-R96E 
cell lines continued to form donut-like structures in a similar manner to the gskA null 
cells (Figure 4.2). Furthermore, this cell line took considerably longer to complete 
development (nearly 48 hours compared to the normal 24 hours). The finding that both 
the GskA-GFP R96E and GskA-GFP Y214G cell lines were capable of partially rescuing 
development was surprising given the results from the kinase assay described in Chapter 
3. That both of these cell lines, but not the GskA-GFP K85R mutant were capable of 
some level of rescue would argue that these fusion proteins did retain some activity. The 
possible causes of this discrepancy will be discussed at the end of this chapter.
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Figure 4.1. Analysis of the terminal morphology of gskA null fruiting bodies 
and the ability of GskA-GFP to rescue
106 cells were allowed to terminally differentiate on agar plates (24 hours) before 
being imaged under dark field conditions (se e  later) using a X40 objective. A) Ax2, 
B) gskA null and C) gskA null - GskA-GFP
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Figure 4.2. Analysis of development
106 cells from each cell line were plated onto non-nutrient agar and allowed to develop. 
Images were taken every 5 minutes over a 48hr period. Experiments were repeated on 3 
separate occasions and two independent cell lines expressing each GskA-GFP fusion protein 
were develooed on each occasion. 87
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Figure 4.2. Analysis of development
10 cells from each cell line were plated onto non-nutrient agar and allowed to develop. 
Images were taken every 5 minutes over a 48hr period. Experiments were repeated on 3 
separate occasions and two independent cell lines expressing each GskA-GFP fusion protein 
were developed on each occasion. go
4.2 gskA null cells do not stream or polarize
During development, Dictyostelium aggregate in response to pulsatile waves of cAMP 
that propagate through a population of cells, directing them to the nearest aggregation 
centre. Throughout aggregation cells undergo characteristic changes in shape; under low 
concentrations of cAMP cells appeal* rounded, extending pseudopodia in multiple 
directions. In high cAMP concentrations cells become elongated and only extend 
pseudopodia in the direction of the cAMP source. These periodic changes in cell shape 
have made it possible to study the propagation of a cAMP signal using a technique 
known as dark field microscopy [263]. Dark field microscopy is a technique that uses 
oblique illumination to enhance the contrast in samples that are not imaged well under 
bright-field conditions. Light passing through the specimen from oblique angles is 
diffracted, refracted, and reflected into the microscope objective to form a bright image. 
Oblique light that does not pass through the specimen is not collected by the objective 
lens and does not form part of the image. This has the affect of producing a dark, almost 
black, background with bright objects on it. Under dark field illumination aggregating 
Dictyostelium appear to form concentric wave patterns. These patterns result from 
periodic changes in cell shape, round non-moving cells do not diffract light and appear 
dark, while elongated cells moving towards a cAMP source diffract more light and 
appear white. These changes in light scattering during cell movement have been shown to 
directly correlate with waves of cAMP [264].
Timelapse movies revealed that during development the gskA null cells failed to stream 
and yet, these cells were still capable of forming mounds and fruiting bodies (Figure 4.2). 
In order to further characterize this phenomenon and monitor changes in cell shape, dark- 
field timelapse microscopy was used to capture cell movements during the first 15 hours 
of development. The resulting time-lapse movies were processed by subtracting each 
frame from the one before, so that changes in cell movements were converted into 
changes in light intensity. By monitoring changes in intensity, it was possible to 
distinguish the early, uncoordinated random movements of individual cells from the 
periodic waves of movement as cells aggregate towards a focal point (Figure 4.3).
These movies revealed that gskA null cells did not form any discernable patterns 
associated with changes in cell shape during cell aggregation. This would suggest that
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gskA null cells were either not capable of generating cAMP pulses or were unable to 
respond to them. The gskA null-GskA-GFP cell line did form wave patterns during 
aggregation although they were not as well defined as those of Ax2 cells and, as with 
development in general, these waves appeared several hours later than in the Ax2 cell 
line. The gskA null-GskA-GFP K85R cell line did not form any discemable patterns 
during the aggregation process similar to the gskA null cell line.
It is unclear whether cells expressing either GskA-GFP-Y214G or GskA-GFP-R96E were 
capable of forming patterns during aggregation. The formation of wave patterns can be 
rather subjective and any patterns relating to these cell lines were poorly defined, and 
were impossible to discern in still images (data not shown).
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Subtracted image
Figure 4.3. Analysis of the cellular morphology of cells during aggregation
105 Ax2(A), gskA null (B) and gskA null-GskA-GFP (C&D) cells were plated onto non­
nutrient agar and allowed to develop.Tim e-lapse, dark field images were taken every 
30 seconds. Images w ere taken after 4 .5  hours (A-C) and 8 hours (D). g\
4.3 GskA performs a role during cytokinesis
When grown in shaking culture for prolonged periods of time, the growth rate of the gskA 
null cells appeared to slow compared to that of the Ax2 cells. Furthermore, after these 
extended periods of growth in shaking culture the gskA null cells appeared larger than 
their Ax2 counterparts.
In order to investigate this phenomenon further cells were grown in shaking culture for 
48 hours before briefly being allowed to settle on coverslips, fixed and dapi stained. Cells 
were then scored on the number of nuclei they contained. The gskA null cell line was 
found to have a significant number of multinucleate cells compared to the wild-type Ax2 
cell line; the average number of nuclei per Ax2 cell was 1.32 and 24.7% of cells were 
multinucleate, while the gskA null cell line contained on average 2.08 nuclei and 60.13% 
of cells were multinucleate (Table 4.1 and Figure 4.5). This multinucleate phenotype was 
only observed when cells were grown in shaking culture. When cells that had been 
growing in shaking culture were plated out onto a solid surface they underwent a series of 
rapid divisions to become mononuclear within a matter of hours (Figure 4.6). These 
divisions were reminiscent of those described for cells lacking the gene encoding myosin 
II heavy chain (mhcA) and appeared to occur independent of the cells' position in the cell- 
cvcle [226].
Expression of wild-type GskA-GFP was capable of rescuing this phenotype (Table 4.1). 
While expression of GskA-GFP-K85R did not result in any rescue of this phenotype, 
indicating that kinase activity was required and that GskA was not simply acting as a 
scaffold in this context. Expression of GskA-GFP carrying either the Y214G or R96E 
mutations was not sufficient to rescue this phenotype, and cells expressing those fusion 
proteins continued to form some multi-nulcelate cells, albeit at a lower frequency (Table 
4.1).
As the gskA null cells only became multinucleate when grown in shaking culture, this 
indicated that they were possibly deficient in Cytokinesis A (myosin-dependent, 
adhesion-independent) but not Cytokinesis B (myosin-independent, adhesion- 
dependent)(Figure 1.6). Cytokinesis B is reported to take twice as long as cytokinesis A 
to complete [224, 225]. In order to investigate further the means of cytokinesis employed 
by the gskA null cells, timelapse movies were generated of cells growing and dividing
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Figure 4.5. Analysis of the role of GskA during cytokinesis
Ax2 (A), gskA null (B) and gskA null GskA-GFP (C) cells were grown in shaking 
culture for 48 hours before being allowed to adhere to coverslips, methanol fixed and 
DAPI stained. DAPI im ages w ere taken using a 60x objective.
Slides containing cells expressing GskA-GFP fusion proteins harbouring Y214G, 
R96E or K85R mutations w ere prepared in a similar fashion. All cells were scored on 
the number of nuclei they contained (D). For each  cell line expressing a GskA-GFP 
fusion protein, data from two independent clones w as pooled (the sam e trend was 
observed for each individual cell line). The data represented here w as collected from 
3 independent experiments, n>2000 cells.
93
Ax2 gskA null gskA null-GskA-GFP
K J  Ax2 
E33 gskA null 
S  gs/<A null-GskA-GFP 
cnna gs/(A null-GskA-GFP K85R 
rzm gskA null-GskA-GFP Y214G 
rw i gskA null-GskA-GFP R96E
Number of nuclei
Figure 4.5. Analysis of the role of GskA during cytokinesis
Ax2 (A), gskA null (B) and gskA null GskA-GFP (C) cells were grown in shaking 
culture for 48 hours before being allowed to adhere to coverslips, methanol fixed and 
DAPI stained. DAPI im ages w ere taken using a 60x objective.
Slides containing cells expressing GskA-GFP fusion proteins harbouring Y214G, 
R96E or K85R mutations w ere prepared in a similar fashion. All cells were scored on 
the number of nuclei they contained (D). For each cell line expressing a GskA-GFP 
fusion protein, data from two independent clones was pooled (the sam e trend was 
observed for each individual cell line). The data represented here was collected from 
3 independent experiments, n>2000 cells.
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Cell Line M ean num ber o f  nuclei per cell
Percen tage  o f  
cells w ith 2 or 
m ore nuclei
Statistically 
different to 
A x2?
Statistically 
different to 
gskA  null?
Ax2 1.32 24 .74 N/A Yes
gskA  null 2 .06 60.13 Yes N/A
gskA  null GskA-GFP 
clone 1&2 1.34 27.47 No Yes
gskA  null GskA-GFP 
K85R clone 1&6 1.93 55.23 Yes No
gskA  null GskA-GFP 
Y216G clone 4&5 1.55 38.33 Yes Yes
gskA  null GskA-GFP 
R96E clone 1&6 1.66 45 .14 Yes Yes
Table 4.1. Analysis of the role of GskA during cytokinesis
Chi squared tests were performed on the data presented in Figure 4.5D. The 
distribution of multinucleate cells is significantly different between the Ax2 and gskA null 
cell lines. Expression of wild-type GskA-GFP w as sufficient to restore a distribution 
similar to that of the Ax2 cells.
Each of the cell lines expressing mutated GskA-GFP also exhibited a distribution that 
was statistically different to that of the Ax2 cells. Those cell lines expressing GskA-GFP 
with R96E or Y214G mutations w ere also statistically different to the gskA null cells.
Tim e 0 T im e 3 0  s e c o n d s  Tim e 6 0  s e c o n d s
Time 9 0  s e c o n d s  T im e 1 2 0  s e c o n d s  Tim e 1 50  s e c o n d s
Figure 4.6. gskA null cells were deficient in Cytokinesis A
gskA null cells were grown in shaking culture for 48 hours before being returned to a 
solid surface. Dark-field, time lapse im ages were taken every 30 seconds using a 20x 
objective. Here, a single gskA null cell is shown undergoing a multi-directional 
division event to becom e uni-nuclear.
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on a solid surface.
These movies were used to score the time taken for cytokinesis events to occur. The start 
of cytokinesis was defined as the time at which a cell became rounded and the end of 
cytokinesis was judged to be the time at which two daughter cells were seen to be clearly 
separated. The timing of these events could be considered to be largely subjective, so in 
order to ensure that the data was not biased, these measurements were made without 
knowing which cell line was being scored.
The timings for the cytokinesis events of the gskA null cells were more closely distributed 
than those of the Ax2 cells, and statistical analysis revealed that the times taken for these 
cell lines to complete cytokinesis were different (Figure 4.7).
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Figure 4.7. Analysis of the tinning of cytokinesis
Cells were plated at a density of 105 cells/ml and imaged every 30 secon d s for 2 
hours. The resulting tim e-lapse m ovies were scored for the time taken for cells to 
complete cytokinesis.
This data represents 3 independent experiments, (n>37 cytokinesis events). The time 
taken for the Ax2 cells to com plete cytokinesis w as statistically different to that of the 
gskA nulls (P>0.05 un-paired T-test).
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4.4 A x2/gsk- cells are sm aller than their Ax2 counterparts
Given that the gskA null cells appear to have some deficiency during cell division I 
looked for alterations in cell size or proliferation rates. Indeed, while culturing the gskA 
null cells it was noted that they appeared to be consistently smaller that their Ax2 
counterparts; gskA null plates consistently yielded more cells than their Ax2 counterparts 
despite appearing similarly confluent. In order to quantify these differences, time-lapse 
movies were generated that were then analysed using the 2-dimension dynamic image 
analysis system (2D-DIAS). This program measured the area occupied by individual 
cells. gskA null cells were found to be smaller than their Ax2 counterparts and expression 
of GskA-GFP was capable of rescuing this phenotype (Figure 4.8).
The ability of gskA null cells to grow both in shaking culture and on bacteria were 
assessed; The gskA null cells were found to proliferate at a similar rate to Ax2 cells when 
grown in shaking culture for a limited time, and produced plaques that were comparable 
to Ax2 when grown on bacteria (Figure 4.9).
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Figure 4.8. Comparison of cell size between cell lines
Timelapse m ovies of each  cell line were analysed using the program 2D-DIAS. 
M easurements of the area occupied by gskA null cells were found to be statistically 
different to both Ax2 and gskA null-GskA-GFP cell lines (P<0.05 One-way Anova, 
Tukey’s multiple comparison test)
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Figure 4.9. Analysis of growth rates
A. Cells were grown in shaking culture and periodically counted, the data presented 
represent 3 separate experiments. Proliferation rates of Ax2 and gskA null cell lines 
were not statistically different (P>0.5, unpaired t-test)
B. Ax2 and gskA null cells w ere allowed to grow on agar plates with bacteria. For 
each strain, colonies were grown in triplicate on 6 separate plates. There w as no 
statistical difference between the plaque size attributed to Ax2 and gskA null cell lines 
(P>0.5, un-paired t-test)
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4.5 Conclusions
In this chapter I have demonstrated that GskA functions during the early stages of 
Dictyostelium development and that expression of wild-type GskA-GFP is sufficient to 
rescue the developmental phenotypes of the gskA nulls. The delay in entering 
development, observed in the gskA null-GskA-GFP cells may result from the GskA-GFP 
fusion protein being imder the control of the actinlS promoter as apposed to the GskA 
promoter. The actinl5 promoter is widely used for expression studies in Dictyostelium as 
it is expressed throughout development. However, the expression profile for the actinl5 
gene {act 15) differs to that of the gene encoding GskA, and may account for the timing 
differences.
In this chapter I further characterised the role of GskA during early development using 
timelapse microscopy. I demonstrated that the gskA null cells did not stream and that 
these cells formed tiny aggregation territories, doughnut like structure and small fruiting 
bodies. Furthermore, the dark-field timelapse movies revealed that the gskA nulls did not 
undergo periodic changes in shape during aggregation, indicating that these cells were 
unable to polarize.
The formation of doughnut-like structures at the mound stage of development has 
previously been described as a consequence of inhibiting cAMP-dependent activation of 
adenylate cyclase (ACA) using caffeine [260, 261]. Dr Jonathan Reddy, a member of our 
lab has performed experiments that further support of a link between GskA and ACA 
activation: Dr Reddy assessed the ability of the gskA null cells to respond to a cAMP 
signal by stimulating cells with 2-deoxyadenosine 3,5-monophosphate (dcAMP), a 
cAMP derivative. Cells respond to this stimulation by activating ACA and synthesizing 
cAMP themselves. However, there was a 5-fold reduction in the amount of cAMP 
produced by gskA null cells compared to Ax2 cells. Indicating that while gskA null cells 
were able to respond to cAMP, the magnitude of that response was severely attenuated. 
This finding would also explain the observation that the gskA nulls formed small 
aggregation territories; these cells were unable to produce sufficient cAMP to propagate a 
signal over a large area.
I have demonstrated that expression of wild-type GskA-GFP was sufficient to rescue the 
gskA null phenotype. Furthermore, I have demonstrated that expression of either GskA-
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GFP-R96E or GskA-GFP-Y214G was also sufficient to rescue many aspects of the gskA 
null phenotype. Cells expressing either GskA-GFP-R96E or GskA-GFP-Y214G were 
able to stream although these cells did form smaller aggregation territories. The cells 
expressing GskA-GFP-Y214G were also able to form fruiting bodies that were 
comparable to wild-type.
The phenotype of cells expressing either GskA-GFP-R96E or GskA-GFP-Y214G 
differed to those expressing kinase dead GskA-GFP K85R indicating that these proteins 
must retain some catalytic activity. The kinase assays described in chapter 1 indicated 
that these proteins were not catalytically active. One possible reason for this apparent 
contradiction may be the method of detection. In previous studies mutation of either R96 
or Y214 was shown to result in a reduction in kinase activity but not it’s complete 
abolishment [81, 259]. It may be that the kinase assay used in this study was not 
sufficiently sensitive to detect the low levels of specific activity retained by the 
constructs. A more sensitive, radioactive method may have yielded different results.
That these proteins were able to rescue some but not all aspects of the gskA null 
phenotype would suggest that GskA performs multiple functions during development and 
that these compromised proteins are capable of fulfilling some but not all of these roles.
In this chapter I described a novel, previously uncharacterised phenotype of the gskA null 
cells. I demonstrated that the gskA null cells became multinucleate when grown in 
shaking culture. A defect that was rescued by growing cells on a solid surface, indicating 
that the gskA null cells are deficient in cytokinesis A and divide using a surface- 
dependent mechanism (cytokinesis B). In support of this conclusion, the gene cor A, 
encoding coronin, a protein involved in cytokinesis B, w?as reported to be over-expressed 
in gskA null cells[196]. Again, expression of wild-type GskA-GFP was sufficient to 
rescue this phenotype, whereas expression of either GskA-GFP-R96E or GskA-GFP- 
Y214G resulted in an intermediate phenotype, perhaps indicating that these compromised 
kinases were only capable of a partial rescue and that absolute levels of phosphorylated 
substrate were an important feature of the affected pathway.
Given that the gskA null cells were found to become multi-nucleate when grown in 
shaking culture it is surprising that they were found to proliferate at a similar rate to Ax2
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cells. One might expect the proliferation rate of the gskA null cells to lag over time as 
multi-nucleate cells accumulate within the population. It may be that the gskA null cells 
are only partially defective in Cytokinesis A, and that a difference in proliferation rates is 
only detectable following prolonged culturing. The observed phenotype is similar to that 
of pi$k!'2~ null cells [229](see Chapter 1), and could indicate that GskA and PI3K act 
through a common pathway to regulate cytokinesis.
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Chapter 5
Identification of GSK-3 binding partners
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Mass spectrometric analysis has furthered our understanding of how proteins interact 
within signaling pathways through the mapping covalent protein modifications and 
identification of protein complexes. The generation of GFP-tagged GskA and GSK3|3 
constructs provided a means of performing large-scale affinity purifications in a cost 
efficient manner. GFP itself binds very few proteins and is largely free in the cytosol [3] 
making it ideal as a fusion partner. In this chapter I will demonstrate that the addition of a 
GFP tag did not prevent GSK-313 from interacting with known binding partners. I will 
then describe the approaches used to identify a series of potential GskA and GSK-3 (3 
binding proteins.
5.1 GSK-3P-GFP still associates with known binding partners
Several mammalian GSK3J3 binding partners have previously been identified [19, 41. 43. 
96, 98, 265], including the Wnt signalling components Axin and FRAT [41, 96, 98]. In 
order to demonstrate that the addition of a GFP tag had not compromised the ability of 
GSK3|3 to interact with these binding partners a control pull-down w?as performed: A 
FLAG-tagged portion of Axinl (residues 367-701) or FLAG-tagged FRAT were 
expressed in both the T-REx GSK3|3-GFP and T-REx GFP cell lines. As a control, 
FLAG-Axinl (367-701) containing the point mutation L392P and FLAG-FRAT 
containing point mutations K208A/E209Q were also expressed. Both of these mutated 
proteins were shown to exhibit a lowered affinity for GSK3j3 [98, 266].
Following induction with doxycycline for 24 hours, cells were lvsed in a non-ionic 
detergent lysis buffer (containing 150mM NaCl). This relatively gentle lysis buffer was 
used in order to stabilize and preserve protein:protein interactions. After cell lysis, 
samples were centrifuged to remove the insoluble fraction and the supernatants were 
subjected to immimoprecipitation using a commercially available antibody raised against 
GFP, covalently coupled to Protein-G sepharose beads. Angus Lamond and colleagues 
have achieved good results using this approach [3, 267, 268] and their protocol was 
utilized for the preparation of these anti-GFP sepharose beads.
Samples were incubated with anti-GFP beads for 1 hour at 4°C. Following incubation the 
beads were pelleted and washed in buffers containing increasing concentrations of NaCl
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to demonstrate that interactions were stable and specific. Subsequent western transfers 
were probed with an anti-FLAG antibody (Figure 5.1).
Both FLAG-Axinl (367-701) and FLAG-FRAT co-immunoprecipitated with GSK3J3- 
GFP (Figure 5.1 A and B). Control experiments using cells expressing GFP alone 
indicated that FLAG Axinl (367-701), FLAG-Axinl (367-701) L392P and FLAG FRAT 
all bound to either GFP or the bead matrix (Figure 5.1C and D). Recognition of this ‘non­
specific’ binding was possible as a result of performing washes with increasing 
concentrations of NaCl and including these fractions on the blot. This highlighted the 
need for care when validating GSK-3 specific interactions later; proteins identified as 
GSK-3 binding proteins as the result of mass spectrometry analysis may also bind non- 
specifically to GFP alone or more likely the bead matrix at levels detectable on a Western 
blot. Performing increasingly stringent washes on samples to be used for validation 
experiments would make it possible to distinguish between proteins that a) bound 
specifically to GSK-3 alone, b) bound specifically to GSK-3, but also to GFP or the bead 
matrix or c) bound non-specifically to GFP or bead matrix.
To date, no GskA binding partners have been identified so it was not possible to perform 
a similar experiment using Dictyostelium extracts.
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Figure 5.1. GSK30-GFP interacts with known binding partners
T-REx GSK3(3-GFP and T-REx GFP cells were transfected separately with plasmids 
expressing Flag-Axin1, FLAG Axinl L392P, Flag-FRAT or FLAG-FRAT K208A/E209Q. 
Cells were allowed to recover for 24 hours before being treated with 2ng/ml of doxycycline 
for a further 24 hours to induce GSK3|3-GFP/GFP expression. Cells were then harvested, 
and immuno-precipitations were performed using beads coupled to an anti-GFP antibody. 
Beads were w ashed with increasing concentrations of NaCl prior elution. Western blots 
were probed with an anti-FLAG antibody.
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5.2 Isolation of potential GSK-3 interaction proteins
5.2.1 Initial affinity purifications
Having demonstrated that known GSK-3 p binding partners could be immunoprecipitated 
using the protocol described above, the same approach was used to identify novel GSK-3 
binding partners using both mammalian and Dictyostelium cell extracts.
Mammalian cell extracts were prepared as before, and proteins were immunoprecipitated 
using the anti-GFP beads described above. These beads were washed three times in wash 
buffer containing 150mM NaCl, before bound proteins were eluted directly into 
NuPAGE buffer.
My earlier Dictyostelium work demonstrated that GskA performs a role during the early 
stages of Dictyostelium development. In order to assess whether GskAs roles involve 
protein:protein interactions, affinity purifications were performed using Dictyostelium 
cells that were starved for 4 hours. I have previously demonstrated that the gskA null- 
GskA-GFP cell line was capable of rescuing the developmental phenotype of the gskA 
null parental cell line. Therefore, in order to reduce any variability caused by differential 
gene expression, an Ax2 cell line expressing GFP was used as a control. Both 
Dictyostelium cell lines were cultured with Klebsiella aerogenes on SM agar before being 
washed and starved in KK2 for 4 hours. Cells were lysed and immunoprecipitations were 
performed in the same way as the mammalian samples.
Eluted proteins from all samples were separated on a 1- dimensional gel and stained with 
colloidal coomassie (Figure 5.2 A and B). These gels revealed that there was insufficient 
protein for mass spectrometry analysis, despite performing these experiments with a large 
amount of starting material (a packed cell volume of 2ml per mammalian cell line and 
5ml per Dictyostelium cell line).
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Figure 5.2. Colloidal coomassie stained gels following affinity purification.
Affinity purifications were performed using non-fixed sam ples from (A) T-REx GSK-3p-GFP 
and T-REx GFP cell lines and (B) Dictyostelium gskA null-GskA-GFP and Ax2-GFP cell lines. 
Later experiments were performed with PFA fixed sam ples from (C) T-REx GSK-3p-GFP and 
T-REx GFP cell lines and (D) Dictyostelium gskA null-GskA-GFP and Ax2-GFP cell lines. 
Bands selected  for further analysis are marked.
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5.2.2 Utilization of chemical cross-linking
Many biologically important proteimprotein interactions are transient or relatively weak 
and are only poorly preserved during protein purification. Chemical cross-linking has 
previously been used as a technique for retaining proteimprotein interactions as a 
precursor to affinity chromatography experiments [269-272].
In order to increase the mass of material recovered following affinity purification and 
preserve interactions between GskA or GSK-3|3 and their interaction partners, proteins 
were chemically cross-linked in vivo.
Paraformaldehyde works by rapidly permeating the cell membrane and cross-linking 
proteins primarily through lysine residues exposed on the surface of the protein. 
Paraformaldehyde is considered to be a ‘zero length’ cross-linking agent (the actual 
cross-link distance = 2A) and only forms cross-links between closely associated proteins 
[273], making it ideal for this study. Furthermore, paraformaldehyde cross-linking is fully 
reversible at high temperature (>67 °C) in aqueous solution, making it compatible with 
subsequent mass spectrometry analysis [273].
Mammalian T-REx cells that were induced for 24 hours with 2ng/ml doxycycline and 
Dictyostelium cells that had been starved for 4 hours were harvested and treated with 1% 
paraformaldehyde for 20 minutes. Cross-linking was quenched by the addition of glycine 
to a final concentration of 125mM, cells were then lysed and cell extracts prepared as 
before.
The anti-GFP sepharose beads used for previous experiments were replaced with a 
commercially available GFP-Trap coupled to sepharose beads; The ‘GFP-Trap’ is a 16- 
kD protein derived from a llama heavy chain antibody that was found to bind with high 
affinity and specificity7 to GFP [274].
Cell lysates were incubated with the GFP Trap coupled to sepharose beads, washed as 
before and bound proteins were eluted into NuPage buffer. Cross-linking was then 
reversed prior to separation on a 1 -dimensional gel, which was then stained with colloidal 
coomassie (Figure 5.2 C and D).
Staining revealed that several unique bands were present in the lane corresponding to the 
Dictyostelium GskA-GFP sample and five bands were isolated and digested with trypsin. 
Peptides were extracted, separated by nanoflow LC, and introduced into an LTQ Orbitrap
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hybrid mass spectrometer. MS/MS analysis and database searching of the sequenced 
peptides resulted in the identification of 33 proteins, each of which matched to at least 4 
unique peptide sequences and had a combined ‘protein score’ deemed to be statistically 
significant.
For each protein match, Mascot calculates an overall ‘protein score’ that reflects the 
combined scores of all observed mass spectra that can be matched to amino acid 
sequences within that protein. The higher score the more confident match. Mass 
spectrometry experiments do not produce “perfect” data. There is always some level of 
noise in the data and not every ion that a protein could theoretically generate will be 
observed in every experiment. Therefore, the analysis software could produce false or 
random matches; some matches could arise simply by chance. To address this, Mascot 
calculated a “threshold” score representing a 5% confidence threshold. This score for 
statistical significance varies from experiment to experiment and was indicated in the 
Mascot report.
Bands of the equivalent size were not isolated from the control track because at the time 
as it was felt that it would be impossible to ensure the gel slices of exactly the same size 
were taken from exactly the same position. However, in hindsight this may have 
simplified the process of identifying specific GskA interactor proteins as mass 
spectrometry analysis revealed that each gel slice contained a mixture of multiple 
proteins. This is likely to be because proteins were only separated on a 1-dimensional gel 
and multiple proteins migrated close together.
5.3 Analysis of proteins that co-purified with GskA
33 proteins were identified as co-purifying with GskA and each of these proteins roughly 
correlated in size to the gel band they were extracted from (Table 5.1). These putative 
interaction partners required validation to confirm their physiological relevance. These 
downstream validation experiments and detailed molecular characterization are both 
costly and time consuming and as such it was imperative to focus resources on a subset of 
potential interactions with a high probability of biological significance. To that end I 
initially used a bioinformatics approach to narrow the scope of my investigations and 
eliminate proteins that were unlikely to be biologically relevant.
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Protein ID Protein Name (as it 
appears in STRING)
Human
homolog
(where
available)
Description MW of band 
identified in 
Figure 5.2 
(kDa)
MW of 
protein 
(kDa)
DDB0230067 accA ACACA acetyl-CoA carboxylase 270(Band 1) 256.7
DDB0185543 DDBDRAFT_0185543 N/A unknown 27 0 (Band 1) 268.7
DDB0201646 Pyr1-3 CAD Dihydroorotase aspartate carbamoyltransferase 
glutamine-dependent carbamoyl-phosphate 
synthase
270(Band 1) 245.9
DDB0191526 talB TLN2 talinB 270(Band 1) 277.6
DDB0233340 DDB_0233340 PABPC1 RNA-binding region RNP-1 domain-containing 
protein RNA recognition motif-containing protein 
RRM
35 (Band 2) 31.8
DDB0234265 DDBDRAFT_0167100 TGDS NAD-dependent epimerase/dehydratase family 
protein
35 (Band 2} 40
DDB0230193 pdhA PDHE1-A pyruvate dehydrogenase E1 alpha subunit 35 (Band 2) 42
DDB0185040 pdil ERp72 protein disulfide isomerase 35 (Band 2) 39.9
DDB0304584 zpr1 ZPR1 ZPR1-type zinc finger-containing protein 35 (Band 2) 53.5
DDB0201558 ancA SLC25A4 ADP/ATP translocasetransmembrane protein 
mitochondrial substrate carrier family protein
27 (band 3) 33.5
DDB0233903 DDBDRAFT_0189501 THUMP putative SAM dependent methyltransferase 27 (band 3) 22.3
DDB0233914 DDBDRAFT_0202301 COQ3 putative SAM dependent methyltransferase 27 (band 3) 33.8
DDB0231242 rpl5 RPL5 60S ribosomal protein L5 27 (band 3) 32.8
DDB0230021 rps3a MFTL 40S ribosomal protein S3a 27 (band 3) 30.4
DDB0231470 uox N/A urate oxidase, uricase 2 7 (band 3) 33
DDB0235141 atp6v1d VMA8 vacuolar ATP synthase subunit D 2 5 (Band 4) 28.6
DDB0237960 DDBDRAFT_0187734 COQ3 methyltransferase type 11 domain-containing 
protein
25 (Band 4) 29
DDB0215400 dscA-1 N/A discoidin I, A chain 25 (Band 4) 28.29
DDB0215401 dscC-1 N/A discoidin I, C chain and B chain 25 (Band 4) 28.4
DDB0232938 fttb YWHAE 14-3-3 protein 25 (Band 4) 28.7
DDB0185073 rpl7 RPL7 S60 ribosomal protein L7 25 (Band 4) 27.9
DDB0185202 rpl8 RPL8 60S ribosomal protein L8 25 (Band 4) 27.5
DDB0215391 rps2 RPS2 ribosomal protein S2 25 (Band 4) 28.7
DDB0230023 rps6 RPS6 40S ribosomal protein S6 25 (Band 4) 26.2
DDB0230016 rpsA RPSA 40S ribosomal protein SA 25 (Band 4) 27.1
DDB0231383 sdhB SDHB succinate dehydrogenase 25 (Band 4) 31.6
DDB0185070 vatE M9.2 vacuolar H+-ATPase E subunit 2 5 (Band 4) 26.6
DDB0214935 arcB P34-ARC ARP Complex subunit 2 20 (Band 5) 32.9
DDB0214939 limE MLN50 LIM-type zinc finger-containing protein 20 (Band 5) 22
DDB0233888 mcfN SLC25A3 mitochondrial substrate carrier family 25 member 3 20 (Band 5) 31.6
DDB0229951 rpl13 RPL13 S60 ribosomal protein L13 20 (Band 5) 23.67
DDB0231338 rpl6 RPL6 60S ribosomal protein L6 20 (Band 5) 25.8
DDB0230170 udpB UPP1 uridine phosphorylase 20 (Band 5) 32.3
--------------
Table 5.1. Proteins identified as co-purifying with Dictyostelium GskA
109
STRING is a database of known and predicted protein associations. These interactions 
include both direct (physical) and indirect (functional) associations. Information is 
collated from multiple sources and includes data from direct experiments, co-expression 
data, previously collated databases and text mining[275-277].
STRING was used to highlight any previously characterized interactions between the 
putative GskA interaction partners identified from the mass spectrometry analysis. This 
analysis revealed that a series of interacting ribosomal proteins were included in the 
dataset (Figure 5.3). STRING also identified 2 previously characterized interactions 
between VatE and atp6vld (also known as VatD), between Pyrl-3 and FttB and between 
sdhB and pdhA. The potential significance of these interactions is discussed briefly 
below.
STRING did not highlight any previously characterized interactions between GskA, Zakl 
or STATa and the dataset. This was not unexpected, as the role of GskA has not been 
extensively researched in Dictyostelium and several of the proteins identified through 
these experiments remain to be characterized.
In order to ensure that no previously characterized interactions were overlooked, the 
mammalian homologues of these Dictyostelium proteins were identified using BLAST 
searches and these were used for an additional search of the STRING database. However, 
this search failed to identify any additional links within the dataset.
Despite the bioinformatics approach used to highlight potentially interesting, biologically 
relevant interactions, validation was largely limited to those proteins that have previously 
been characterized and details of antibodies had been published. Fresh immuno- 
precipitations were performed, and probed with antibodies against LimE, FttB and TalB. 
These westerns revealed that both LimE and FttB bound non-specifically to GFP or the 
bead matrix. While the antibody raised against TalB failed to detect a band at the 
appropriate height.
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Figure 5.3. STRING analysis of potential GskA interaction partners
33 proteins were identified as co-purifying with GskA and the on-line database STRING was 
used identified any previously characterised interactions between these proteins. Lines 
between proteins indicates a previously characterized interaction, and the thickness of the 
line indicated the confidence of the interaction; the thicker the line the more well 
characterized the interaction. STRING revealed that several interacting ribosomal proteins 
were included within the dataset, and also identified previously characterised interactions 
between fttB and pyr1-3 and between VatE and atp6v1d. The nature of these interactions is 
discussed in the text.
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5.4 SILAC-linked Mass Spectrometry
Despite cross-linking samples to preserve proteimprotein interactions I failed to identify 
any potential GSK-3 (3 binding partners from mammalian extracts as there was 
insufficient material in the resulting coomassie stained gel to identify unique bands of 
interest. This failure to identify binding partners may be because GSK-3 p does not form 
any proteimprotein interactions in this cell type. However, this is unlikely to be the case 
as the Wnt signalling pathway is active within HEK 293 cells [278-282]. Furthermore, 
Ewing et al [4] identified several GSK-3 p interaction partners using HEK 293 cells, 
albeit through gross over-expression of GSK-3 p.
Alternatively, this lack of material may be the result of using non-optimal purification 
conditions, although I have already demonstrated that it is possible to co-immuno- 
precipitate both Axin and FRAT with GSK-3 p using these conditions. Furthermore, 
similar conditions were used by Ewing et al. [4] in their study.
It may be that only a small portion of the available GSK-3 p was bound within protein 
complexes. Furthermore this bound fraction may be shared between several different 
multi-protein complexes. By looking at the coomassie stained gels prepared from 
previous experiments, one can conclude that any GSK-3 p-interaction partners would 
need to bind all of the available GSK-3 p in a 1:1 ratio to be clearly identifiable. Binding 
to only a fraction o f the available GSK-3 p, even as much as 50%, may be insufficient to 
visualize on a coomassie stained gel and render the associated band imperceptible.
If the failure to identify GSK-3 p interaction partners is the result of insufficient material,
i.e. a portion of GSK-3p does form stable interactions in HEK 293 cells and these 
interactions are maintained during the immunoprecipitation process, but there is 
insufficient mass to be seen on a coomassie stained gel, then increasing the amount of 
starting material may alleviate the problem. However, increasing the amount of starting 
material used for affinity purifications is often associated with incomplete cell lysis and 
increased background. Furthermore, there are technical difficulties associated with this 
approach; previous experiments used cells harvested from 15 T180 flasks (per cell line), 
even simply doubling the number of flasks would greatly complicate the process of
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seeding, inducing and harvesting cells, and would ultimately lead to increased variability 
between samples.
Instead of increasing the amount of starting material, it was decided to adopt an approach 
that offered increased sensitivity. Accordingly, SILAC-linked mass spectrometry 
techniques were employed to identify GSK-3 (3 binding partners from T-REx HEK 293 
cells.
Stable isotope labelling by amino acids in cell culture (SILAC) followed by mass 
spectrometry is a sensitive technique that is used increasingly for the identification of 
specific but low affinity protein;protein interactions [283-286] (outlined in Figure 5.4). 
The rationale behind this approach is that two populations of cells are cultivated in cell 
culture. One is cultured in media containing normal amino acids and the second is grown 
in media supplemented with amino acids labeled with stable, non-radioactive, heavy 
isotopes (in this case argenine and lysine containing L,C). Heavy amino acids are 
completely incorporated into every protein within 5 cell doubling [246]. Equal amounts 
of protein from both cell populations can then be combined, affinity purified and 
analyzed together by Mass Spectrometry (Figure 5.4). Pairs of chemically identical 
peptides of different stable-isotope composition can be differentiated in a mass 
spectrometer owing to their mass difference. The ratio of peak intensities in the mass 
spectrum for such peptide pairs accurately reflects the abundance ratio for the two 
proteins. This approach also reduces experimental variability that inevitably occurs when 
samples are processed separately.
In this study, TREx GSK3(3-GFP cells were cultured in 'heavy' media while the TREx 
GFP control cells were cultured in Tight’ media. This offered an additional control as any 
environmental contaminants, which would not be present in equal ratios in both light and 
heavy cell extracts and therefore might appear to be significant can easily be identified 
and excluded from analysis.
In previous experiments, both mammalian TREx cell lines were treated with the same 
concentration of doxycycline. However, this consistently led to higher levels of GFP 
expression compared to GSK3-|3-GFP. This was not unexpected, as one would imagine 
levels of GSK-3 p expression within a cell would be tightly controlled and over 
expression of GSK-3 p would be countered by increased degradation while no such
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Figure 5.4. Schematic representation SILAC based analysis
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regulation of protein turnover is likely to exist for GFP. In order to limit any differences 
between the two protein samples doxycvcline titrations were performed to match as 
closely as possible the levels of GFP within both cell lines. As such, TREx GSK-3 p cells 
were induced with 2ng/ml doxycycline while TREx GFP cells were induced with 
0.4ng/ml doxycycline.
Cells were harvested and lysed in 50mM NaCl, lOmM Tris, 0.5% NP-40 supplemented 
with a Roche complete inhibitor tablet before being centrifuged to remove the insoluble 
fraction. The total protein content was quantified for each cell sample and equal amounts 
of supernatant from each were combined. Affinity purifications were performed using 
the GFP-Trap coupled to agarose beads as before. Followdng incubation with the 
combined lysate, beads were rapidly washed once with PBS in order to maintain low 
affinity proteimprotein interactions.
5.3 Analysis of SILAC results
Mass spectrometry analysis identified 249 proteins with differential SILAC (heavy/light 
amino acid) ratios (Appendix Table 4). As with earlier experiments, it was necessary to 
eliminate those proteins that were likely to bind non-specifically, and focus resources on 
a subset of potential interactions with a high probability of biological significance.
In order to facilitate the identification of specific GSK3|3 binding partners, multiple data 
analysis approaches w?ere taken (outlined in Figure 5.5). First, the frequency of specific 
SILAC ratios were plotted for the entire dataset to determine the distribution of these 
ratios among the proteins identified (Figure 5.6A). Proteins clustered in a bell shaped 
curve distribution around 0.6. The threshold for detection of bona fide interaction 
partners was set to the right of this (indicated by red line) and proteins beyond this line 
were considered for further validation.
A ‘sepharose bead proteome” detailing proteins that commonly bind non-specifically to 
this bead matrix was compiled by Trinkle et al [3] using data collated from 27 
independent SILAC experiments, using 11 different GFP fusion proteins. The authors 
also compiled a list of proteins that may bind specifically to GFP.
115
IjM jfc- I 1  -------------------------------------------------------------------------------------------------------
Proteins identified as the result of SILAC-coupled
mass spectrometry
▼
Analysis of the frequency of 
specific SILAC ratios within 
the dataset (Figure 5.6 A)
Analysis of the SILAC ratios 
for proteins identified as the 
result of SILAC-coupled 
mass spectrometry known to 
bind non-specifically to the 
bead matrix or GFP {Figure 
5.6 B)
Proteins selected 
for further 
validation
Analysis of SILAC ratios for 
the remainder of the dataset 
(those proteins NOT known 
to bind non-specifically to the 
bead matrix or GFP) (Figure 
5.6 C)
STRING analysis of those 
proteins NOT known to bind 
non-specifically to the bead 
matrix or GFP
Figure 5.5. Workflow to identify proteins for further validation
249 proteins were identified a s  the result of SILAC-coupled m ass spectrometry analysis. 
The above work-flow w as used to identify proteins likely to represent biologically relevant 
roles in the regulation of GSK-3 activity for further validation.
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Analysis of the current dataset was taken further by applying the ‘sepharose bead 
proteome’ and list o f potential GFP-binders as a filter and grouping the SILAC ratios of 
proteins that commonly bind nonspecifically to the matrix or to GFP (Figure 5.6B). 
Proteins known to bind sepharose and potential GFP-binding proteins had ratios near or 
below 1. One protein, CSRP2, was identified with a significantly higher ratio that 
required further consideration as a potential real interacting protein. SILAC ratios 
calculated for the remaining proteins in the dataset, i.e., those not known to bind either 
the GFP tag or the bead matrix, were then plotted separately (Figure 5.6C) and proteins 
with a ratio higher than 1 were selected for further consideration.
5.3.1 STRING analysis
The distribution of SILAC ratios described here very clearly formed a bell shaped curve, 
with no outliers that could be considered ‘strong’ candidates as GSK-3 p interaction 
partners (as defined in [3]). This may reflect the dynamic nature of interactions between 
GSK-3 (3 and its binding partners. If these interactions were transient or low affinity then 
during the incubation period, while GSK-3 p-GFP and its binding partners were being 
captured and immobilized on the GFP-Trap, interacting proteins may have dissociated 
and re-associated with GSK-3 p multiple times. Since GSK-3 p would associate with 
interaction partners at random (there would be no selection against forming interactions 
with proteins from the Tight’ fraction), over time, the differential SILAC ratio for these 
proteins would become diminished.
In order to address this issue, the STRING database was used to highlight interactions 
between those proteins not known to bind either GFP or the bead matrix (Figure 5.7). By 
limiting this analysis to a subset of the data I hoped to focus on those interactions that 
were most likely to be biologically relevant. The objective of this step was to identify 
clusters of proteins that interact and operate within a common pathway. The rationale 
being that these clusters of proteins may represent a protein complex that GSK-3 p may 
associate with. Key proteins within these clusters were selected for further analysis.
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Figure 5.6. Systematic analysis of SILAC results
(A)The frequency of SILAC ratios w ere plotted for the dataset to determine the distribution of 
ratios across the dataset. (B) SILAC ratios for proteins known to bind non-specifically to 
sepharose beads and potential GFP binding partners (as defined by Trinkle et al [1] were 
plotted separately to those not known to bind to sep h arose  beads of GFP (C).
9153482353485323235348232330239030482323
KPNB1
6EF1AI
SUPT16H
TBC104
PGAMi
ACTOI
AHftR
UTHFOl
Figure 5.7. STRING analysis of potential GSK-3p interaction partners
246 proteins were identified through SILAC-coupled m ass spectrometry analysis a s  co- 
immunoprecipitating with GSK-3|3-GFP. Of th ese  proteins, 93 are known not to bind to either 
GFP or the bead matrix. STRING w as used  highlight any previously characterised  
interactions between th ese  proteins. Lines betw een  proteins indicates that th ese  proteins 
interact, and the thickness of the line indicates the confidence of that interaction; the thicker 
the line the more well characterized the interaction. Proteins considered to represent ‘key 
nodes’ of this interaction w eb w ere se lec ted  for further validation a s  GSK-3p interaction 
partners.
5.4 Validation of interactions
A total of 22 proteins were selected for further validation as GSK-3 (3 interaction partners 
(Table 5.2). Requests for antibodies were sent to researchers currently studying these 
proteins and antibodies were obtained commercially for SUPT16H, CSRP2 and 
CSNK2A1. Antibodies were also available in-house that recognized SOD-1 and 
HNRPA1. Fresh immunoprecipitations were performed using the same conditions as 
those used to demonstrate that GSK-3 (3-GFP was able to interact with both Axin and 
FRAT (section 5.1 of this chapter).
This experiment failed to confirm any of the proteins mentioned above as GSK-3 p 
interaction partners; The antibody raised against CSRP2 failed to recognize the protein. 
Antibodies against SUPT16H, CSNK2A1, SOD-1 and FINRPA1 did identify bands at the 
correct height in the Tysate’ and ‘flow-through’ fractions for both T-REx GSK-3(3-GFP 
and T-REx GFP samples, however no bands were observed in the ‘elution’ fractions 
corresponding to either cell line.
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Proteins selected based on SILAC ratio (these Droteins are not known to bind GFP or the
bead matrix!
Protein Description Ratio
SSR Pl Structure-specific  recogn it ion  protein  1 0.90595
PSME1 Proteasom e activator com plex  su b u n it  1 0.92353
LDHB L-Iactate deh yd rogen ase  B chain 0.93528
MTHFD1 M ethy len ete trah yd rofo la te  deh yd rogen ase 0.94856
KPNB1 K aryopherin su b u n it  beta-1 0.94971
PEF1 Peflin 0.95303
TPI1 Triosephosphate isom erase 0.96401
VIM V im en tin 0.96855
ST13 Suppression  o f  tu m or igen ic ity  protein 13 0.99195
PTGES3 Prostaglandin  E syn th ase  3 1.0244
MARS M ethionyl-tR N A  sy n th e ta se 1.0793
TNP02 Transportin-1 1.0902
LDHAL6B L-lactate deh yd rogen ase  A -l ik e  6B 1.1147
SUPT16H FACT com plex su b u n it  SPT16 1.1213
MYH10 M yosin heavy chain  10 1.1585
Proteins selected based on SILAC ratio (these proteins are  known to bind GFP or the
bead matrix)
Protein Description Ratio
CSRP2 C y ste in e  and g lycine-r ich  protein 2 1.5081
Proteins selected based on STRING analysis
Protein Description Ratio
RAN GTP-binding nuclear  protein Ran 0.68553
CSNK2A1 C a se in  k in ase  II alpha su b u n it 0.01516
HNRPC
H ete ro g e n e o u s  nuclear  r ibonucleoprote ins  
C1/C2
0.55516
HNRPD H ete ro g e n e o u s  nuclear  r ibonucleoprote in  DO 0.85161
HSP90AA1 H eat shock  protein H SP 90-alpha 0.70741
MARS M ethionyl-tR N A  syn th e tase , 1.0793
Table 5.2. Potential GSK-30 interaction partners selected for further validation
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5.5 Conclusions
In this chapter I have outlined the immuno-precipitation approaches that were adapted to 
identify a number of potential GskA and GSK-3 (3 interaction partners. I have highlighted 
the problems associated with these techniques and discussed the logic used to overcome 
them.
While I have failed to validate any of the interactions identified in this current study, it is 
worth noting that several of the proteins identified here have previously been reported to 
interact with GSK-3 either as substrates or as part of a protein complex (Table 5.3). The 
SILAC coupled mass spectrometry data collected during this study would argue that 
these interactions are transient or very dynamic.
As part of a much larger study, Ewing et al [4] over-expressed a FLAG-tagged protein 
library in HEK 293 cells and performed immuno-precipitations to identify binding 
partners. GSK-3 (3 was included in this library and a personal communication with Dr 
Ewing revealed that a number of the GSK-313 interaction partners identified in this study 
were also identified as part of his own work (Table 5.4). The overlap identified between 
this current study and the work of others is certainly encouraging and would suggest that 
genuine, novel GSK-3 (3 binding partners remain to be validated from this study, although 
it remains a case of sorting the wheat from the chaff.
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Protein Description
SELAC
Ratio
Nature of interaction with 
GSK-3P
Known
contaminant Ref
ACLY ATP-citrate synthase 0.73801 Substrate for GSK3 No
CSDA Cold shock domain- containing protein A 0.64898 Substrate for GSK3 Yes
DDX3X ATP-dependent RNA helicase DDX3X 0.68483 Associated in protein complex Yes
HNRNPD
Heterogeneous 
nuclear 
ribonucleoprotein DO
0.85161 Substrate for GSK3 No
NACAP1
Nascent polypeptide- 
associated complex 
subunit alpha
0.75588 Substrate for GSK3 Yes
PPP1CC
Serine/th reonine- 
protein phosphatase 
PPl-gamma catalytic 
subunit
0.46046
Forms a complex with GSK3 
and PPP1R3, also component of 
insulin signalling pathway
No
PSME1 Proteasome activator complex subunit 1 0.92353
Linked through curated database 
as component o f  destruction 
complex for degradation o f {$- 
eatenin
No
PSMD1
26S proteasome non- 
ATPase regulatory 
subunit 1
0.22629
Linked through curated database 
as component o f destruction 
complex for degradation o f beta 
eaten in
No
Table 5.3. Proteins identified as part of this study that have previously been identified 
as interacting with GSK-30
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Protein
name Description
SILAC
Ratio Confidence
ACLY ATP-citrate synthase 0.73801 +
ACTC1 Alpha-cardiac actin 0.54352 +
ALDOA Fructose-bisphosphate aldolase A 0.21821 +
CAD Glutamine-dependent carbamoyl-phosphate synthase 0.22187 +
CAND1 Cullin-associated and neddylation-dissociated protein 1 0.71704 +
CCT6A T-complex protein 1 subunit epsilon 0.6126 +
CCT7 T-complex protein 1 subunit eta 0.56339 +
CCT8 T-complex protein 1 subunit theta 0.58345 +
CSDA Cold shock domain-containing protein A 0.64898 +
DDX3X DEAD box protein 3 0.68483 +
DHX9 DEAH box protein 9 0.46934 ++
EIF3C Eukaryotic translation initiation factor 3 subunit C 0.68907 +
EEF2 Elongation factor 2 0.48854 +
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.9251 +
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 0.15382 +
HNRNPK Heterogeneous nuclear ribonucleoprotein K 0.63133 +++
HNRNPU Heterogeneous nuclear ribonucleoprotein U 0.6413 +
HSP90AB1 Heat shock protein HSP 90-beta 0.59347 +
HSP90B1 Heat shock protein 90 kDa beta member 1 0.60293 +
HSPA1A Heat shock 70 kDa protein 1 0.57409 +
HSPA5 Heat shock 70 kDa protein 5 0.65864 +
NCL Nucleolin 0.70134 +
PKM2 Pyruvate kinase isozyme M2 0.4234 +
PPP1CC Serine/threonine-protein phosphatase PP1-gamma catalyticsubunit 0.46046
+
PRKDC DNA-dependent protein kinase catalytic subunit 0.55606 +
PTBP1 Polypyrimidine tract binding protein 1 0.47554 +
RPLP1 60S acidic ribosomal protein P1 0.5683 +
RPS20 40S ribosomal protein S20 0.6198 ++
RPS2 Similar to 40S ribosomal protein S2 0.57133 ++
SLC25A5 ADP/ATP translocase 2 1.1693 +
SLC25A6 ADP/ATP translocase 3 0.79247 +++
SNRPD3 Small nuclear ribonucleoprotein Sm D3 0.75624 +
SSBP1 Single-stranded DNA-binding protein 0.29163 ++
SYNCRIP Synaptotagmin-binding, cytoplasmic RNA-interacting protein 0.71368 +
TKT Transketolase 0.59957 +
TPI1 Triosephosphate isomerase 0.96401 +++
TRAP1 Tumor necrosis factor type 1 receptor-associated protein 0.019344 +
TUBA4A Tubulin alpha-1 B chain 0.45655 +
TUBB Tubulin beta chain 0.28665 +
TUBB2C Tubulin beta-2C chain 0.45531 +
UBA1 Ubiquitin-like modifier-activating enzyme 1 0.64777 +
UBA52 Ubiquitin B 0.56589 +
VIM Vimentin 0.96855 +
XRCC5 ATP-dependent DNA helicase 2 subunit 2 0.56935 +
Table 5.4. Proteins identified as potential GSK-3P binding partners both as part of this 
study and by Ewing et al.
Confidence refers to arbitrary scoring by Ewing et al 124
Chapter 6 
Discussion
The primary objectives of this project were to better characterize the role of GSK-3 in 
Dictyostelium discoideum, and to investigate the possibility that protein-binding partners 
may direct GSK-3 activity in both Dictyostelium and mammalian cells.
In Chapter 3, I described the generation of both Dictyostelium and mammalian TREx 
HEK 293 cell lines expressing GskA-GFP and GSK3f3-GFP fusion proteins, respectively. 
I demonstrated that cellular localization was not altered by the addition of a GFP tag. 
Furthermore, I established that these GFP fusion proteins retained kinase activity. I also 
described the generation of a series of Dictyostelium cell lines expressing point mutated 
GskA-GFP fusion proteins that would be used to further investigate the regulation of 
GskA activity in Dictyostelium.
In Chapter 4 I described a role for GskA during the early stages of Dictyostelium 
development and demonstrated that expression of GskA-GFP was sufficient to rescue the 
developmental phenotypes of the gskA null cell line. Furthermore, I reported that fusion 
proteins harbouring either R96E or Y214G mutations were also capable of partially 
rescuing this phenotype. I also described a previously unrecorded cytokinesis defect in 
the gskA null cell line and again demonstrated that expression of wild-type GskA-GFP 
was sufficient to rescue this phenotype.
Finally, in Chapter 5 I demonstrated that GSK-3 (3-GFP was still able to bind two known 
GSK-3 interaction partners: Axin and FRAT, proving in principle that the addition of a 
GFP tag would not hinder an interaction between GSK-313 and its binding partners. I also 
described the difficulties I encountered when trying to identify GskA and GSK-313 
interaction partners and discussed the optimization steps that were implemented in order 
to identify a series of potential GSK-3 interaction partners.
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6.1 The role of GskA in Dictyostelium
During the course of this project, roles for GskA in both early development and 
cytokinesis were identified. Loss of GskA resulted in a failure of cells to polarize and 
stream during development. Loss of GskA also resulted in a cytokinesis defect that 
presented itself when cells were grown in shaking culture.
As part of a separate study, the gskA null cells were also found to be deficient in 
chemotaxis; Dr Regina Teo pulsed cells with cAMP for 5 hours before placing them in a 
gradient formed from a lpM  cAMP source and observing their ability to move toward 
the source of cAMP. Under these conditions the gskA null cells exhibited a complete loss 
in chemotaxis, a phenotype that was again rescued by expression of wild-type GskA- 
GFP. Dr Teo also looked at the ability of PI(3,4,5)P3 to localize to the membrane; the 
PI(3,4,5)P3-specific binding protein P H c r a c - G F P  was expressed in both Ax2 and gskA 
null cells. When Ax2 cells were globally stimulated with cAMP, PI(3,4,5)P3 was 
generated on the entire plasma membrane causing translocation of P H c r a c - G F P  from the 
cytosol to the membrane. No P H c r a c - G F P  translocation was seen in the gskA null cells, 
indicating that PI(3,4,5)P3 accumulation did not occur.
During polarization, chemotaxis and surface independent cytokinesis common signalling 
pathways operate to coordinate changes in both microtubule dynamics and the actin 
cytoskeleton. The PI3K / PI(3,4,5)P3 signalling pathway is one of these pathways and is 
involved in coordinating cellular polarization and movement during chemotaxis in 
Dictyostelium (discussed in Chapter 1). In response to a cAMP signal, Dictyostelium 
accumulate PI(3,4,5)P3 at the leading edge of the cell while membrane bound PTEN 
becomes restricted to the lateral sides and rear [206-208]. Similarly, during myosin- 
dependent cytokinesis (cytokinesis A) PI(3,4,5)P3 accumulates at the poles of the 
dividing cell and PTEN localization becomes restricted to the site of the developing 
cleavage furrow [229]. In both cases, localization of these factors is required for F-actin 
polymerization at the leading edge of the cell (PI(3,4,5)P3) and the formation of an 
actomyosin network at the rear or furrow region (PTEN).
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The finding that the gskA null cells fail to polarize, chemotax, localize PI(3,4,5)P3 to the 
membrane or complete cytokinesis in shaking culture indicates that GskA may perform 
some role in co-ordinating one or more aspects of the PI3K / PI(3,4,5)P3 signalling 
pathway. However, it remains unclear whether this function involves the direct action of 
GskA, i.e. GskA phosphorylates a substrate involved in PI3K / PI(3,4,5)P3 signal 
transduction, or if GskA acts by regulating transcription of specific genes that are 
themselves involved PI3K/ PI(3,4,5)P3 signal transduction.
6.1.1 Potential mechanisms linked to direct action of GskA
1. In mammalian systems, GSK-3 acts to inhibit of glycogen synthase (GS) and regulate 
the conversion of glucose-6-phosphate (Glc-6-P) to glycogen (discussed in chapter 1). 
Glc-6-P is also the precursor for myo-inositol production, a reaction catalysed by the 
enzyme myo-inositol-3 phosphate synthase (inol) [287]. It is possible therefore that 
GSK-3 activity is required to regulate the availability of Glc-6-P for the synthesis of 
myo-inositol, which is itself a precursor for PI(3,4)P2 production. In the absence of GSK- 
3 there would be no inhibition of GS, this would lead to more Glc-6-P being converted to 
glycogen and mean that there would be less available Glc-6-P to be converted into myo­
inositol. Consequently, this would lead to less PI(3,4)P2 being available to be converted 
into PI(3,4,5)P3 following PI3K activation.
2. A previous member of the lab, Dr Hazel Williams reported that GskA localized to 
microtubules during mitosis (unpublished). This is consistent with other reports that 
GSK-3 regulates microtubule dynamics (Discussed in Chapter 1). Previously, it was 
reported that microtubules did not perform an active role during Dictyostelium 
chemotaxis, but rather they were required for anchoring of the nucleus and other 
organelles within the cell [200]. However, there is emerging evidence that this may not 
be their only role; disruption of microtubules through treatment with nocodozole was 
found to lead to a loss in chemotaxis [288]. Furthermore, two microtubule-associating 
proteins, CP250 and Tsunami were recently reported to be required for efficient
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chemotaxis [289, 290]. Tsunami is the Dictyostelium homologue of Fused, a protein 
shown to interact with GSK-3 in the context of Hedgehog signaling. It remains far from 
clear whether this kinase interacts with GskA. However, the parallels between the WNT 
and Hh signaling pathways in terms of signal transduction and the observed role of 
components of the WNT pathway in regulating microtubule dynamics could lead one to 
propose that these kinases act through a common pathway to exert an affect on 
microtubule dynamics resulting in the observed phenotypes.
6.1.2. Potential mechanisms linked to changes in gene expression
The genes encoding SglA, RaclB  and GefKi were identified by Stremeki et al [196] as 
exhibiting altered expression patterns in the gskA null cell line. These genes are also 
associated with GO terms linking them to chemotaxis and/or cytokinesis. Details of the 
affects of loss- or over-expression of each of these genes have been reported and their 
phenotypes, and how they might relate to the phenotype of the gskA null cell line are 
discussed below.
1. The gene sglA was found to be under-expressed in the gskA null cell line [196]. This 
gene encodes sphingosine-1 -phosphate lyase (SIP lyase) a protein involved in the last 
step in sphingomyelin catabolism where sphingosine-1-phosphate (SIP) is degraded to 
phosphoethanolamine and hexadecanal [291]. In mammals, ceramide and SIP are both 
intermediate substrates of the sphingomyelin degradation pathway and both of these 
molecules perform regulatory roles in controlling cell proliferation and cell death [292]. 
SIP has also been shown to perform roles in the release o f intracellular Ca2+ stores, actin 
polymerization, cell motility, chemotaxis and cell differentiation in mammalian 
systems[293].
An sglA knock-out cell line w'as generated by Li et al [294] in order to characterize the 
role of SIP in Dictyostelium. sglA null cells were found to aggregate faster than their 
wild-type counterparts and exhibited an inability to form slugs, similar to the phenotype 
of the gskA nulls. These cells also exhibited aberrant F-actin localization and were unable 
to suppress lateral pseudopodia during chemotaxis [295]. While it remains unclear 
whether loss of SglA also resulted in an inability complete cytokinesis in shaking culture,
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it is reasonable to conclude that the phenotype of the gskA nulls may in part be explained 
by reduced expression of SglA.
2. RasGEFM is a multi-domain protein containing six poly-proline stretches, a DEP, 
RasGEFN and RasGEF catalytic domain. Inactivation of the gene encoding this protein 
resulted in cells that formed small, flat aggregates and failed to develop further. 
Chemotaxis towards cAMP was also impaired in this mutant, due to inability to inhibit 
lateral pseudopods. Adenylyl cyclase activation in response to cAMP pulses was strongly 
reduced, and the actin polymerization response to cAMP was also altered in the mutant. 
Expression of the Geflvl gene was found to be under-expressed in the gskA null cells, and 
could explain the inability7 of the gskA cells to activate adenylyl cyclase in response to 
cAMP stimulation.
3. RaclB is a small G-protein in the Ras superfamily that has been implicated in the 
control of cell growth, adhesion, and the actin-based cytoskeleton. Stremeki et al [196] 
reported that this gene is over-expressed in the gskA null cell line. RaclB was found to 
co-localize with F-actin in lamellipodia and at sites of cell-to-eell contact. Palmieri et al 
[296] reported that over expression of this protein led to aberrant F-actin localization. 
Cells over-expressing RaclB also became multi-nulceate when grown in shaking culture 
and divided via cytokinesis C when plated out onto a solid surface [297], similar to the 
phenotype of the gskA null cells.
In reality, it is likely that the phenotype of the gskA null cells results from a combination 
of both an inability to phosphorylate specific substrates and downstream changes in gene 
expression. In order to dissect the role of GskA further and assess the relative 
contributions of genes with altered expression patterns in the gskA nulls it would be 
necessary to perform further experiments. These could include re-expression of genes in 
the gskA null cells under an alternative promoter (such as actinlS) and assessing the 
ability of these constructs to rescue aspects of the gskA null phenotype.
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6.2 The role of key residues of GskA
In the course of this project cell lines expressing GskA-GFP constructs carrying K85R, 
R96E or Y214G point mutations were generated and characterized. The ability of each 
cell line to rescue aspects of the gskA null phenotype differed; kinase dead K85R failed to 
rescue any aspect of the gskA null phenotype, indicating that the role performed by GskA 
was an active one, GskA does not simply function as a scaffold. Constructs carrying 
either R96E or Y214G mutations offered partial rescue of the cytokinesis phenotype. 
These cell lines also rescued some, but not all, aspects of the developmental phenotype of 
the gskA nulls perhaps indicating that GskA performs multiple roles during early 
development.
6.2.1 Separation of the functions performed by GskA during 
development
Cell lines expressing either GskA-GFP R96E or GskA-GFP Y214G were able to 
aggregate and stream during early development, although the aggregation territories 
observed for these cell lines were smaller than that of Ax2 or gskA null-GskA-GFP cell 
lines. This observation may be evidence of a direct role for GskA in enabling cells to 
propagate a cAMP signal. In Chapter 4 I described the phenotype of the gskA null cells 
during development and reported that prior to mound formation these cells formed 
doughnut like structures that were indicative of an inability to activate adenylate cyclase. 
Experiments performed by Dr Reddy also demonstrated that loss of GskA resulted in an 
inability of cells to synthesize cAMP. In Chapter 3 I reported that the GskA-GFP R96E 
and GskA-GFP Y214G fusion proteins were catalytically compromised. The observation 
that these cell lines formed smaller aggregation territories may be evidence that the 
GskA-GFP R95E and GskA-GFP Y214G proteins were able to function to activate 
cAMP synthesis, but not to the same extent as wild-type GskA. Performing a similar 
experiment to Dr Reddy, and looking at the levels of cAMP production in these cell lines 
following stimulation with 2-deoxyadenosine 3,5-monophosphate (dcAMP) would shed 
light on this matter and may help to further characterise the role of GskA.
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In chapter 4 I demonstrated using dark filed optics that the gskA null cells failed to 
polarize or undergo periodic changes in cell shape during aggregation. Similarly, when 
viewed under dark filed conditions, cell lines expressing either GskA-GFP R96E or GskA- 
GFP Y214G fusion proteins did not clearly polarize despite an obvious ability to stream. 
Again, this would indicate that GskA may action multiple effects at this stage of 
development, and the catalytically compromised GskA-GFP R96E and GskA-GFP 
Y214G fusion proteins were capable of performing some but not all of these functions.
By looking directly at the ability of these cell lines to chemotax in a gradient of cAMP 
and whether these cell lines were able to localize PI(3,4,5)P3 to the membrane following 
stimulation with cAMP, one may be able to separate out further the multiple affects 
coordinated by GskA during early development.
6.2.2. Regulatory roles of Y214 and R96
While the phenotypes of cells expressing GskA-GFP R96E or GskA-GFP Y214G fusion 
proteins were very similar, and both were able to rescue aspects of the gskA null 
phenotype there are key differences between these cell lines that require further 
consideration.
In chapter 4 I reported that cells expressing GskA-GFP R96E continued to form 
doughnut-like structures at the mound stage, a phenotype of the gskA nulls that was 
rescued by expression of GskA-GFP Y214G. Furthermore, cells expressing GskA-GFP 
R96E took considerably longer to complete development.
As described in Chapter 3, where possible I tried to ensure that the cell lines used were 
expressing GskA-GFP at similar levels to that of endogenous GskA. However, in case of 
GskA-GFP R96E this was not possible as all cell lines exhibited significantly higher 
levels of expression. This is an important consideration when dissecting the ability of this 
fusion protein to rescue aspects of the gskA null phenotype. Given that GskA-GFP R96E 
was expressed at higher levels than GskA-GFP Y214G and still failed to rescue some 
aspects of the gskA null phenotype this wnuld indicate that the ability of GskA to 
recognize primed substrates is central to the regulation of GskA activity'.
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6.3 Identification of potential GSK-3 interaction partners
In chapter 5, I presented experiments that resulted in the identification of a series of 
potential GskA or GSK-3 (3 binding partners. Difficulties were encountered while 
performing these experiments and insufficient material meant that standard affinity 
purification and mass spectrometry techniques were not sufficient to identify proteins of 
interest. In chapter 5 I also described the modifications that were applied to this 
methodology in order to improve yields and facilitate the identification of potential 
binding partners.
The underlying reasons for the difficulties encountered may in part be due to the methods 
used to prepare cellular extracts; cells were lysed and clarified prior to the addition of 
anti-GFP beads. This clarification step was performed in order to prevent sedimentation 
of large, insoluble proteins with the bead matrix. Sedimentation would represent a non­
specific interaction and could potentially limit the ability of the anti-GFP antibody to 
recognize and bind GFP. However, it is probably that GSK-3 is contained in this 
insoluble fraction, bound to nuclei or the cytoskeleton. Therefore, by discarding this 
fraction I was reducing the amount of GSK-3 available for immunoprecipitation and 
potentially excluding specific interaction partners.
Difficulties may also have encountered due to the nature of the proteins I was attempting 
to identify. By definition, scaffolding proteins that direct GSK-3 activity' towards specific 
substrates are likely to be large unstructured proteins. This creates problems when 
performing immuno-precipitations as these proteins are more likely to undergo 
proteolysis. Furthermore, samples were separated by 2D-gel electrophoresis prior to mass 
spectrometry analysis, any particularly large proteins may be too big to pass into the gel.
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6.3.1 Identification of ribosomal proteins as GSK-3 binding partners
Several ribosomal proteins were identified as potential GskA or GSK-3 |3 binding 
partners. There is some evidence that GSK-3 interacts with, or regulates components of 
the ribosome. For example, Kim et al [124] reported that lithium inhibition of GSK-3 (3 
activity resulted in proteosomal degradation of 3 ribosomal proteins (rpll4B, rpllSA and 
rpS15). This treatment also prevented degradation of two other ribosomal proteins (rpL30 
and rpSlO) indicating perhaps that GSK-3 performs both positive and negative roles in 
the regulation of ribosomal turnover. Furthermore, GSK-313 has also previously been 
shown to phosphorylate and inhibit the translation initiation factor eIF2B [179, 180], 
indicating that it is possible that GSK-3 may perform some additional role in regulating 
translation and the ribosomal proteins identified in this study are evidence of this role. 
However, it is also possible that the ribosomal proteins identified in this study do not 
represent biologically relevant interactions and only co-purified with either GskA or 
GSK-3 [3 during their synthesis. Furthermore, Trinkle et al [3] reported that ribosomal 
proteins frequently bound non-specifically during their affinity purification experiments. 
Given the difficulties associated with demonstrating that any interactions between either 
GskA or GSK-3 p and any ribosomal proteins were specific and biologically important, 
these proteins were excluded from further analysis.
6.3.2 Potential GskA interaction partners
Expression of wild-type GskA-GFP was found to rescue all aspects of gskA null 
phenotype investigated in this study, indicating perhaps, that if GskA activity was 
directed by binding to specific protein partners, that the addition of a GFP tag did not 
abrogate this interaction.
In chapter 5 I identified a number of potential GskA binding partners although a lack of 
available antibodies means that these interactions remain to be validated. Interactions 
between GskA and several o f the proteins highlighted in this study are certainly worthy 
of further investigation. One such protein is AncA. The mammalian homologue of this 
protein, adenine nucleotide translocase (ANT), is a component of the mitochondrial 
permeability transition pore (mPTP). These pores are present in mitochondrial
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membranes and perform an important role in cell necrosis associated with ischemia and 
neurodegeneration (reviewed in [298]). The mPTP is a nonselective, high conductance 
channel that minimally consists of Adenine nucleotide translocase (ANT), Voltage- 
dependent anion channel (VDAC) and Cyclophilin-D (cyP-D). Opening of this channel is 
associated with immediate loss of mitochondrial membrane potential and cell death. 
Mammalian GSK-3 was found to translocate to mitochondria [299, 300] and reportedly 
binds to ANT [301]. Antibodies that recognise Dictyostelium AncA were not available 
for the purpose of this current study. However, they have been generated and it would be 
interesting to investigate whether this interaction is conserved between mammals to 
Dictyostelium.
The protein ArcB was also identified as a potential GskA binding partner. This protein is 
a component of the Arp2/3 complex and is recruited to the cell perimeter, and into 
pseudopodia following stimulation with cAMP [302]. The Arp2/3 complex performs a 
crucial role mediating the actin polymerization response to chemotactic stimulation and 
contributes to cell motility7, pseudopod extension and adhesion in Dictyostelium [302]. A 
direct interaction between GskA and components of this complex may represent a 
mechanism by which GskA acts to directly to regulate both cellular polarization and 
chemotaxis.
Both the proteins VatD and VatE were identified as potential GskA binding partners in 
chapter 5. The genes encoding these proteins were also found to be over-expressed in the 
gskA null cell line. VatD and VatE are both subunits of the peripheral V 1 complex of 
vacuolar H+-ATPase. V-ATPase is an ATP-driven proton pump that functions to both 
acidify intracellular compartments and to transport protons across the plasma membrane 
of eukaryotic cells [303, 304]. Expression of several other V-ATPase subunits, namely 
VatB, VatH, VatP were also found to be up-regulated in the gskA null cell line [196]. 
However, it remains unclear at this time whether these findings represent a biological role 
for GskA or are simply co-incidence.
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6.3.3 Potential GSK3P interaction partners
A series of potential GSK-3(3 interaction partners were identified in this study. Again, 
these interactions largely remain to be validated. Of particular interest are those proteins 
that were highlighted in Table 5.3 of chapter 5 and those proteins that were also identified 
as part of the study conducted by Ewing et al. [4].
Difficulties were encountered during the course of this project in trying to identify GSK- 
3(3 binding partners. Insufficient material meant that standard affinity purification and 
mass spectrometry techniques could not be employed and SILAC analysis failed to 
identify any strong candidates for interaction partners.
In chapter 5 I demonstrated that the addition of a GFP tag did not hinder the ability of 
GSK-3(3 to interact with either Axin or FRAT. Izumi et al [43] similarly demonstrated 
that the addition of a GFP tag did not prevent GSK-3 (3 from binding to GCP5. It is 
unlikely therefore that the failure to identify strong GSK-3 (3 binding partners wras the 
result of the choice of affinity tag.
A plethora of GSK-3 binding partners have previously been identified (Table 6.1). These 
interactions were largely identified using yeast-2-hybrid screens and through over­
expression studies. These techniques have limitations with the potential to produce false 
positives in the form of in-direct interactions (yeast-2-hybrid) and the inclusion of GSK-3 
in non-physiologically relevant complexes (over-expression). However, it is interesting 
that very fewr studies have identified GSK-3 binding partners using endogenous levels of 
protein expression. Furthermore, only one previously documented GSK-3 binding 
protein, PPP1CC, was identified as part of this study. It may be that GSK-3(3 binding 
partners are only present in very' low abundancy in cell or have very high turnover. Axin, 
a known GSK-3 binding partner wras not identified as a binding partner in the SILAC 
experiment despite demonstrating that this protein does interact with GSK-3 |3-GFP when 
over expressed. Axin is present in the cell at very low levels, and is subject to rapid 
turnover [305]. Indeed, recent immunoprecipitation experiments conducted with a view 
to identifying Axin binding partners required the culturing and harvesting of 100 9cm 
plates of HEK 293 cells to yield enough material for mass spectrometry analysis 
(personal communication with Prof. Hans Clevers). If GSK-3 (3
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Species In teractan t D escrip tion Method o f  Identification REF
Homo sapiens ACLY ATP citrate lyase Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens AKAP11 A kinase (PRKA) anchor protein 11 Yeast-2-hybrid [5]
Homo sapiens APC adenomatous polyposis coli In vitro Co-IP [9]
Homo sapiens AR Androgen receptor In vitro Co-IP [10]
Homo sapiens AXIN1 In vitro affinity capture [U ]
Homo sapiens BCL3 B-cell CLL/lymphoma 3 Co-IP with endogenous proteins [14]
Caenorhabditis elegans BED finger and Zn-finger C2H2 type (1J430) Yeast-2-hybrid [15]
Homo sapiens BXDC1 Brix domain containing 1 Over-expression of FLAGGSK3p in HEK 293 cells [4]
Caenorhabditis elegans C01G12.1 Hypothetical protein Yeast-2-hybrid [15]
Caenorhabditis elegans C07G1.6 Hypothetical protein Yeast-2-hybrid [18]
Homo sapiens C14orf129 GSK3-beta interaction protein (GSKIP)
Yeast-2-Hybrind and Over-expression of FLAG- 
GSK3p in HEK 293 cells
[4,
19]
Caenorhabditis elegans CC8.1 Hypothetical protein Yeast-2-hybrid [15]
Drosophila melanogaster CGI 5185 Hypothetical protein Yeast-2-hybrid [20]
Drosophila melanogaster Cos2 Costal-2 Co-IP with endogenous proteins [21]
Mus musculus Csnk2a1 casein kinase 2, alpha 1 polypeptide In vitro affinity capture [25]
Homo sapiens CTNNB1 Beta-catenin Over-expression of FL4GGSK3P in HEK 293 cells [4]
Drosophila melanogaster Cubitus Interruptus cubitus interruptus Over-expression [21]
Homo sapiens DDX20 DEAD box protein 20 Over-expression of FLAGGSK3f5 in HEK 293 cells [4]
Homo sapiens DDX5 DEAD box protein 5 Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens DHX36 ATP-dependent RNA helicase /  DEAH box protein 36 Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens DISCI Disrupted in schizophrenia 1 Co-IP with endogenous proteins [34]
Homo sapiens DNM1L Dynamin 1 -like protien isoform 1 Yeast-2-hybrid [35]
Homo sapiens E2F1 E2F transcription factor 1 Co-IP with endogenous proteins [36]
Homo sapiens EWSR1 Ewing sarcoma breakpoint region 1 protein Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens FIP1L1
Isoform 1 of Pre-mRNA 3'- 
endprocessing factor FIP1 
(Factor interacting with PAP)
Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens FRAT1 Frequently re-arranged in advanced T-cell lymphomas
[40]
Homo sapiens FRAT2 Frequently re-arranged in advanced T-cell lymphomas
[40,
41]
Homo sapiens FUS Isoform Long of RNA-binding protein FUS Over-expression of FLAGGSK3P in HEK 293 cells [4]
GCP5 tubulin, gamma complex associated protein 5 Over-expression of GSK-3bGFP in HeLa cells
[43]
Homo sapiens GEMIN4 Gem (nuclear organelle) associated protein 4 Over-expression of FLAGGSK3f> in HEK 293 cells [4]
Homo sapiens HIST1 HIT Histone H it Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens HSD17B4 Peroxisomal multifunctional enzyme type 2 (MFE-2) Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens IKBKAP IkappaB kinase complex- associated protein (pi 50) Over-expression of FLAGGSK3p in HEK 293 cells [4]
Caenorhabditis elegans MAC-1
Member of AAA family 
binding CED-4 family 
member
Yeast-2-hybrid [15]
Homo sapiens MAP2K5
Dual specificity mitogen- 
activated protein kinase 
kinase 5
Over-expression of FLAGGSK3p in HEK 293 cells 
-------------------------------------------------------
[4]
Homo sapiens MUC1 Mucin-1 [1, 2]
Homo sapiens MYCN N-myc proto-oncogene protein Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens NIN Isoform 1 of Ninein Yeast-2-hybrid [8]
Homo sapiens NIN Isoform 2 of Ninein Yeast-2-hybrid [8]
Homo sapiens NOTCH Over-expression of HA-GSK3p in HEK 293 cells [17]
Homo sapiens POLR2B DNA-directed RNA polymerase II subunit RPB2 Over-expression of FLAGGSK3b in HEK 293 cells [4]
Homo sapiens PPP1CA protein phosphatase 1, catalytic subunit, alpha Co-IP with endogenous proteins [5]
Homo sapiens PRKAR2A
cAMP-dependent protein 
kinase type ll-alpha regulatory 
subunit
Co-IP with endogenous proteins [5]
Drosophila melanogaster Prune Yeast-2-Hybrid
Homo sapiens PTK2 protein tyrosine kinase 2 isoform b Co-IP with endogenous proteins [24]
Homo sapiens QPCTL
Isoform 1 of Glutaminyl- 
peptide cyclotransferase-like 
protein
Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens RGS22 Regulator of G-protein signaling 22 Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens SF3A1 Splicing factor 3 subunit 1 Over-expression of Fl_AGGSK3p in HEK 293 cells [4]
Homo sapiens SF3B1 Splicing factor 3B subunit 1 Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens SGK3 serum/glucocorticoid regulated kinase 3 isoform 1 Yeast-2-hybrid [33]
Homo sapiens SMAD3 Co-IP with endogenous proteins [38]
Homo sapiens SMARCA2
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily a, member 2
Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens SMN1 Isoform 1 of Survival motor neuron protein Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens SMN2 Isoform 2 of Survival motor neuron protein Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens SMYD2 SET and MYND domain containing protein 2 Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens SNRNP70 Isoform 1 of U1 small nuclear ribonucleoprotein 70 kDa Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens SREBP1
sterol regulatory element 
binding transcription factor 1 
isoform a
In vitro affinity capture [46]
Homo sapiens STRAP Serine-threonine kinase receptor-associated protein Over-expression of FLAGGSK3b in HEK 293 cells [4]
Caenorhabditis elegans T12G3.1 Hypothetical protein Yeast-2-hybrid [15]
Caenorhabditis elegans T24H7.3 Hypothetical protein Yeast-2-hybrid [15]
Rattus norvegicus Tat Human immunodeficiency virus 1 Co-IP with over-expressed tat
[47]
Homo sapiens TP53 Tumor protein p53 Co-IP with endogenous proteins [52]
Homo sapiens TPPP
Tubulin polymerization 
promoting protein
Co-purify in sae fraction following gel- 
chromatography [53]
Homo sapiens TSC1
Isoform 1 ofTuberin 
(Tuberous sclerosis 2 
homolog protein)
Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo sapiens TSC2
Isoform 2 of Tuberin 
(Tuberous sclerosis 2 
homolog protein)
Over-expression of FLAGGSK3p in HEK 293 cells [4]
Homo Sapiens UPF3A
UPF3 regulator of nonsense 
transcripts homolog A 
isoform hUpf3p
Yeast-2-hybrid [61]
Homo sapiens XP06 Exportin-6 Over-expression of FLAGGSK30 in HEK 293 cells [4]
Caenorhabditis elegans Y48E1B. 10 Glutathione S-Transferase family member (gst-20)
Yeast-2-hybrid [15]
Caenorhabditis elegans ztf-26
Zinc finger transcription 
factor 26
Yeast-2-hybrid [15]
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activity towards specific substrates is regulated through interactions with scaffolding 
proteins, it would make sense for these scaffolding proteins to be present at low levels, 
thus ensuring they are the rate-limiting factor. It is also possible that GSK-3 (3 interacts 
with other proteins only in a transient manner or that the majority of interactions are low 
affinity. This would mean that during the incubation period with the GFP-binder GSK-3 
interaction partners were able to associate and dissociate freely, thus altering the ratio of 
heavy : light amino acids.
In order to identify GSK-3p binding partners in future using an affinity purification 
approach it may be necessary to significantly increase the levels of protein expression, 
amount of starting material or perform a SILAC experiment were samples are only 
combined following affinity purification.
It would also be an appreciable goal to extend this research and investigate how GSK-3 
binding partners change in response to specific stimuli such as cAMP, WNT or Hh 
ligands. In the context of the WNT signalling, activation of the pathway has already been 
shown to alter the binding properties of GSK-3; in chapter 1 I discussed how there is 
emerging evidence that WNT signal transduction involved the re-localization of GSK-3 
and Axin to the plasma membrane and an association between GSK-3 (3 and LRP6. By 
looking at how GSK-3 binding partners change in response to specific stimuli we would 
gain significant insight into the regulatory mechanisms by with GSK-3 activity is 
directed.
Recently, tissue specific roles for each mammalian GSK-3 isofonns have also been 
identified; glycogen metabolism was found to be regulated by different GSK-3 isoforms 
in a tissue specific manner [29, 86]. As such, in order to exhaustively identify all GSK-3 
interaction partners and fully understand the regulatory mechanisms of this protein it may 
be necessary to move over to a mouse model and identify GSK-3 binding partners in a 
tissue specific manner.
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6.4 Conclusions
In summary, I have identified a novel role for GskA in the regulation of myosin- 
dependent cytokinesis in Dictyostelium. I, along with others, have also expanded on our 
understanding of the role of GskA during the early stages of Dictyostelium development. 
And, I have demonstrated that GskA performs multiple roles during aggregation and is 
required both for cellular polarization and chemotaxis.
Both cytokinesis and chemotaxis occur as a result of co-ordinated responses involving 
multiple signalling pathways. The function performed by GskA in co-ordinating these 
responses can in part be explained through GskA directed regulation of gene expression. 
However, there is also evidence for a direct role for GskA and as part of this study I have 
identified a series of potential GskA binding partners than may be involved in directing 
GskA activity.
The mammalian aspect o f this project and the SILAC coupled mass spectrometry 
experiments did not identify any strong candidates for GSK-3 (3 binding proteins. 
However a number of potential binding partners, that were also highlighted as part of a 
separate study have been identified. Validation of these interactions will continue within 
the lab.
This study did indicate that any protein:protein interactions involving GSK-3 are likely to 
be highly dynamic or transient. A finding that reflects the dynamic nature of a protein 
that functions as a global regulator of cellular processes, acting to co-ordinate multiple 
changes in the cell.
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Appendix
Genes with altered expression in askA null cell line
Gene ID Gene name Protein ID Description
Log2 (ratio  
gskA null Vs 
Ax2)
DDB G0277861 patA DDB0214945 P-type ATPase, Ca2+-ATPase 2.0176758
DDB G0268212 DDB G0268212 DDB0233906 putative DEAD/DEAH box helicase 1.9205188
DDB G0269322 DDB G0269322 DDB0190177 1.8811491
DDB G0288055 DDB_G0288055 DDB0238154 K+ potassium transporter 1.8808755
DDB G0277503 amtA DDB0185017 ammonium transporter 1.7702776
DDB G0284535 CYP508A4 DDB0232355 cytochrome P450 family protein 1.7295033
DDB_G0285871 DDB_G0285871 DDB0237751 Ran GTPase binding protein, Mogl family protein, RAN quanine nucleotide release factor 1.6751536
DDB G0273809 DDB G0273809 DDB0266641 zinc/iron permease, ZIP family zinc transporter 1.6737599
DDB G0271672 DDB G0271672 DDB0232108 ZIP zinc transporter protein, zinc/iron permease 1.672326
DDB G0277489 DDB G0277489 DDBO169205 1.6396084
DDB G0275253 DDB G0275253 DDB0229926 1.6204642
DDB G0279713 DDB G0279713 DDB0230087 putative saposin putative cerebroside sulfate activator 1.5885049
DDB G0275523 DDB G0275523 DDB0167196 1.5364555
DDB G0275475 DDB G0275475 DDB0167118 1.5274893
DDB G0293182 expl8 DDB0304867 expansin-like protein 1.4972502
DDB G0291111 DDB G0291111 DDB0219645 1.4804599
DDB G0268208 DDB G0268208 DDBO189867 1.4209803
DDB G0279185 cprF DDB0215002 cysteine proteinase 1.4184733
DDB G0268208 DDB_G0268208 DDBO189867 1.3275763
DDB G0290001 DDB G0290001 DDB0188678 1.3025722
DDB G0279819 DDB_G0279819 DDB0206309 1.2929857
DDB G0292736 pipA DDB0201656 phosphoinositide-specific phospholipase C 1.2869461
DDB_G0289167 DDB_G0289167 DDB0188292 Similar to Rhizobium loti (Mesorhizobium loti). Short-chain oxidoreductase 1.2687382
DDB G0274181 DDB G0274181 DDB0252580 1.2280192
DDB G0292016 - DDBO184163 1.2202076
DDB G0291123 gipD DDB0191397 glycogen phosphorylase 2 glycogen phosphorylase a 1.2096769
DDB G0277401 vatB DDB0185207 vacuolar H+ ATPase B subunit 1.2081223
DDB G0284793 - DDBO186196 1.1985631
DDB G0284763 DDB G0284763 DDB0186177 1.1876217
DDB G0269892 DDB_G0269892 DDBO190650 1.172243
DDB G0290431 DDB G0290431 DDBO188901 1.1307283
DDB_G0285981 DDB_G0285981 DDB0232083 type A von Willebrand factor (VWFA) domain-containing protein 1.125797
DDB_G0277969 DDB_G0277969 DDB0238145 NADH:flavin oxidoreductase/NADH oxidase domain- containinq protein 1.1097461
DDB G0287717 DDB G0287717 DDB0187589 1.0885663
DDB_G0282209 DDB_G0282209 DDB0238178 type A von Willebrand factor (VWFA) domain-containing protein 1.0842277
DDB G0281443 DDB G0281443 DDB0205585 1.0823777
DDB G0275701 vatE DDBO185070 vacuolar H+-ATPase E subunit 1.0592366
DDB_G0276067 ddcB DDB0237754 group IV decarboxylase, putative diaminopimelate decarboxylase 1.0566069
DDB G0271988 DDB G0271988 DDB0168608 1.0524534
DDBJ30275695 ampA DDBO185088 adhesion modulation protein A prestalk D l l  protein precursor 1.0316899
DDB G0271818 DDB G0271818 DDB0238818 1.0155513
DDB G0275469 DNaseV DDB0233087 putative endonuclease V 1.0148357
DDB G0268614 msh6 DDB0229918 mutS homoloq, DNA mismatch repair protein 1.0068844
DDB G0275693 DDB G0275693 DDB0185020 peptidase C53 family protein 0.9956591
DDB G0288947 DDB G0288947 DDB0233866 0.9942231
DDB G0279187 cprG DDB0215005 cysteine proteinase 0.989646
DDB G0268622 raclB DDB0219941 Rho GTPase 0.9886429
DDB G0286197 DDB G0286197 DDB0305103 0.9859124
DDB G0272434 DDB G0272434 DDB0217004 0.9807131
DDB_G0285981 DDB_G028598l DDB0232083 type A von Willebrand factor (VWFA) domain-containing protein 0.9499135
DDB G0274259 DDB G0274259 DDBO167806 0.9421814
DDB G0287671 DDB G0287671 DDB0219255 0.9368011
DDB G0281325 DDB G0281325 DDB0305072 alkaline phosphatase-like protein 0.9327649
DDB G0278481 DDB G0278481 DDB0234075 UPF0027 family protein 0.9192288
DDB_G0277429 DDB_G0277429 DDB0237856
regulator of chromosome condensation (RCC1) domain- 
containing protein BTB/POZ domain-containing proteinator 
of chromosome condensation (RCC1) domain-containing 
protein
0.9161506
DDB G0274331 DDB G0274331 DDB0235141 vacuolar ATP synthase subunit D 0.8845514
DDB G0269454 trpS DDB0231245 tryptophanyl-tRNA synthetase tryptophan-tRNA liqase 0.8787375
DDB_G0287765 DDB_G0287765 DDB0238148
NADH:flavin oxidoreductase/NADH oxidase domain- 
containinq protein 0.8543896
DDB G0278649 DDB G0278649 DDB0218082 0.8463857
DDB G0285615 DDB G0285615 DDB0238155 0.8457415
DDB_G0285725 dhps DDB0266388 deoxyhypusine synthase 0.8218971
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DDB_G0289481 glnS DDB0201644 glutamine-tRNA ligase glutaminyl-tRNA synthetase veqetative specific protein H4 0.8218605
DDB_G0289595 prpf31 DDB0304959 pre-mRNA processing factor 31 0.8169809
DDB_G0292894 DDB_G0292894 DDB0305175 putative ornithine cyclodeaminase 0.8139456
DDB_G0286725 vpsl3A DDB0234198 vacuolar protein sorting-associated protein 13 family protein 0.8086366
DDB_G0279443 DDB_G0279443 DDB0205768 0.7907435
DDB_G0271068 DDB_G0271068 DDB0216762 0.7850833
DDB_G0293038 DDB_G0293038 DDB0191738 phosphatidylinositol-4-phosphate 5-kinase (PIP5K) family protein 0.7752078
DDB_G0292978 DDB_G0292978 DDB0219806 0.7711197
DDB_G0275413 DDB_G0275413 DDB0234182 ransmembrane protein vacuolar sorting protein 9 domain- containing protein DUF726 family protein 0.7609096
DDB_G0274553 vatH DDB0234266 vacuolar ATP synthase subunit H 0.7527619
DDB_G0277729 DDB_G0277729 DDB0233559 0.7464713
DDB_G0290317 psiJ DDB0232407 PA14 domain-containing protein 0.7375259
DDB_G0283977 DDB_G0283977 DDBO185789 Probable short-chain dehydrogenase 0.7248511
DDB_G0285975 DDB_G0285975 DDB0218765 Mast cell surface antigen-1. 0.7221299
DDB_G0292214 DDB_G0292214 DDB0267116 protein phosphatase 2C-related protein 0.7171591
DDB G0286555 racA DDB0191173 Rho GTPase RhoBTB family protein 0.7137651
DDB_G0293436 abcA3 DDB0201662 ABC transporter A family protein 0.7060042
DDB G0281815 DDB_G0281815 DDBO266864 DUF410 family protein, UPF0363 family protein 0.6589781
DDB_G0294040 m rp lll DDB0201601 S60 ribosomal protein L ll ribosomal protein L ll, mitochondrial 0.6572212
DDB_G0274553 vatH DDB0234266 vacuolar ATP synthase subunit H 0.6279824
DDB_G0274381 vatP DDB0185071 vacuolar ATPase proteolipid subunit, Vacuolar ATP synthase proteolipid subunit 0.5995834
DDB G0293438 abcB2 DDB0201670 ABC transporter B family protein 0.5862193
DDB_G0278333 SppA DDB0205381 0.5656316
DDB_G0280969 prdD DDB0214953 proteasome subunit alpha type 4, 20S proteasome subunit alpha-4 -0.5220274
DDB G0278271 DDB G0278271 DDB0205337 -0.5463779
DDB_G0270358 - DDB0304448
UAS domain-containing protein, UBX domain-containing 
protein, ubiquitin interacting motif (UIM) domain-containing 
protein
-0.5503816
DDB G0291988 ifl DDB0216175 FIFO-ATPase putative regulatory protein IF1 -0.5635355
DDB_G0271264 USpl4 DDB0237695
ubiquitin domain-containing protein, peptidase C19 family 
protein, putative ubiquitin carboxyl-terminal hydrolase 
(UCH)
-0.5708384
DDB_G0281865 adh5 DDB0238276 zinc-containing alcohol dehydrogenase (ADH), alcohol dehydrogenase, class 3, formaldehyde dehydrogenase -0.578092
DDB G0288933 cda DDB0230205 cytidine deaminase -0.5865414
DDB_G0286195 nagBl DDB0234127 glucosamine-6-phosphate isomerase glucosamine-6- phosphate deaminase PIG-L family protein -0.5875792
DDB_G0278873 gnpdal DDB0234126 glucosamine-6-phosphate isomerase glucosamine-6- phosphate deaminase -0.5922923
DDB_G0280047 yelA DDB0214918 initiation factor eIF-4 gamma middle domain-containing protein -0.5996218
DDB_G0268538 psmA5 DDB0232930 proteasome subunit alpha type 5, 20S proteasome subunit alpha-5 -0.6225098
DDB_G0276933 mcfX DDB0234131 putative transmem brane protein, mitochondrial substrate carrier family protein -0.6244587
DDB_G0284553 gmd DDB0231676 GDP-mannose 4,6-dehydratase, GDP-mannose 4,6-hydro- lyase, GDP-mannose dehydratase -0.625974
DDB_G0273865 pakH-2 DDB0266965
STE20 family protein kinase protein kinase, STE group PAKL 
subfamily protein kinase putative protein serine/threonine 
phosphatase
-0.6290553
DDB G0274041 - DDB0217433 -0.6352066
DDB_G0272684 qdpr DDB0237752 dihydropteridine reductase quinoid dihydropteridine reductase -0.6353745
DDB G0291265 gloA DDB0230987 lactoylglutathione lyase, glyoxylase I -0.640263
DDB_G0283679 psmB7 DDB0232933
proteasome subunit beta type 7 20S proteasome subunit 
beta-7 -0.6458286
DDB G0274579 pitB DDB0219979 phosphatidylinositol transfer protein 2 -0.6627077
DDB G0288495 DDB_G0288495 DDB0187960 -0.6646256
DDB_G0293538 dcd2A DDB0215370
neutrai/alkaiine nonlysosomal ceramidase family protein acid 
ceramidase -0.6664104
DDB G0276269 sgcA DDB0191330 guanylyl cyclase -0.6708314
DDB_G0272052 DDB_G0272052 DDB0232387
leucine-rich repeat-containing protein (LRR) putative cell 
surface glycoprotein -0.6870475
DDB G0274067 DDB G0274067 DDB0266924 -0.6917882
DDB_G0271694 DDB_G0271694 DDB0168459 1 « 7485-
DDB_G0274409 pakF DDB0229410
putative protein serine/threonine kinase STE20 family 
protein kinase protein kinase, STE group PAKL subfamily 
protein kinase
-0.7038544
DDB_G0274471 tpiA DDB0231425 triose phosphate isomerase triosephosphate isomerase -0.7046855
DDB_G0277589 gtaC DDB0220470 putative GATA-binding transcription factor GATA zinc finger domain-containing protein 3 -0.7196232
DDB_G0279159 acol DDB0229908 putative iron regulatory protein, aconitate hydratase, aconitase -0.7266059
DDB_G0292754 DDB G0292754 DDBO184545 -0.7304029
DDB_G0292552 dscE DDB0215382 -0.7405732
DDB_G0276965 gltA DDB0214944 citrate synthase -0.7433903
DDB_G0290073 DDB_G0290073 DDB0188711 -0.7449488
DDB_G0270994 psaA DDB0231238 puromycin-sensitive aminopeptidase-like protein metallopeptidase -0.7482988
DDB_G0272566 psmD14 DDB0191298 26S proteasome non-ATPase regulatory subunit 14, putative multidrug resistance protein -0.7503709
DDB_G0285899 DDB_G0285899 DDB0232139 alanine transaminase alanine aminotransferase glutamate pyruvate transaminase -0.7528904
DDB_G0290405 tpsC DDB0231988
glycosyltransferase, alpha,alpha-trehalose-phosphate 
synthase, rehalose 6-phosphate synthase, trehalose- 
phosphatase
-0.7699584
DDB_G0275441 gtpA DDB0191350 GTP-binding protein, HSRl-related domain-containing protein -0.7735737
DDB_G0271086 DDB_G0271086 DDB0216772 -0.7837746
DDB_G0277001 cpiC DDB0252666 cystatin A3 putative cysteine protease inhibitor -0.78414
DDB_G0267446 cnbA DDB0191204,DDB0231422
protein phosphatase 2B, protein serine/threonine 
phosphatase, CaM-dependent protein phosphatase, 
requlatory subunit, calcineurin B
-0.7879655
DDB G0272666 - DDBO168867 putative ankyrin repeat protein -0.7933328
DDB G0282819 sglA DDB0214888 sphingosine-1-phosphate lyase SIP lyase -0.7946592
DDB G0276205 DDB G0276205 DDB0203511 -0.7993476
DDB_G0270990 DDB G0270990 DDB0234155 putative acyl-CoA oxidase -0.7998533
DDB G0277675 DDB G0277675 DDB0233770 RasGTPase-activating protein -0.8073312
DDB G0284353 osbl DDB0237802 oxysterol binding family protein, member 9 -0.8166823
DDB G0280135 DDB G0280135 DDB0231749 methionine adenosyltransferase regulatory beta subunit -0.818261
DDB G0283483 srfD DDB0220493 putative MADS-box transcription factor -0.8231618
DDB_G0273979 psmD8-2 DDB0266350 26S proteasome regulatory subunit S14, 26S proteasome non-ATPase regulatory subunit 8 -0.8251649
DDB G0285989 DDB_G0285989 DDB0218772 -0.8285445
DDB_G0289145 pde7 DDB0238626 cAMP phosphodiesterase cGMP phosphodiesterase -0.8341998
DDB_G0290883 DDB_G0290883 DDB0238325
RING zinc finger-containing protein TRAF-type zinc finger- 
containing protein meprin and TRAF homology (MATH) 
domain-containing protein
-0.8386995
DDB_G0274273 DDB G0274273 DDBO167842 -0.8563842
DDB G0283261 acoA DDB0191408 acyl-CoA oxidase -0.8571647
DDB_G0292668 DDB_G0292668 DDB0184513 -0.8617781
DDB_G0277083 DDB_G0277083 DDB0302576 N-terminal delta endotoxin domain-containing protein -0.8621387
DDB_G0286353 erkA DDB0201635
extracellular signal-regulated protein kinase protein 
serine/threonine kinase MAP kinase MAPK family protein 
kinase ERK subfamily protein kinase mitogen-activated 
protein kinase
-0.864247
DDB_G0272969 psmBl DDB0232957 proteasome subunit beta type 1, 20S proteasome subunit beta-1 -0.8751341
DDB_G0292136 hatC DDB0232313 actin binding protein hisactophilin III -0.8753327
DDB_G0270836 fbp DDB0216231 D-fructose-l,6-bisphosphate 1-phosphohydrolase fructose- 1,6-bisphosphatase -0.895145
DDB G0293166 DDB G0293166 DDB0219817 -0.9054417
DDB G0274607 gefM DDB0191326 Ras guanine nucleotide exchange factor -0.906573
DDB_G0272208 idhC DDB0231401 isocitrate dehydrogenase (NADP+) isocitrate dehydrogenase (NADP+), cytosolic -0.9084229
DDB_G0278581 psiF DDB0215398 PA14 domain-containing protein, discoidin-inducing complex (DIC) protein -0.9156646
DDB_G0272210 idhM DDB0231402 isocitrate dehydrogenase (NADP+) isocitrate dehydrogenase (NADP+), mitochondrial -0.9380368
DDB G0274025 DDB G0274025 DDB0238175 -0.9560863
DDB G0291081 pefA DDB0191092 penta EF hand calcium binding protein -0.9680113
DDB G0284357 DDB G0284357 DDB0238182 -0.9979598
DDB G0295801 DDB0252620 B lectin domain-containing protein -1.004698
DDB G0280171 psiP DDB0232405 PA14 domain-containing protein -1.0205791
DDB G0289145 pde7 DDB0238626 cAMP phosphodiesterase, cGMP phosphodiesterase -1.030317
DDB_G0292790 CYP508D1 DDB0232976 cytochrome P450 family protein - 1 . ^ 7 1 3
DDB_G0274085 DDB_G0272628 DDB0238196 zinc-containing alcohol dehydrogenase (ADH) -1.0363343
DDB G0278787 DDB G0278787 DDB0206191 -1.0365695
DDB G0293066 DDB G0293066 DDB0191758 -1.0396728
DDB G0280575 DDB_G0280575 DDB0206051 -1.0511661
DDB_G0283847 DDB_G0283847 DDB0238256 cyclopropane fatty acid synthase cyclopropane-fatty-acyl- phospholipid synthase -1.0600885
DDB G0267930 DDB G0267930 DDB0238238 -1.0747543
DDB G0277569 DDB0252835 GNS1/SUR4 family protein -1.0803989
DDB G0289551 DDB G0289551 DDB0219450 -1.0926258
DDB_G0272738 iunH DDB0231227 N-D-ribosylpurine ribohydrolase, inosine-uridine nucleoside N-ribohydrolase -1.0938916
DDB G0274369 DDB_G0274369 DDB0167931 -1.1013836
DDB G0290177 DDB G0290177 DDB0238177 putative transmem brane protein -1.1173406
DDB_G0269160 nxnA DDB0191502,DDB0232009 annexin VII -1.1187316
DDB_G0272831 psmA7 DDB0185059 proteasome subunit alpha type 7 20S proteasome subunit alpha-7 -1.1452071
DDB G0286963 DDB_G0286963 DDB0215712 -1.1467406
DDB_G0273641 fnkD-2 DDB0304863 FNIP repeat-containing protein protein kinase, STE group FNIPK subfamily protein kinase -1.1472071
DDB_G0275559 DDB_G0275559 DDB0238156 short-chain dehydrogenase/reductase (SDR) family protein, glucose/ribitol dehydrogenase family protein -1.1878153
DDB G0274051 cpnB-2 DDB0238176 phospholipid-binding protein copine B -1.1910011
DDB G0282993 sodC DDB0232186 superoxide dismutase -1.1975426
DDB G0291029 DDB_G0291029 DDB0230064 sulfate adenylyltransferase adenylylsulfate kinase -1.2631565
DDB_G0277863 pdiA DDB0214948 cAMP phosphodiesterase inhibitor, phosphodiesterase inhibitor -1.272552
DDB G0270826 abcG22 DDB0214899 ABC transporter G family protein -1.3340623
DDB G0277697 DDB_G0277697 DDB0304392 -1.3876734
DDB G0272396 DDB_G0272396 DDB0235352 putative transmem brane protein -1.4668139
DDB G0285995 pdsA DDB0219974 cAMP phosphodiesterase cGMP phosphodiesterase -1.4736577
DDB_G0291710 rocolO DDB0201665
Kelch repeat-containing protein, RGS domain-containing 
protein, eucine-rich repeat-containing protein (LRR) RhoGAP 
domain-containing protein protein kinase, TKL group 
tyrosine kinase-like protein ROCO family protein kinase
-1.4767169
DDB G0275551 DDB G0275551 DDB0167353 -1.5359432
DDB G0268090 DDB G0268090 DDB0238183 glycoside hydrolase family 18 protein -1.5658384
DDB G0273919 dscA-2 DDB0266623 discoidin I, A chain discoidin I, alpha chain -1.6539738
DDB G0281113 DDB G0281113 DDB0238194 -1.6824252
DDB G0273887 dscD-2 DDB0266625 discoidin I, D chain -1.6941822
DDB G0278577 DDB G0278577 DDB0205548 -1.7087304
DDB G0282121 DDB G0282121 DDB0238184 -1.7366221
DDB_G0278313 DDB_G0278313 DDB0238239 pectin lyase-like family protein polymorphic membrane protein repeat-containing protein -1.7382121
DDB G0273887 dscD-2 DDB0266625 discoidin I, D chain -1.7956611
DDB G0274045 3B-2 DDB0238744 prespore-specific protein -1.8794726
DDB G0270726 DDB G0270726 DDB0238162 pyridoxal phosphate-dependent decarboxylase family protein -2.0785263
DDB G0279815 DDB G0279815 DDB0238808 putative transm em brane protein -2.0835617
DDB G0283885 DDB G0283885 DDB0231670 -2.1064092
DDB G0268600 DDB G0268600 DDB0233913 -2.1146566
DDB G0290885 DDB G0290885 DDB0238168 -3.6581148
DDB_G0282749 bzpG DDB0216335 putative basic-leucine zipper (bZIP) transcription factor -3.8507577
This list of g e n e s  w a s  provided in a personal com m unication with Gareth Bloomfield and 
w as the described by Strem ecki e t al [169]
145
GO term analysis
The Gene Ontology project provides a categorization system that separates genes into 
three categories based on molecular functions, biological processes and cellular 
localization, each with several subcategories. By collating the available gene ontology 
(GO) terms for genes whose expression is altered by loss of GskA it was possible to 
assess whether these genes shared a common function. Of the original 193 genes, GO 
terms relating to biological processes were available for 129 genes. These GO terms were 
used to cluster genes together under higher-level GO parents terms (often referred to as 
GOslim terms). This clustering revealed that the genes affected by loss of GskA were 
associated with a wide range of biological processes, with the largest proportion of these 
involved in metabolic processes.
In order to determine if specific GO terms were enriched within the dataset the program 
'Generic Gene Ontology (GO) Term Finder’ was used to compare the number of genes in 
a given category with the number of genes that might appeal* in the same category if 
genes were selected at random from the genome. This analysis was performed separately 
on those genes that are over- or under-expressed and revealed that several GO terms were 
over-represented in each group. A higher than average number of genes that are under- 
expressed in gskA null cells were associated with catabolic and proteolytic processes 
(Table 4.1). While a significant number of genes that were over-expressed are associated 
with processing of ATP, and biosynthetic and metabolic pathways linked to 
ribonucleotides
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Over represented GO terms am ong th ose  gen es that were over-expressed in the
oiskA  null cell line
Gene ontology term Clusterfrequency
Genome
frequency
Corrected
P-value Genes annotated to the term
cation transport
9 of 81 
genes, 
11.1%
106 of 
12098 
genes, 0.9%
7.93E-06
DDB0185207, DDB0234266, DDB0185017, 
DDB0185071, DDB0235141, DDB0238154, 
DDB0185070, DDB0232108, DDB0214945
energy coupled proton 
transport, down 
electrochemical gradient
5 of 81 
genes, 6.2% 18 of 12098 genes, 0.1%
2.26E-05 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
ATP synthesis coupled 
proton transport
5 of 81 
genes, 6.2%
18 of 12098 
genes, 0.1%
2.26E-05 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
ion transmembrane 
transport
5 of 81 
genes, 6.2%
18 of 12098 
genes, 0.1%
2.26E-05 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
ATP biosynthetic process 5 of 81 genes, 6.2%
19 of 12098 
genes, 0.2%
3.05E-05 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
ATP metabolic process 5 of 81 genes, 6.2%
20 of 12098 
genes, 0.2%
4.04E-05 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
ion transport
9 of 81 
genes, 
11.1%
138 of 
12098 
genes, 1.1%
7.79E-05
DDB0185207, DDB0234266, DDB0185017, 
DDB0185071, DDB0235141, DDB0238154, 
DDB0185070, DDB0232108, DDB0214945
purine ribonudeoside 
triphosphate biosynthetic 
process
5 of 81 
genes, 6.2%
24 of 12098 
genes, 0.2% 0.0001 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
monovalent inorganic 
cation transport
6 of 81 
genes, 7.4%
46 of 12098 
genes, 0.4% 0.00013
DDB0185207, DDB0238154, DDB0185070, 
DDB0234266, DDB0185071, DDB0235141
purine nucleoside 
triphosphate biosynthetic 
process
5 of 81 
genes, 6.2%
25 of 12098 
genes, 0.2%
0.00013 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
ribonudeoside 
triphosphate biosynthetic 
process
5 of 81 
genes, 6.2%
25 of 12098 
genes, 0.2%
0.00013 DDB0185207, DDBO 185070, DDB0234266, DDB0185071, DDB0235141
purine ribonudeoside 
triphosphate metabolic 
process
5 of 81 
genes, 6.2%
25 of 12098 
genes, 0.2% 0.00013 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
hydrogen transport 5 of 81 genes, 6.2%
26 of 12098 
genes, 0.2% 0.00016
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
purine nucleoside 
triphosphate metabolic 
process
5 of 81 
genes, 6.2%
26 of 12098 
genes, 0.2% 0.00016 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
ribonudeoside 
triphosphate metabolic 
process
5 of 81 
genes, 6.2%
26 of 12098 
genes, 0.2% 0.00016 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
proton transport 5 of 81 genes, 6.2%
26 of 12098 
genes, 0.2% 0.00016
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
nucleoside triphosphate 
biosynthetic process
5 of 81 
genes, 6.2%
29 of 12098 
genes, 0.2% 0.00029
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
purine nucleoside 
biosynthetic process
5 of 81 
qenes, 6.2%
31 of 12098 
genes, 0.3% 0.00041
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
purine ribonudeoside 
biosynthetic process
5 of 81 
genes, 6.2%
31 of 12098 
genes, 0.3% 0.00041
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
nucleoside triphosphate 
metabolic process
5 of 81 
qenes, 6.2%
32 of 12098 
qenes, 0.2%
0.00049 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
oxidative phosphorylation 5 of 81 genes, 6.2%
33 of 12098 
qenes, 0.3% 0.00057
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
nucleoside biosynthetic 
process
5 of 81 
qenes, 6.2%
33 of 12098 
qenes, 0.3% 0.00057
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
ribonudeoside biosynthetic 
process
5 of 81 
genes, 6.2%
33 of 12098 
genes, 0.3% 0.00057
DDB0185207, DDB0185070, DDB0234266, 
DDBO 185071, DDB0235141
purine ribonucleotide 
biosynthetic process
5 of 81 
qenes, 6.2%
38 of 12098 
qenes, 0.3%
0.00119 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
purine ribonucleotide 
metabolic process
5 of 81 
genes, 6.2%
40 of 12098 
genes, 0.3% 0.00154
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
ribonucleotide biosynthetic 
process
5 of 81 
genes, 6.2%
40 of 12098 
genes, 0.3% 0.00154
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
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Gene ontology term Clusterfrequency
Genome
frequency
Corrected
P-value Genes annotated to the term
ribonucleotide metabolic 
process
5 of 81 
genes, 6.2%
42 of 12098 
genes, 0.3% 0.00197
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
transmembrane transport 5 of 81 genes,
42 of 12098 
genes 0.3% 0.00197
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
nucleobase, nucleoside and 
nucleotide biosynthetic 
process
5 of 81 
genes, 6.2%
43 of 12098 
genes, 0.4%
0.00222 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
nucleobase, nucleoside, 
nucleotide and nucleic acid 
biosynthetic process
5 of 81 
genes, 6.2%
43 of 12098 
genes, 0.4% 0.00222 DDB0185207, DDB0185070, DDB0234266, DDB0185071, DDB0235141
purine ribonudeoside 
metabolic process
5 of 81 
genes,
44 of 12098 
genes, .4% 0.0025
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
localization
17 of 81 
genes, 
21.0%
774 of 
12098 
genes, 6.4% 0.00268
DDB0201662, DDB0185088, DDB0185017, 
DDB0235141, DDB0219941, DDB0205768, 
DDB0230087, DDB0234198, DDB0191173, 
DDB0238154, DDB0232108, DDB0201670, 
DDB0214945, DDB0185207, DDB0234266, 
DDB0185071, DDB0185070
purine nucleoside 
metabolic process
5 of 81 
genes, 6.2%
45 of 12098 
genes, 0.4% 0.00279
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
ribonudeoside metabolic 
process
5 of 81 
genes,
48 of 12098 
genes, 0.4% 0.00386
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
generation of precursor 
metabolites and energy
6 of 81 
genes,
82 of 12098 
genes, 0.7% 0.00414
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141, DDB0191397
nitrogen compound 
biosynthetic process
6 of 81 
genes, 7.4%
91 of 12098 
genes, 0.8% 0.00753
DDB0237754, DDB0185207, DDB0185070, 
DDB0234266, DDB0185071, DDB0235141
nucleoside metabolic 
process
5 of 81 
genes, 6.2%
58 of 12098 
genes, 0.5% 0.0098
DDB0185207, DDB0185070, DDB0234266, 
DDB0185071, DDB0235141
Table A.2. GO term enrichment within genes that are over-expressed in gskA null
cell line
Data correct - Wed Sep 2 05:21:06 EDT 2009, P-value cutoff = 0.01, Annotation file = 
gene_association.ddb, Evidence codes used - IEA (14589), IEP (80), IGI (103), NAS (16), 
IP! (201) ND (4191), IC (212), ISS (8901), IDA (1435), IMP (978), TAS (485
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Over represented GO term s am ong th ose  g en es that were under-expressed in the
askA  null cell line
Gene ontology 
term
Cluster
frequency
Genome
frequency
Corrected
P-value Genes annotated to the term
cellular
catabolic
process
14 of 113  
genes, 
12 .4%
218 of 
12098
genes, 1 .8%
2.92E -06
D D B 0185059, DD B0230205, DDB0219974, 
DD B0232933, DDB0232957, DDB0191408, 
D D B0238626, DD B0231227, DDB0191298, 
DD B0214953, DDB0214888, DDB0214944, 
DD B0232930, DDB0237695
catabolic
process
16 of 113 
genes, 
14 .2%
424  of 
12098
genes, 3 .5 %
0.00039
D D B0185059, DDB0230205, DDB0219974, 
D D B0232933, DDB0232957, DDB0231425, 
D D B 0191408, DDB0238626, DDB0231227, 
D D B 0191298, DDB0214953, DDB0214888, 
D D B 0231238, DD B0214944, DDB0232930, 
DDB0237695
ubiquitin- 
dependent 
protein catabolic 
process
7 of 113  
genes, 
6 .2 %
72 of 12098  
genes, 0 .6 % 0.00094
D D B 0185059, DD B0232933, DDB0232930, 
D D B 0232957, DD B0237695, DDB0191298, 
DDB0214953
modification- 
dependent 
protein catabolic 
process
7 of 113  
genes, 
6 .2 %
72 of 12098  
genes, 0 .6 % 0.00094
D D B0185059, DD B0232933, DDB0232930, 
D D B0232957, DD B0237695, DDB0191298, 
DDB0214953
modification-
dependent
macromolecule
catabolic
process
7 of 113  
genes, 
6 .2 %
72 of 12098  
genes, 0 .6 % 0.00094
D D B0185059, DD B0232933, DDB0232930, 
DD B 0232957, DD B0237695, DDB0191298, 
DDB0214953
cellular protein 
catabolic 
process
7 of 113  
genes, 
6 .2 %
72 of 12098  
genes, 0 .6 % 0 .00094
DD B0185059, D D B 0232933, DDB0232930, 
DD B 0232957, D D B 0237695, DDB0191298, 
DD B0214953
proteolysis 
involved in 
cellular protein 
catabolic 
process
7 of 113  
genes, 
6 .2 %
72 of 12098  
genes, 0 .6 % 0.00094
D D B 0185059, DD B0232933, DDB0232930, 
D D B 0232957, DD B0237695, DDB0191298, 
DD B0214953
carbohydrate
biosynthetic
process
5 of 113  
genes, 
4 .4 %
31 of 12098  
genes, 0 .3 % 0.00186
D D B 0231676, DDB0231425, DDB0216231, 
DD B0231749, DDB0231988
cellular
biopolymer
catabolic
process
7 of 113  
genes, 
6 .2 %
98 of 12098  
genes, 0 .8 %
0.00724
DD B0185059, DD B0232933, DDB0232930, 
DD B0232957, DDB0237695, DDB0191298, 
DDB0214953
cellular
macromolecule
catabolic
process
Table A.3. GO 
cell line
Data correct - 
gene associatk 
IPI (201) ND (4
7 of 113  
genes, 
6 .2 %
term enri
Wed Sep  
jn.ddb, Ev 
191), IC (2
98 of 12098  
genes, 0 .8 %
chment wit
2 05:21:06  
idence code 
12), ISS (89
0.00724
hin genes
EDT 200£ 
(S used - 1 
01), IDA (1
D D B0185059, DDB0232933, DDB0232930, 
D D B0232957, DD B0237695, DDB0191298, 
DDB0214953
that are under-expressed in gskA  null
), P-value cutoff = 0.01, Annotation file = 
EA (14589), IEP (80), IGI (103), NAS (16), 
435), IMP (978), TAS (485
149
Proteins identified through S1LAC analysis
Protein n a m e  ( a s  it 
a p p e a r s  in 
STRING)
P rote in  D escr ip t io n Ratio H/L
ACLY ATP-citrate synthase 0 . 7 3 8 0 1
ACPI Adipocyte acid phosphatase 0 . 5 4 5 3 9
ACTC1 Actin, alpha cardiac muscle 1 0 . 5 4 3 5 2
ACTG1 Actin, cytoplasmic 2;Gam m a-actin 0 . 2 1 4 5 4
ACTN4 Alpha-actinin-4 0 . 6 2 1 7
AHCY Adenosylhomocysteinase 0 . 4 2 4 9 9
ALDOA Fructose-bisphosphate aldolase A 0 . 2 1 8 2 1
AMFR Autocrine motility factor receptor 0 . 0 4 3 1 1 6
ANXA2 Annexin A2 0 . 7 3 6 5 8
ARF3 ADP-ribosylation factor 3 0 . 7 6 6 7 6
AS 1 6 0 Akt substrate of 160 kDa 0 . 6 1 7 2 9
ATP5A ATP synthase subunit alpha, mitochondrial 0 . 7 4 5 1 9
ATP5B ATP synthase subunit beta, mitochondrial 0 . 8 1 4 0 3
AUF1 AU-rich elem ent RNA-binding protein 1 0 . 8 5 1 6 1
BAT1 DEAD box protein UAP56;ATP-dependent RNA helicase DDX39 0 . 6 8 7 7 4
C1QBP
Com plem ent component 1 Q subcomponent-binding protein, mitochondrial
0 . 6 9 7 9 5
CAD G lutam ine-dependent carbamoyl-phosphate synthase 0 . 2 2 1 8 7
CALM 3 calmodulin 3 0 . 5 9 8 9 5
CAND1 Cullin-associated and neddylation-dissociated protein 1 0 . 7 1 7 0 4
CANX Calnexin 0 . 4 4 1 2 5
CAPRIN1 Cytoplasmic activation- and proliferation-associated protein 1 0 . 9 7 3 4 8
CAPZA1 F-actin-capping protein subunit alpha-1 0 . 1 9 0 7 4
CCT1 T-com plex protein 1 subunit alpha;CCT-alpha 0 . 5 2 1 3 4
CCT2 T-com plex protein 1 subunit beta;CCT-beta 0 . 5 3 0 4 8
CCT3 T-com plex protein 1 subunit gam m a;CCT-gam m a 0 . 5 8 4 3 4
CCT4 T-com plex protein 1, delta subunit;CCT-delta 0 . 5 1 6 4 3
CCT6A T-com plex protein 1 subunit epsilon;CCT-epsilon 0 . 6 1 2 6
CCT6A T-com plex protein 1 subunit zeta;C C T-zeta ;C C T-zeta -l 0 . 6 0 7 1 4
CCT7 T-com plex protein 1 subunit eta;CCT-eta 0 . 5 6 3 3 9
CCT8 T-com plex protein 1 subunit theta;CCT-theta 0 . 5 8 3 4 5
CFL1 Cofilin-1 0 . 6 1 8 7 3
CIP29 Cytokine induced protein 29 kDa 0 . 0 0 8 8 6 4 2
CKB Creatine kinase B-type 0 . 4 1 2 5 2
CLTC Clathrin heavy chain 1 0 . 3 5 1 6 8
COPG
Coatomer subunit gam m a;G am m a-coat protein;Coatom er subunit gamm a- 
2;G am m a-2-coat protein 0 . 8 1 7 2 3
CRKL Crk-like protein 0 . 5 2 1 4 3
CSDA Cold shock domain-containing protein A 0 . 6 4 8 9 8
CSE1L Chromosome segregation 1-like protein 0 . 5 2 7 4 3
CSNK2A1 casein kinase 2, alpha 1 polypeptide 0 . 0 1 5 1 6
CSRP2 Cysteine and glycine-rich protein 2 1 .5 0 8 1
CSTB Cy stati n - B; S tef i n - B 0 . 4 8 4 2 9
CTPS CTP synthase 1 0 . 5 3 6 6 2
DDX21 Nucleolar RNA helicase 2; DEAD box protein 21 0 . 6 0 2 2 6
DDX3X ATP-dependent RNA helicase DDX3X 0 . 6 8 4 8 3
DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 0 . 8 6 6 4 3
DHX35 DEAH (Asp-Glu-Ala-His) box polypeptide 35 1 .0 6 8 2
DHX9 ATP-dependent RNA helicase A;DEAH box protein 9 0 . 4 6 9 3 4
DUT Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 0 . 2 8 3 3 8
' EIF3C Eukaryotic translation initiation factor 3 subunit C ° - 6 O T  -
EEF1D Eukaryotic translation elongation factor 1 delta 0 . 8 8 6 7 5
Protein n a m e  ( a s  it 
a p p e a r s  in 
STRING)
P rotein  D escr ip t io n Ratio H/L
EEF1E1 Eukaryotic translation elongation factor 1 epsilon-1 0 . 7 5 5 2 4
EEF1E1 Elongation factor 1-alpha 1 0 . 6 9 8 0 8
EEF2 Elongation factor 2 0 . 4 8 8 5 4
EEFIB2 Elongation factor 1-beta 0 . 7 1 6 5 9
EIF3B Eukaryotic translation initiation factor 3 subunit B 0 . 6 0 3 5 6
EIF4A2 Eukaryotic initiation factor 4A -I 0 . 7 4 3 2 2
EIF5A Eukaryotic translation initiation factor 5A-1 0 . 3 5 7 8 5
ENO-1 Alpha-enolase 0 . 6 1 1 0 7
EPB4IL3
Band 4 .1 -like  protein 3;4.1B;D ifferentially expressed in adenocarcinoma of
the lung protein 1 0 . 7 6 3 4 6
ERCC2 Telophase disk protein of 60 kDa 0 . 5 8 7 7
FARSA Phenylalanyl-tRNA synthetase alpha chain 0 . 1 7 0 2 3
FARSB Phenylalanyl-tRNA synthetase beta chain 0 . 3 2 8 8
FASN Fatty acid synthase 0 . 2 8 8 5 3
FILIP1L Filamin-A 0 . 7 9 9 6 5
FKBP4 FK506-binding protein 4 0 . 5 2 0 7 8
G3BP1 Ras GTPase-activating protein-binding protein 1 0 . 3 7 4 3 8
GANAB
Neutral alpha-glucosidase AB;Glucosidase I I  subunit alpha;Alpha-
glucosidase 2 0 . 6 7 0 1 5
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0 . 9 2 5 1
GART Trifunctional purine biosynthetic protein adenosine-3 0 . 3 1 7 8 3
GDI2 Rab GDP dissociation inhibitor beta 0 . 0 4 7 9 8 2
GLOl Lactoylglutathione lyase 0 . 5 2 8 0 7
GNB2L1
Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1
variant 0 . 0 3 3 6 0 8
GPI Glucose-6-phosphate isomerase 0 . 5 2 6 0 3
GSK3 Glycogen synthase kinase-3 beta 2 5 . 9 9 5
GSR Glutathione reductase, mitochondrial 0 . 7 2 9 7 9
H2AFX H2A histone family, m ember V, isoform CRA_b 0 . 6 1 0 3 8
H3F3A Histone H3.3 0 . 5 1 3 7 4
HAGH Hydroxyacylglutathione hydrolase 0 . 2 8 1 1 7
HDAC6 Histone deacetylase 6 0 . 2 1 4 1 6
HIST1H1T Histone H i t 0 . 6 5 3 9 7
HIST1H2AD Histone H2A type 2-B 0 . 4 4 3 3 9
HIST1H2BN Histone H2B type 1-N 0 . 2 3 4 7 3
HIST1H4A Histone H4 0 . 6 3 4 8 3
HIST2H2BE Histone H2B type 2-E 0 . 6 4 5 0 1
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 0 . 1 5 3 8 2
HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 0 . 2 3 6 8 2
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 0 . 5 5 5 1 6
HNRNPF Heterogeneous nuclear ribonucleoprotein F 0 . 1 8 4 0 9
HNRNPK Heterogeneous nuclear ribonucleoprotein K 0 . 6 3 1 3 3
HNRNPM Heterogeneous nuclear ribonucleoprotein M 0 . 6 6 2 5 6
HNRNPU Heterogeneous nuclear ribonucleoprotein U (Scaffold attachm ent factor A) 0 . 6 4 1 3
HPRT1 Hypoxanthine-guanine phosphoribosyltransferase 0 . 7 6 6 8
HSC 70 Heat shock 70 kDa protein 8 0 . 6 1 1 4 4
HSP90AA1 Heat shock protein HSP 90-alpha 0 . 7 0 7 4 1
HSP90AB1 Heat shock protein HSP 90-beta 0 . 5 9 3 4 7
H SP90B 1 Heat shock protein 90 kDa beta m ember 1 0 . 6 0 2 9 3
HSPA1A Heat shock 70 kDa protein 1 0 . 5 7 4 0 9
HSPA1A cDNA F U 54 30 3 , highly similar to Heat shock 70 kDa protein 1 0 . 3 1 5 4 1
HSPA4 Heat shock 70 kDa protein 4 0 .3 4 6 Y 1
Protein n a m e  ( a s  it 
a p p e a r s  in 
STRING)
P rote in  D e sc r ip t io n Ratio H/L
HSPA5 Heat shock 70 kDa protein 5 0 . 6 5 8 6 4
HSPA9 Heat shock 70 kDa protein 9 0 . 2 6 7 8 8
HSPD1 Heat shock protein 60 ;60  kDa chaperonin 0 . 6 7 6
HSPH1 Heat shock protein 105 kDa 0 . 7 7 2 1 9
ILF2 Interleukin enhancer-binding factor 2 0 . 4 8 2 9 1
IP 0 5 Im portin -5 0 . 7 0 6 7 1
ISYNA1 Inositol-3-phosphate synthase 0 . 6 4 1 3 2
K appa-actin Beta-actin-like protein 2 ;Kappa-actin 0 . 2 4 1 9 3
KIF14 Kinesin-like protein KIF14 0 . 2 7 6 8 6
KPNB1 Im portin subunit beta-1 0 . 9 4 9 7 1
KT3K Ketosam ine-3-kinase 0 . 5 5 8 9 5
LDHA L-lactate dehydrogenase A chain 0 . 9 4 9 3
LDHAL6B L-lactate dehydrogenase A-like 6B 1 . 1 1 4 7
LDHB L-lactate dehydrogenase B chain 0 . 9 3 5 2 8
LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial 0 . 5 6 1 4 4
MARS Methionyl-tRNA synthetase 1 . 0 7 9 3
MATR3 Uncharacterized protein MATR3;Matrin-3 0 . 4 6 6 2 1
MCM6 DNA replication licensing factor MCM6 0 . 4 2 3 3 4
MIF
Macrophage migration inhibitory factor;Phenylpyruvate  
tautomerase;Glycosylation-inhibiting factor 0 . 0 4 8 7 2 9
MTHFD1 M ethylenetetrahydrofolate dehydrogenase 0 . 9 4 8 5 6
MYH10 Myosin heavy chain 10 1 . 1 5 8 5
MYH9 Myosin heavy chain 9 0 . 8 3 2 7 1
NACAP1 Nascent polypeptide-associated complex subunit alpha 0 . 7 5 5 8 8
NAP1L1 Nucleosome assembly protein 1-like 1 0 . 6 5 9 6 3
NCL Nucleolin 0 . 7 0 1 3 4
NME1 Nucleoside diphosphate kinase 1 0 . 9 3 2 8 9
NME2 Nucleoside diphosphate kinase 2 0 . 7 3 3 4 5
NPM1 Nucleophosmin 0 . 5 3 9 5 3
NSUN2 tRNA (cytosine-5-)-m ethyltransferase NSUN2 0 . 2 4 4 9 6
NUP155 Nuclear pore complex protein N u p l5 5 0 . 8 1 9 3 6
NVL Transitional endoplasmic reticulum ATPase 0 . 5 5 2 4 8
O K /S W -c l .83 40S ribosomal protein S8;Ribosomal protein S8 0 . 4 4 2 9
OPA1 Optic atrophy protein l;D ynam in -like  120 kDa protein 0 . 3 8 2 7 4
P4HB Prolyl 4-hydroxylase subunit beta 0 . 6 4 1 6 3
PABPC3 PolyaKJenylate-binding protein 3 0 . 4 0 9 4 6
PAICS Phosphoribosylaminoimidazole-succinocarboxamide synthase 0 . 8 1 8 8 2
PARK7 Protein DJ-l;O ncogene DJl;Parkinson disease protein 7 0 . 6 5 9 2 7
PARP1 Poly |ADP-ribose] polymerase 1 0 . 7 8 8 6 2
PCBP1 Porfy(rC)-binding protein 1 0 . 4 4 8 7 2
PCBP2 Poly(RC)-binding protein 2 isoform b variant 0 . 5 4 4 9 3
PDCD6 Programmed cell death protein 6 0 . 2 4 3 6 3
PDIA3 Protein disulfide-isomerase A3 0 . 5 1 9 1 6
PEF1 Peflin 0 . 9 5 3 0 3
PFN1 Profilin-1 0 . 7 5 6 7 2
PGAM1 Phosphoglycerate mutase 1 0 . 5 8 3 0 4
PGD 6-phosphogluconate dehydrogenase 0 . 6 3 0 7 6
PGK1 Phosphoglycerate kinase 1 0 . 6 3 9 1 9
PHB2 Prohibitin-2 0 . 1 3 5 1 1
PHGDH D -3 -p h o sphoglycerate dehydrogenase 1 .0 1 5
PKM2 Pyruvate kinase isozymes M1/M2 0 . 4 2 3 4
PPA1 Pyrophosphate phospho-hydrolase 0 . 8 9 & g
’rotein n a m e  ( a s  it 
a p p e a r s  in 
STRING)
P rote in  D e sc r ip t io n Ratio H/L
PPIA Peptidyl-prolyl cis-trans isomerase A 0 . 7 0 1 4 4
PPMIG Protein phosphatase 1G 0 . 8 3 1 7 5
PPP1CC Serine/threonine-protein phosphatase PP l-gam m a catalytic subunit 0 . 4 6 0 4 6
PPP2R1B Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit R l-alpha isoform 0 . 5 0 7 7
PRDX1 Peroxiredoxin-1 0 . 5 3 1 7
PRDX2 Peroxiredoxin-2 0 . 6 5 4 4 1
PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial 0 . 6 8 2 7 9
PRDX6 Peroxiredoxin-6 0 . 8 4 9 4
PRKDC DNA-dependent protein kinase catalytic subunit 0 . 5 5 6 0 6
PSMD1 26S proteasome non-ATPase regulatory subunit 1; 0 . 2 2 6 2 9
PSME1 Proteasome activator complex subunit 1 0 . 9 2 3 5 3
PTBP1 Polypyrimidine tract binding protein 1 0 . 4 7 5 5 4
PTGES3 Prostaglandin E synthase 3 1 . 0 2 4 4
PTMA Prothymosin alpha;Thymosin alpha-1 0 . 7 3 3 6 1
RAN GTP-binding nuclear protein Ran 0 . 6 8 5 5 3
RANBP1 Ran-specific GTPase-activating protein 0 . 7 6 6 1 2
RARS Arginyl-tRNA synthetase, cytoplasmic;Arginine—tRNA ligase 0 . 4 8 6
RPL11 60S ribosomal protein L l l 0 . 6 0 0 0 4
RPL12 60S ribosomal protein L12 0 . 6 4 1 4 7
RPL17 60S ribosomal protein L23 0 . 6 8 5 9 7
RPL18A 60S ribosomal protein L18a 1 . 1 5 3 2
RPL22 60S ribosomal protein L22 0 . 9 7 5 3 6
RPL23 60S ribosomal protein L23 0 . 6 6 1 8 4
RPL23A 60S ribosomal protein L23a 0 . 5 2 2 1
RPL24 60S ribosomal protein L24 0 . 8 1 5 1 1
RPL27 60S ribosomal protein L27 0 . 5 0 5 8 8
RPL3 60S ribosomal protein L3 0 . 6 4 1 8 8
RPL31 60S ribosomal protein L31 0 . 6 6 1 6 2
RPL35A 60S ribosomal protein L35a 0 . 7 6 7 8 5
RPL7 60S ribosomal protein L7 0 . 5 5 5 5 7
RPL9 60S ribosomal protein L9 0 . 8 1 1 5 3
RPLPO 60S acidic ribosomal protein PO 0 . 7 9 2 5 9
RPLP1 60S acidic ribosomal protein P I 0 . 5 6 8 3
RPLP2 60S acidic ribosomal protein P2 0 . 6 6 1 8 3
RPS10 40S ribosomal protein S10 0 . 1 5 3 0 8
RPS12 40S ribosomal protein S12 0 . 6 9 2 0 8
RPS13 40S ribosomal protein S13 0 . 4 9 1 9 9
R PS15A 40S ribosomal protein S15a 0 . 1 6 6 6 5
RPS16 40S ribosomal protein S16 0 . 3 4 8 4 6
RPS17 40S ribosomal protein S17 0 . 7 6 1 5 7
RPS18 40S ribosomal protein S18 0 . 7 0 8 9 6
RPS19 40S ribosomal protein S19 0 . 3 0 3 0 3
R PS20 40S ribosomal protein S20 0 . 6 1 9 8
RPS2 40S ribosomal protein S2 0 . 5 7 1 3 3
RPS23 40S ribosomal protein S23 0 . 7 8 7 8 9
R PS24 40S ribosomal protein S24 0 . 9 4 9 7 6
R PS25 40S ribosomal protein S25 0 . 8 4 0 1 2
R PS26 40S ribosomal protein S26 0 . 6 3 1 7 2
RPS3 40S ribosomal protein S3 0 . 4 5 9 9 1
RPS3A 40S ribosomal protein S3a 0 .31*53
RPS4X 40S ribosomal protein S4, X isoform 0 . 7 6 6 6 5
..
Protein n a m e  ( a s  it 
a p p ea r s  in 
STRING)
P rotein  D e sc r ip t io n Ratio H/L
RPS5 40S ribosomal protein S5 0 . 6 2 6 2 8
RPS7 40S ribosomal protein S7 0 . 5 2 3 4 9
RPSA 40S ribosomal protein SA 0 . 5 6 1 9 1
SERBP1 SERPINE1 mRNA-binding protein 1 0 . 6 2 1 7 5
SET Protein SET;Phosphatase 2A inhibitor I2PP2A 0 . 6 4 7 9 9
SFRS3 Splicing factor, arginine/serine-rich 3 0 . 1 8 8 2 9
SLC25A5 ADP/ATP translocase 2;Solute carrier family 25 member 5 1 .1 6 9 3
SLC25A6 ADP/ATP translocase 3;Solute carrier family 25 m ember 4 0 . 7 9 2 4 7
SNRPD3 Small nuclear ribonucleoprotein Sm D3;snRNP core protein D3 0 . 7 5 6 2 4
S 0 D 1 Superoxide dismutase [Cu-Zn] 0 . 6 9 6 7 6
SSB Sjoegren syndrome type B antigen 0 . 8 0 9 8 9
SSBP1 Single-stranded DNA-binding protein, mitochondrial 0 . 2 9 1 6 3
SSRP1 FACT complex subunit SSRP1;Structure-specific recognition protein 1 0 . 9 0 5 9 5
ST 13 Suppression of tumorigenicity protein 13 0 . 9 9 1 9 5
STIP1 Stress-induced-phosphoprotein 1 0 . 7 2 8 1 2
SUB1 Activated RNA polymerase I I  transcriptional coactivator p l5 0 . 7 1 6 2 9
SU M 03 Small ubiquitin-related modifier 3 0 . 6 8 9 8 1
SUPT16 FACT complex subunit SPT16 1 . 1 2 1 3
SYNCRIP Synaptotagmin-binding, cytoplasmic RNA-interacting protein 0 . 7 1 3 6 8
SYT7 cDNA F U 53554 0 . 0 0 6 2 1 0 5
TAGLN2 Transgelin-2;SM 22-alpha homolog 0 . 8 2 9 4 3
TARS Threonyl-tRNA synthetase 0 . 5 7 7 4 9
TBA4B Putative tubulin-like protein alpha-4B;Alpha-tubulin 4B 0 . 5 9 0 9 8
TKT Transketolase 0 . 5 9 9 5 7
TKTL1 Transketolase-like protein 1 0 . 0 6 1 5 5 5
T N P 0 2 Transportin-2 1 . 0 9 0 2
TPI1 Triosephosphate isomerase 0 . 9 6 4 0 1
TRAP1 Heat shock protein 75 kDa, mitochondrial 0 . 0 1 9 3 4 4
TRIM28 Transcription intermediary factor 1-beta 0 . 4 6 7 1 2
TUBA4A Tubulin a lp ha -lB  chain 0 . 4 5 6 5 5
TUBB Tubulin beta chain 0 . 2 8 6 6 5
TUBB2A Tubulin beta-2A chain;Tubulin beta-2B chain 0 . 8 5 2 3 7
TUBB2C Tubulin beta-2C chain 0 . 4 5 5 3 1
TUBB4Q Tubulin beta-4 chain 0 . 4 7 8 7 4
TXN Thioredoxin 0 . 8 3 6 9 8
UBA1 Ubiquitin-like modifier-activating enzyme 1 0 . 6 4 7 7 7
UBA52 Ubiquitin B 0 . 5 6 5 8 9
UBE2E2 Ubiquitin-conjugating enzyme E2 N 0 . 5 3 3 0 1
UBE2L3 Ubiquitin-conjugating enzyme E2 L3 0 . 3 3 2 5
VDAC3 Voltage-dependent anion-selective channel protein 3 0 . 7 6 3 2 3
VIM Vimentin 0 . 9 6 8 5 5
XPOl Exportin-1 0 . 6 5 2 0 4
XRCC5 ATP-dependent DNA helicase 2 subunit 2 0 . 5 6 9 3 5
XRCC6 ATP-dependent DNA helicase 2 subunit 1 0 . 6 2 4 4 7
YWHAE 14-3-3  protein epsilon 0 . 6 3 4 6 7
YWHAQ 14-3-3  protein theta 0 . 5 8 2 5 7
YWHAZ 14-3-3  protein zeta 0 . 7 2 5 7 5
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REVIEWED P.EFSEC: This record has been curated by NCBI staff. The 
reference sequence was derived from AFO0 6 010.2. AB020703■3.
AL8 3 35 5 5 . 1 and 3C0 37B4 3 ■1.
On Aug 10, 2001 this sequence version replaced cri: 7705340.
Summary: This gene encodes a progestin-induced protein, which 
belongs to the HECT (homology to E6-AP carboxyl terminus) family. 
The HECT family proteins function as E3 ubiquitin-protein ligases, 
targeting specific proteins for ubiquitin-mediated proteolysis.
This gene is localized to chromosome 8q22 which is disrupted in a 
variety of cancers. This gene potentially has a role in regulation 
of cell proliferation or differentiation, [provided by RefSeq].
Publication Note: This RefSeq record includes a subset of the
publications that are available for this gene. Please see the 
Entrez Gene record to access additional publications. 
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